

The background of the entire page is a photograph of the Parthenon on the Acropolis in Athens, Greece, taken at dusk. The temple is illuminated with warm yellow lights, contrasting with the cool blue and purple tones of the twilight sky. The foreground shows the rocky slopes of the Acropolis and some greenery.

9TH SYSTEMIC SCLEROSIS WORLD CONGRESS

FINAL PROGRAMME

MARCH 5 - 7, 2026
ATHENS, GREECE

<https://worldsclerofound.org>

COMMITTEES

Patron WSF

Prof. Dame Carol Black (UK)

Honorary Presidents

Thomas Medsger (USA), Kazuhiko Takehara (Japan), Alan Tyndall (Switzerland), Frank Wollheim (Sweden)

Senior Advisors

Phil Clements (USA), Nemanja Damjanov (Serbia), Ariane Herrick (UK), Jim Seibold (USA)

Steering Committee

Yannick Allanore (France), Shervin Assassi (USA), Francesco Del Galdo (UK), Chris Denton (UK), Oliver Distler (Switzerland), Jorg Distler (Germany), Dan Furst (USA), Dinesh Khanna (USA), Thomas Krieg (Germany), Masataka Kuwana (Japan), Robert Lafyatis (USA), Marco Matucci-Cerinic (Italy), Maureen Mayes (USA), Susanna Proudman (Australia), John Varga (USA)

- EULAR Liaison: Ulf Muller-Ladner (Germany)
- ACR Liaison: Zsuzsanna McMahan (USA)
- EUSTAR Liaison: Marie-Elise Truchetet (France)
- Meet the Professors: Laszlo Czirjak (Hungary)
- Workshops: Phil Clements (USA)
- Patients representatives: Sue Farrington (UK), Ilaria Galetti (Italy)
- Country members: Petros P. Sfikakis, Nic Lioussis, Theodoros Dimitroulas, Stylianos Panopoulos (Greece)

Co-Chairs of the Scientific Programme Committee

Clinical: Vanessa Smith (Belgium)

Basic: Benjamin Korman (USA)

Co-Chairs of the Abstract Committee

Clinical: Rong Mu (China), Silvia Bellando-Randone (Italy),

John Pauling (UK), Zsuzsanna McMahan (USA)

Basic: Michal Tomcik (Czech Republic), Yukie Yamaguchi (Japan)

Local Organising Committee

Petros P. Sfikakis, *Chairperson*
Stamatis Nick Lioussis, Theodoros Dimitroulas,
Stylianos Panopoulos, Maria Tektonidou, George Fragoulis,
Vasiliki Bournia, Nikos Vlachogiannis, Argiryos Tzouveleakis
(*pulmonologist*), Sophie Mavrogeni (*cardiologist*)

Scientific Committee

D. Abraham (UK), Y. Asano (Japan), A. Balbir-Gurmann (Israel), M. Baron (Canada), C. Bruni (Switzerland, Italy), C. Campochiaro (Italy), P. Carreira (Spain), I. Castellvi (Spain), J. Colic (Serbia), M. Cutolo (Italy), L. Dagna (Italy), G. De Luca (Italy), JK. De Vries-Bouwstra (The Netherlands), C. Foocharoen (Thailand), T. Frech (USA), D. Giuggioli, (Italy), E. Hachulla (France), M. Hinchcliff (USA), M. Hughes (UK), A. Hoffmann-Vold (Norway), M. Hughes (UK), L. Hummers (USA), N. Hunzelmann (Germany), M. Inanc (Turkey), JB. Jun (South Korea), B. Kahaleh (USA), C. Kayser (Brazil), Y. Kawaguchi (Japan), O. Kowal-Bielecka (Poland), D. Launay (France), EB. Lee (South Korea), A. Lescoat (France), Y. Levy (Israel), MT. Li (China), C. Mihai (Switzerland), GL. Moroncini (Italy), OL. Mouthon (France), V. Nagaraja (USA), M. Nikpour (Australia), J. Pope (Canada), G. Riemekasten (Germany), P. Sampaio Barros (Brazil), L. Sakkas (Greece), P. Shenoy (India), K. Solanki (New Zealand), V. Steen (USA), Y. Suliman (Egypt), E. Volkman (USA), M. Vonk (The Netherlands), J. Wang (China), H. Yasuoka (Japan), Y. Wang (China), X. Zeng (China)

FESCA Board

Sue Farrington, *President*

Ilaria Galetti, *Vice-President*

Linda Schraven, *Secretary*

Annelise Rønnow, *Communications Manager*

Monica Holmner, *Board Member*



TABLE OF CONTENTS

CONGRESS AT A GLANCE pag. 4

POSTER SESSION pag. 28

SCIENTIFIC PROGRAMME pag. 8

CHAMPIONS OF PROGRESS pag. 51

POSTER TOUR LIST pag. 16

GENERAL INFORMATION pag. 52

PRE-CONGRESS WORKSHOPS & COURSES pag. 18

SCIENTIFIC INFORMATION pag. 54

SATELLITE SYMPOSIA pag. 21

CONGRESS FLOORPLANS pag. 55

PATIENT CONGRESS pag. 24

ACKNOWLEDGEMENT pag. 63

CONGRESS AT A GLANCE

THURSDAY, MARCH 5					
	TRIANTI HALL (level 0)	MC 2 (level -1)	MC 3 (level -1)	MC 3.2 (level -1)	MC 3.4 (level -1)
09:00 10:30 1st slot				PRE-CONGRESS WORKSHOP 1 FIBROTIC SKIN MANIFESTATIONS - NEW DIAGNOSTIC AND THERAPEUTIC APPROACHES	PRE-CONGRESS WORKSHOP 2 DIGITAL ULCERS IN SSC - A COMPREHENSIVE APPROACH TO THE ASSESSMENT AND MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS
10:30 11:00		PRE-CONGRESS COURSE 1 CAPILLAROSCOPY (08:30-13:30)	PRE-CONGRESS COURSE 2 WSF/SCTC MRSS-TRAINING AND STANDARDIZATION (08:30-12:30)	COFFEE BREAK	
11:00 12:30 2nd slot				PRE-CONGRESS WORKSHOP 1 FIBROTIC SKIN MANIFESTATIONS - NEW DIAGNOSTIC AND THERAPEUTIC APPROACHES	PRE-CONGRESS WORKSHOP 2 DIGITAL ULCERS IN SSC - A COMPREHENSIVE APPROACH TO THE ASSESSMENT AND MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS
13:45 14:45	SESSION 1 LUNG				
14:45 15:10	INVITED LECTURE 1 Bridging biology to clinical practice in PAH: future opportunities for SSc-PAH				
15:10 16:00	SESSION 2 HEART				
16:00 16:30	ASTRAZENECA SATELLITE SYMPOSIUM				
16:30 17:30	MSD SATELLITE SYMPOSIUM				
17:30 18:10	OPENING OF THE CONGRESS				
18:10 19:10	OPENING LECTURES				
19:10	WELCOME RECEPTION				



FRIDAY, MARCH 6

	TRIANTI HALL (level 0)	MC 3 (level -1)	MC 3.2 (level -1)	MC 3.4 (level -1)	BANQUETING ROOM (level -2)
07:30 08:30			MEET THE EXPERT How to evaluate circulation in SSc	MEET THE EXPERT Myositis in SSc, so hidden so important	
08:00 09:00	SESSION 3 IMAGING				
09:00 10:00	SESSION 4 VASCULAR				PATIENT CONGRESS (09:00-16:15)
10:00 10:30	COFFEE BREAK				
10:30 11:50	SESSION 5 VERY EARLY DISEASE AND PREVENTION OF DAMAGE IN IMMUNE MEDIATED DISEASES				
11:50 13:20	BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM				
13:20 14:25	POSTER TOUR AND LUNCH				
14:25 15:25	BRISTOL-MYERS SQUIBB SATELLITE SYMPOSIUM				
15:25 15:50	INVITED LECTURE 2 Fibroblasts in Inflammation and Fibrosis				
15:50 16:30	SESSION 6 JOURNALS				
16:30 17:00	COFFEE BREAK				
17:00 17:25	INVITED LECTURE 3 Antibodies, on the interface between SSc, myositis and cancer				
17:25 18:15	PARALLEL SESSION 7 ENVIROMENTAL FACTORS	PARALLEL SESSION 9 BASIC (OMICS) (17:25-19:25)			
18:15 19:00	PARALLEL SESSION 8 DIFFERENCES AND SIMILARITIES BETWEEN JUVENILE AND ADULT ONSET SYSTEMIC SCLEROSIS				

SATURDAY, MARCH 7

	TRIANTI HALL (level 0)	MC 3 (level -1)	MC 3.2 (level -1)	MC 3.4 (level -1)	BANQUETING ROOM (level -2)
07:30 08:30			MEET THE EXPERT How to manage a SRC	MEET THE EXPERT Vasculopathy, from pathogenesis to management	
08:30 09:30	PARALLEL SESSION 10 ORAL PRESENTATION CLINICAL (08:30-09:20)	PARALLEL SESSION 11 INFLAMMATORY CELLS/ PATHWAYS (08:30-09:20)			
09:30 10:30	PARALLEL SESSION 12 ORAL PRESENTATION CLINICAL	PARALLEL SESSION 13 PRESENTATION BASIC III (HODGEPODGE) (09:30-10:40)			PATIENT CONGRESS (09:00-16:30)
10:30 11:00	COFFEE BREAK				
11:00 11:50	SESSION 14 ORAL PRESENTATION ON GI				
11:50 12:35	BOEHRINGER INGELHEIM ROUND TABLE				
12:35 13:50	POSTER TOUR AND LUNCH				
13:50 14:20	ARGENX SATELLITE SYMPOSIUM				
14:20 14:45	INVITED LECTURE 4 Activity and damage				
14:45 16:45	SESSION 15 THERAPY				
16:45 17:00	WRAP UP LECTURE				
17:00	CLOSING REMARKS				



Improving the patient journey in SSc: from early diagnosis to treatment and ongoing care

Date:

Friday, 6 March 2026, 11:50–13:20 (EET)

Venue:

Trianti Auditorium, Megaron Athens International
Conference Centre, Athens, Greece

Don't miss the chance to hear from experts in the field of systemic sclerosis at the Boehringer Ingelheim-sponsored satellite symposium.

During this symposium, a panel of expert rheumatologists will explore the current treatment options for patients with SSc, highlighting the importance of multidisciplinary care and discussing methods to optimize its implementation across various clinical settings.

Agenda

Speakers: Dinesh Khanna (Chair, Professor at University of Michigan), Francesco Del Galdo (Professor at University of Leeds), Zsuzsanna McMahan (Associate Professor and Co-Director of the Scleroderma Program at UTHealth Houston), Vanessa Smith (Professor and Head of Clinics at Ghent University Hospital)

Time (EET)	Session	Speaker/s
11:50–11:55	Introduction and welcome	Dinesh Khanna
11:55–12:35	Optimizing treatment approaches for patients with SSc: now and in the future	All
12:35–13:15	Working together to deliver best practice multidisciplinary care for patients with SSc	All
13:15–13:20	Wrap-up and close	Dinesh Khanna

We look forward to welcoming you to our symposium!

Visit Boehringer Ingelheim at Booth 04 for more information and resources.

SCIENTIFIC PROGRAMME

THURSDAY, MARCH 5

08:00

Registration opens

PRE-CONGRESS WORKSHOPS

09:00-10:30 First slot pre-congress Workshops

10:30-11:00 Coffee break

11:00-12:30 Second slot pre-congress Workshops

PRE-CONGRESS WORKSHOP 1 Room MC 3.2, level -1
FIBROTIC SKIN MANIFESTATIONS - NEW DIAGNOSTIC AND THERAPEUTIC APPROACHESConvenor: **Thomas Krieg (Germany)****PRE-CONGRESS WORKSHOP 2** Room MC 3.4, level -1
DIGITAL ULCERS IN SSC - A COMPREHENSIVE APPROACH TO THE ASSESSMENT AND MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSISConvenor: **Michael Hughes (UK)**

PRE-CONGRESS COURSES

08:30-13:30 Room MC 2, level -1
PRE-CONGRESS COURSE 1 - CAPILLAROSCOPYConvenor: **Vanessa Smith (Belgium)**08:30-12:30 Room MC 3, level -1
PRE-CONGRESS COURSE 2 - WSF/SCTC MRSS-TRAINING AND STANDARDIZATIONConvenor: **Dinesh Khanna (USA)**

13:45-14:45

SESSION 1 - LUNG

Trianti Hall

Chairs: **Petros Sfikakis (Greece), Argiryos Tzouveleakis (Greece), Elizabeth Volkman (USA)**The view of the patient: **Ilaria Galetti (Italy)**The view of the pulmonologist: **Vincent Cottin (France)**The view of the rheumatologist: **Anna-Maria Hoffman-Vold (Norway)**

• 14:25-14:35

OC 01 - CONTEMPORARY TREATMENT PATTERNS AND CLINICAL DETERMINANTS OF THERAPYCHOICES IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: INSIGHTS FROM THE EUSTAR DATABASE - **Corrado Campochiario et al (Italy)**

• 14:35-14:45

OC 02 - RISK FACTORS AND TRAJECTORIES OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS IN THE EUSTAR COHORT - **Antonio Tonutti et al (Italy)**14:45-15:10
INVITED LECTURE 1

Trianti Hall

Chairs: **Madelon Vonk (The Netherlands), Susanna Proudman (Australia)**Bridging biology to clinical practice in PAH: future opportunities for SS_c-PAH - **Katerina Antoniou (Greece)**15:10-16:00
SESSION 2 - HEART

Trianti Hall

Chairs: **Monique Hinchcliff (USA), Gabriela Riemekasten (Germany), Michael Hughes (UK)**

• 15:10-15:30

Unmasking and managing pHl - **Giacomo De Luca (Italy)**

• 15:30-15:40

OC 03 - INITIAL THERAPY IN SSC-PAH IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE
Hilde Jenssen Bjørkekjær et al (Norway)

THURSDAY, MARCH 5

• 15:40-15:50

OC 04 - HIGH TYPE 1 INTERFERON ASSOCIATES WITH SUBCLINICAL MYOCARDIAL INVOLVEMENT IN SYSTEMIC SCLEROSIS

Maia Buch et al (UK)

• 15:50-16:00

OC 05 - ARRHYTHMIC BURDEN, MYOCARDIAL MARKERS, AND LONG-TERM SURVIVAL IN DISTINCT CARDIAC MAGNETIC RESONANCE SUBSETS OF SYSTEMIC SCLEROSIS - **Davide Patti Gaspare et al (Italy)**

16:00-16:30

ASTRAZENECA SATELLITE SYMPOSIUM

See programme at page 21

Trianti Hall

16:30-17:30

MSD SATELLITE SYMPOSIUM

See programme at page 21

Trianti Hall

17:30-18:10

OPENING OF THE CONGRESS

Trianti Hall

18:10-19:10

OPENING LECTURES

Chairs: **Dan Furst (USA), Yannick Allanore (France)**

Trianti Hall

• 18:10-18:30

Clinical - **Virginia Steen (USA)**

• 18:30-18:50

Basic - **Joerg Distler (Germany)**

• 18:50-19:10

Is it time to implement patient care through patient
Sue Farrington (UK)

19:10

WELCOME RECEPTION

Foyer Level 0

FRIDAY, MARCH 6

07:30-08:30

MEET THE EXPERT

Room MC 3.2, level -1

• How to evaluate circulation in SSC - **Michael Hughes (UK)**

MEET THE EXPERT

Room MC 3.4, level -1

• Myositis in SSC, so hidden so important - **Dan Furst (USA)**

08:00-09:00

SESSION 3 - IMAGING

Trianti Hall

Chairs: **Vanessa Smith (Belgium), Yair Levy (Israel)**

• 08:00-08:20

Ultrasound of the Gastrointestinal SSC - **Giulia Bandini (Italy)**

• 08:20-08:40

Cardiac Magnetic Resonance in SSC
Sophie Mavrogeni (Greece)

• 08:40-08:50

OC 06 - ELEVATED MORTALITY LINKED TO MYOCARDIAL FIBROSIS IN SYSTEMIC SCLEROSIS: A MULTICENTER CMR STUDY IN AUTOIMMUNE RHEUMATIC DISEASES - **Attila Feher et al (USA)**

• 08:50-09:00

OC 07 - UNSUPERVISED CLUSTERING IDENTIFIES DISTINCT CMR DERIVED PHENOTYPES IN A COHORT OF SSC PATIENTS WITH LOW CARDIOVASCULAR RISK AND NO PRIOR CARDIAC
Mohammed Amr et al (UK)

09:00-10:00

SESSION 4 - VASCULAR

Trianti Hall

Chairs: **Tracy Frech (USA), Bashar Kahaleh (USA), Dilia Giuggioli (Italy)**

• 09:00-09:20

The complex world of Extracellular Vesicles as markers of vascular injury - **Jelena Colic (Serbia)**

• 09:20-09:30

OC 08 - UNMASKING LOWER LIMB PERIPHERAL ARTERIAL DISEASE IN SYSTEMIC SCLEROSIS THROUGH DOPPLER WAVEFORM ANALYSIS - **Begonya Alcaccer-Pitarch et al (UK)**

FRIDAY, MARCH 6

• 09:30-09:40

OC 09 - RISK FACTORS OF PROGRESSION OF CALCINOSIS AND ACRO-OSTEOLYSIS IN THE HANDS OF PATIENTS WITH SYSTEMIC SCLEROSIS : A LONGITUDINAL OBSERVATIONAL STUDY

Alain Lescoat et al (France)

• 09:40-09:50

OC 10 - ASSOCIATION BETWEEN VASOACTIVE-VASODILATING THERAPY AND REDUCED DETECTION OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: EVIDENCE FROM A EUSTAR STUDY

Cosimo Bruni et al (Switzerland)

• 09:50-10:00

OC 11 - POINTS TO CONSIDER FOR REPORTING OUTCOMES MEASURES IN SYSTEMIC SCLEROSIS INTERVENTIONAL STUDIES ON DIGITAL ULCERS: AN INITIATIVE FROM THE WORLD SCLERODERMA FOUNDATION DIGITAL ULCER AD HOC COMMITTEE

Corrado Campochiaro et al (Italy)

10:00-10:30 • Coffee break

10:30-11:50

Trianti Hall

SESSION 5 - VERY EARLY DISEASE AND PREVENTION OF DAMAGE IN IMMUNE MEDIATED DISEASES

Chairs: **Silvia Bellando Randone (Italy), Masataka Kuwana (Japan), Laszlo Czirjak (Hungary)**

• 10:30-10:40

Very Early Disease in SSc- what have we learnt so far
Francesco Del Galdo (UK)

• 10:40-11:00

Delaying the onset of Type I Diabetes: a model and a new opportunity - **Ana Llego-Delgado (USA)**

• 11:00-11:20

The APPIPRA study in RA - **Kulveer Mankia (UK)**

• 11:20-11:30

OC 12 - EARLY PROGRESSION OF SYSTEMIC SCLEROSIS: A LONGITUDINAL COHORT STUDY ON DISEASE EVOLUTION AND MICROVASCULAR CHANGES

Dieneke Haverkort et al (The Netherlands)

• 11:30-11:40

OC 13 - MULTIMODAL IMAGING DIFFERENCES BETWEEN PRE-SYSTEMIC SCLEROSIS (PRE-SSC) PATIENTS VERSUS HEALTHY CONTROLS: A CROSS-SECTIONAL STUDY - **Ramona Govender et al (Belgium)**

• 11:40-11:50

OC 14 - SPATIAL TRANSCRIPTOMICS REVEALS DISTINCT AND OVERLAPPING PROFILES IN SPECIFIC SKIN REGIONS OF VERY EARLY SYSTEMIC SCLEROSIS

Ifeoluwa Emmanuel Bamigbola et al (UK)

11:50-13:20

Trianti Hall

BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM

See programme at page 22

13:20-14:25 • Poster tour and lunch

14:25-15:25

Trianti Hall

BRISTOL-MYERS SQUIBB SATELLITE SYMPOSIUM

See programme at page 22

15:25-15:50

Trianti Hall

INVITED LECTURE 2

Chairs: **Robert Lafyatis (USA), Oliver Distler (Switzerland)**

Fibroblasts in Inflammation and Fibrosis

George Kollias (Greece)

15.50-16:30

Trianti Hall

SESSION 6 - JOURNALS

Chairs: **Marco Matucci-Cerinic (Italy), Ernst Choy (UK), Sarah Onuora (UK), Anna Clark (UK)**

• 15:50-16:00

Journal of Scleroderma and Related Disorders

Evaluation of autologous fat grafting in the treatment of juvenile localized scleroderma with facial involvement

Ivan Foeldvari et al (Germany)

• 16:00-16:10

Rheumatology

Live course management of Systemic Sclerosis from Children to Adult. A prospective from the BSR Guidelines

Clare Pain et al (UK)

• 16:10-16:20

Nature Rheumatology

Perspective: An international perspective on the future of SSc research - **David Abraham et al (UK)**

FRIDAY, MARCH 6

• 16:20-16:30

Lancet Rheumatology

Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in SSc

John Pauling et al (UK)

16:30-17:00 • Coffee break

17:00-17:25

INVITED LECTURE 3

Trianti Hall

Chairs: **Masataka Kuwana (Japan), Gianluca Moroncini (Italy)**

Antibodies, on the interface between SSc, myositis and cancer

Livia Casciola-Rosen (USA)

17:25-18:15

Trianti Hall

PARALLEL SESSION 7 - ENVIRONMENTAL FACTORS

Chairs: **Lorenzo Beretta (Italy), Eugene Kucharz (Poland), Theodoros Dimitroulas (Greece)**

• 17:25-17:45

Silica, an inducer of SSc? - **Alain Lescoat (France)**

• 17:45-18:05

Breast implants and SARDs - **Maria Grazia Lazzaroni (Italy)**

• 18:05-18:15

OC 15 - SYSTEMIC SCLEROSIS IN ISRAEL: A 20-YEAR NATIONWIDE STUDY OF PREVALENCE, HOT SPOTS AND SURVIVAL ANALYSIS

Doron Rimar et al (Israel)

18:15-19:00

Trianti Hall

PARALLEL SPECIAL SESSION 8: DIFFERENCES AND SIMILARITIES BETWEEN JUVENILE AND ADULT ONSET SYSTEMIC SCLEROSIS

Chairs: **Ivan Foeldvari (Germany), Clare Pain (UK)**

Speakers: **Kathryn Torok (USA) vs Chris Denton (UK)**

• 18:50-19:00

OC 16 - PULMONARY FUNCTION AND INTERSTITIAL LUNG DISEASE IN JUVENILE SYSTEMIC SCLEROSIS: INSIGHTS FROM THE LARGEST SINGLE-SITE PEDIATRIC SCLERODERMA REGISTRY

Kathryn Torok et al (USA)

17:25-19:25

Room MC 3, level -1

PARALLEL SESSION 9 - BASIC (OMICS)

Chairs: **John Varga (USA), Jorge Distler (Germany), Benjamin Korman (USA), Shervin Assassi (USA)**

• 17:25-17:55

Novel insights from renal and cardiac fibrosis - implications for SSc
Christoph Kuppe (Germany)

• 17:55-18:25

Synovial Fibroblasts and their Interactions in the Rheumatoid Arthritis Tissue Microenvironment - **Kartik Bhamidipati (USA)**

• 18:25-18:35

OC 17 - SPATIAL PROTEOMIC-BASED PHENOTYPING OF FIBROBLAST POPULATIONS AND THEIR MICROENVIRONMENT IN SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT

Andrea-Hermina Györfi et al (Germany)

• 18:35-18:45

OC 18 - SPATIAL PROFILING OF SCLERODERMA RENAL CRISIS REVEALS FIBROBLAST EXPANSION AND COMPLEMENT ACTIVATION

Minrui Liang et al (China)

• 18:45-18:55

OC 19 - MAPPING THE RNA METHYLOME IN SYSTEMIC SCLEROSIS: REGULATION AND ROLE IN TGF- β SIGNALING

Nikolaos Vlachogiannis et al (Greece)

• 18:55-19:05

OC 20 - ONE PROTEIN, MANY PATHS: MINDIN ORCHESTRATES SUBTYPE-SPECIFIC PROFIBROTIC FIBROBLAST RESPONSES IN SCLERODERMA

Gaurav Prafullbhai Kansagara et al (India)

• 19:05-19:15

OC 21 - MAPPING CELLULAR METABOLIC CHANGES IN SSC SKIN USING IMAGING MASS CYTOMETRY

Andrea Hermina Györfi et al (Germany)

• 19:15-19:25

OC 22 - MULTI-OMIC ANALYSIS IDENTIFIES A MONOCYTE-VASCULAR SIGNATURE LINKED TO SKIN FIBROSIS REGRESSION IN SYSTEMIC SCLEROSIS - **Astrid Hofman et al (Switzerland)**

SATURDAY, MARCH 7

07:30-08:30

MEET THE EXPERT

Room MC 3.2, level -1

- How to manage a SRC - **Chris Denton (UK)**

MEET THE EXPERT

Room MC 3.4, level -1

- Vasculopathy, from pathogenesis to management
Marco Matucci-Cerinic (Italy)

08:30-09:20

PARALLEL SESSION 10 - ORAL PRESENTATION CLINICAL

Trianti Hall

Chairs: **Carina Mihai (Switzerland), Ivan Castellvi (Spain), Silvia Bosello (Italy), Alexandra Balbir-Gurman (Israel)**

- 08:30-08:40

OC 23 - CALCINOSIS IN SYSTEMIC SCLEROSIS: FREQUENCY, CHARACTERISTICS AND ASSOCIATIONS IN AN AUSTRALIAN COHORT
Lauren Host et al (Australia)

- 08:40-08:50

OC 24 - REAL-WORLD EVIDENCE PREVALENCE AND CLINICAL OUTCOME OF PATIENTS MEETING THE INCLUSION CRITERIA OF THE PHASE 3 TRIAL DAISY (DETECTING EFFECTIVENESS OF ANIFROLUMAB IN SSC) - A EUSTAR COHORT STUDY - **Lesley Anne Bissell et al (UK)**

- 08:50-09:00

OC 25 - PREVALENCE OF ORGAN INVOLVEMENT AND BASELINE PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: INSIGHTS FROM THE CONQUER DATABASE - **Alain Lescoat et al (France)**

- 09:00-09:10

OC 26 - WHICH ANTI-CENTROMERE ANTIBODY-POSITIVE SYSTEMIC SCLEROSIS PATIENTS ARE LESS LIKELY TO DEVELOP ORGAN INVOLVEMENT? INSIGHTS FROM THE EUSTAR COHORT
Jelena Colic et al (Serbia)

- 09:10-09:20

OC 27 - CLINICAL CHARACTERISTICS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE IN MIXED CONNECTIVE TISSUE DISEASE AND SYSTEMIC SCLEROSIS: INSIGHTS FROM AN EMR-DERIVED COHORT
Alana Haussmann et al (USA)

08:30-09:30

PARALLELS SESSION 11 - INFLAMMATORY CELLS/PATHWAYS

Room MC 3, level -1

Chairs: **Eun Bong Lee (South Korea), Uma Kumar (India), Yukie Yamaguchi (Japan)**

- 08:30-08:40

OC 28 - SKIN MACROPHAGE SUBTYPES AND IMPACT OF TOFACITINIB IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: RESULTS FROM COMBINED SINGLE-CELL ANALYSES OF AN OBSERVATIONAL DATA SET AND A PHASE I/II RANDOMIZED CONTROLLED TRIAL - **Alain Lescoat et al (France)**

- 08:40-08:50

OC 29 - ANTI-TOPISOMERASE-1 AUTOANTIBODIES INDUCE TYPE I INTERFERON THROUGH THE CGAS-STING PATHWAY
Bent Deleuran et al (Denmark)

- 08:50-09:00

OC 30 - NK CELL IMMUNOTHERAPY REVERSES LUNG FIBROSIS BY ELIMINATING SENESENT FIBROBLASTS3
Wolfgang Merkt et al (Germany)

- 09:00-09:10

OC 31 - NOVEL MONOCYTE GENE SIGNATURES PREDICT PROGRESSION IN SYSTEMIC SCLEROSIS-ASSOCIATED ILD - **Cristina Padilla et al (USA)**

- 09:10-09:20

OC 32 - MONOCYTE-DERIVED MACROPHAGES IN SYSTEMIC SCLEROSIS: INTEGRATED SINGLE-CELL ANALYSIS ACROSS TISSUE COMPARTMENTS
Sandra Maribel Lopez Garces et al (UK)

- 09:20-09:30

OC 33 - IL-1<BETA> AND MICROVASCULAR ENDOTHELIAL CELLS SYNERGIZE TO FAVOR ALTERED MACROPHAGE EFFEROCYTOSIS: IMPLICATION IN SSC - **Cécile Contin-Bordes et al (France)**

09:30-10:30

PARALLEL SESSION 12- ORAL PRESENTATION CLINICAL

Trianti Hall

Chairs: **Cosimo Bruni (Switzerland), Cristiane Kayser (Brazil), Otylia Kowal-Bielecka (Poland), Yukai Wang (China)**

- 09:30-09:40

OC 34 - FROM FIRST SYMPTOM TO DIAGNOSIS: INITIAL SYMPTOMS AND DELAYS IN SYSTEMIC SCLEROSIS FROM THE EARLY SYSTEMIC SCLEROSIS LONGITUDINAL ASSESSMENT REGISTRY
Aslihan Avanoğlu Guler et al (Turkey)

SATURDAY, MARCH 7

• 09:40-09:50

OC 35 - PLATELETS' METABOLISM AND FUNCTIONS IN VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS AND IN ESTABLISHED DISEASE - **Annalisa Villa et al (Italy)**

• 09:50-10:00

OC 36 - EXTERNAL VALIDATION AND EXPLORATION OF CONCEPTUAL MODELS OF LATE SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS **Michael Hughes et al (UK)**

• 10:00-10:10

OC 37 - COMPARING LONG-TERM OUTCOMES ACROSS SYSTEMIC SCLEROSIS SUBGROUPS USING A MULTI-ORGAN DISEASE PROGRESSION SCORE - **Philip Yee et al (UK)**

• 10:10-10:20

OC 38 - 68GA-FAPI PET/CT FOR TRACKING DISEASE TRAJECTORY IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE **Panagiotis Garantzotis et al (Germany)**

• 10:20-10:30

OC 39 - MACHINE LEARNING-DRIVEN PHENOTYPING IN SYSTEMIC SCLEROSIS: CRP-DEFINED INFLAMMATION AND CLINICAL CLUSTERS - AN EUSTAR REGISTRY ANALYSIS **Cristiana Sieiro Santos et al (UK)**

09:30-10:40

Room MC 3, level -1

PARALLEL SESSION 13 - PRESENTATION BASIC III (HODGEPODGE)

Chairs: **Jeska De Vries-Bouwstra (The Netherlands), Jiucun Wang (China), Lazaros Sakkas (Greece), Michal Tomcik (Czech Republic)**

• 09:30-09:40

OC 40 - FIBROTIC ECM-TARGETING EXTRACELLULAR VESICLES AS MEDIATORS OF SYSTEMIC PROGRESSION IN SYSTEMIC SCLEROSIS **Shally Tartakover Matalon et al (Israel)**

• 09:40-09:50

OC 41 - CROSS-TRAIT GENETIC ANALYSIS REVEALS MEOX2 AS A NOVEL SUSCEPTIBILITY LOCUS SHARED BETWEEN PRIMARY RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS **Carlos Rangel-Peláez et al (Spain)**

• 09:50-10:00

OC 42 - PULMONARY ARTERIAL HYPERTENSION SUSCEPTIBILITY IN SYSTEMIC SCLEROSIS PATIENTS WITH THE DNASE1L3 RS35677470 (ARG206CYS) VARIANT - **Brian Skaug et al (USA)**

• 10:00-10:10

OC 43 - PROTEOMIC AND TRANSCRIPTOMIC ANALYSES ELUCIDATE THE TRAJECTORY OF PROGRESSION FROM THE ANTIBODY-POSITIVE PHASE TO THE DEVELOPMENT OF SSC - **Fenglin Wu et al (China)**

• 10:10-10:20

OC 44 - N-LACTOYL-AMINO ACIDS AS METABOLIC SIGNATURES OF FIBROTIC TRANSFORMATION IN SYSTEMIC SCLEROSIS SKIN: INSIGHTS FROM INTEGRATED METABOLOMIC AND TRANSCRIPTOMIC ANALYSIS **Amin Ravaei et al (Sweden)**

• 10:20-10:30

OC 45 - MUC16 MUTATIONS ARE ASSOCIATED WITH GENOMIC INSTABILITY AND POOR OUTCOMES IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS **Mohammed Osman et al (Canada)**

• 10:30-10:40

OC 46 - SPATIAL TRANSCRIPTOMIC-BASED PHENOTYPING OF THE FIBROBLAST NICHES IN SYSTEMIC SCLEROSIS-ASSOCIATED PRIMARY HEART INVOLVEMENT - **Alexandru Micu et al (Germany)**

10:30-11:00 • Coffee break

11:00-11:50

Trianti Hall

SESSION 14 - ORAL PRESENTATION ON GI

Chairs: **Marie-Elise Truchetet (France), Murat Inanc (Turkey)**

• 11:00-11:10

OC 47 - ASSOCIATION BETWEEN ESOPHAGEAL SYMPTOMS AND HIGH RESOLUTION MANOMETRY FINDINGS: ENHANCING MOTILITY ASSESSMENT WITH MULTIPLE SWALLOWING TESTS **Carlos Gomes et al (Portugal)**

• 11:10-11:20

OC 48 - HIGH-DEFINITION SPATIAL TRANSCRIPTOMICS REVEALS DISTINCT IMMUNE, FIBROTIC, AND METABOLIC SIGNATURES IN EARLY AND LATE SYSTEMIC SCLEROSIS SMALL BOWEL DISEASE **Laura Much et al (Switzerland)**

• 11:20-11:30

OC 49 - SEGMENTAL LOSS OF MOTILITY DRIVES REDUCED SMALL BOWEL FUNCTION IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: A PILOT MR ENTEROGRAPHY STUDY - **Marco Minerba et al (UK)**

SATURDAY, MARCH 7

• 11:30-11:40

OC 50 - APPLICABILITY AND DIAGNOSTIC VALUE OF CHICAGO CLASSIFICATION 4.0 IN ASSESSING ESOPHAGEAL MOTILITY DISORDERS IN SYSTEMIC SCLEROSIS: A RETROSPECTIVE SINGLE-CENTER STUDY

Carlos Gomes et al (Portugal)

• 11:40-11:50

OC 51 - DELAYED GASTRIC EMPTYING IDENTIFIES A HIGH-RISK CLINICAL SUBGROUP IN PATIENTS WITH SYSTEMIC SCLEROSIS

Francisco Alejandro Felix-Tellex et al (Spain)

11:50-12:35

BOEHRINGER INGELHEIM ROUND TABLE

See programme at page 23

Trianti Hall

12:35-13:50 • Poster tour and lunch

13:50-14:20

ARGENX SATELLITE SYMPOSIUM

See programme at page 23

Trianti Hall

14:20-14:45

INVITED LECTURE 4

Chair: **Takashi Matsushita (Japan), Stamatis Nick Liossis (Greece)**

Trianti Hall

Activity and damage - **Mandana Nikpour (Australia)**

14:45-16:45

SESSION 15 THERAPY

Chairs: **Janet Pope (Canada), Gianluca Moroncini (Italy), Rong Mu (China)**

Trianti Hall

• 14:45-15:05

Evidence to support combination therapies in SSc

Yannick Allanore (France)

• 15:05-15:25

New molecular targets in SSc- current and ongoing trials.

Dinesh Khanna (USA)

• 15:25-15:35

OC 52 - TARGETING THE PLASMA CELL NICHE IN SYSTEMIC SCLEROSIS: A CASE SERIES ABOUT THE BISPECIFIC ANTI-BCMAXCD3 ANTIBODY TECLISTAMAB IN SEVERE, TREATMENT-REFRACTORY PATIENTS

Andrea Hermina et al (Germany)

• 15:35-15:45

OC 53 - USE OF THE CD19/CD3 T CELL ENGAGER BLINATUMOMAB IN REFRACTORY SYSTEMIC SCLEROSIS: A CASE SERIES

Yannick Allanore et al (France)

• 15:45-15:55

OC 54 - TIMING MATTERS: EARLY AUTOLOGOUS STEM CELL TRANSPLANTATION SHOWS A LOWER MORTALITY IN HIGH-RISK DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS - PRELIMINARY RESULTS FROM THE UPSIDE TRIAL - **Julia Spierings et al (The Netherlands)**

• 15:55-16:05

OC 55 - RECONNOITER-1: A PHASE 2, PROSPECTIVE, BLINDED, RANDOMIZED, PARALLEL-GROUP AND CROSSOVER CLINICAL TRIAL EVALUATING AISA-021, A NOVEL CCB, IN SUBJECTS WITH RAYNAUD'S PHENOMENON (SSC-RP) - **Francesco Del Galdo et al (USA)**

CarT Cell Therapies:

• 16:05-16:25

CarT cell therapy, where are we now, opportunities and risks

Sasha Dietrich (Germany)

• 16:25-16:35

OC 56 - SAFETY AND EARLY EFFICACY OF RAPCABTAGENE AUTOLEUCEL, AN AUTOLOGOUS CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN SEVERE REFRACTORY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS - **Dinesh Khanna et al (USA)**

• 16:35-16:45

OC 57 - SAFETY AND EFFICACY OF CD19 NEX-T® (BMS-986353), A CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN SYSTEMIC SCLEROSIS (SSC): FINDINGS FROM THE BREAKFREE-1 TRIAL

Dinesh Khanna et al (USA)

16:45-17:00

WRAP UP LECTURE

Zsuzsanna McMahan (USA) & Ulf Mueller-Ladner (Germany)

Trianti Hall

17:00

CLOSING REMARKS

Trianti Hall

Systemic sclerosis-ILD and TL1A: Bridging pathogenesis, possibility, and patient care

MEGARON ATHENS CONFERENCE CENTER
ROOM: TRIANTI • ATHENS, GREECE

Thursday, 05 March 2026 • 16:30 – 17:30 (EET/UTC+2)

Chair: Petros Sfikakis (Greece)

Agenda

16:30 – 16:35	Welcome and introductions <i>Petros Sfikakis</i>
16:35 – 16:50	Beyond the surface: Tackling the multisystem burden of systemic sclerosis <i>Elizabeth Volkmann</i>
16:50 – 17:05	TL1A/DR3: A new pathway in autoimmune conditions <i>Giorgos Bamias, Dinesh Khana</i>
17:05 – 17:25	Multidisciplinary team in SSc moderation <i>Moderator: Petros Sfikakis; Panel: Giorgos Bamias, Vincent Cottin, Dinesh Khana, Elizabeth Volkmann</i>
17:25 – 17:30	Q&A and close <i>Petros Sfikakis</i>

Symposium sponsored by MSD

This program is not intended for healthcare professionals who practice in, are licensed to practice in, or reside in the U.S., its territories, or Puerto Rico.

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
HQ-NON-01383 03/26 W7757344



Chair

Petros Sfikakis

National and Kapodistrian
University of Athens
Athens, Greece

Faculty

Giorgos Bamias

National and Kapodistrian
University of Athens
Athens, Greece

Vincent Cottin

Hospital Louis Pradel
Lyon, France

Dinesh Khana

University of Michigan
Ann Arbor, Michigan, USA

Elizabeth Volkmann

UCLA
Los Angeles, California, USA

POSTER TOUR LIST

Poster tour will be organized during the Poster Session:

Friday, March 6 from 13:20 to 14:25

Saturday, March 7 from 12:35 to 13:50

Interested participants can meet the Poster Tour leader in front of the poster board of the first poster of the list.

POSTER TOUR BASIC 1 GENETICS, ENVIRONMENT, AND FIBROSIS IN SSC

Leader: **Michal Tomcik (Czech Republic)**

- P.002** The contrasting associations of ERAP1 and HLA class I regions between Systemic Sclerosis and Psoriasis - **Yuki Nishio et al**
- P.003** Analysis of mosaic chromosomal alteration in systemic sclerosis identifies phenotype-specific associations - **Yuki Nishio et al**
- P.018** TGF-beta and Shh induce endothelial-to-mesenchymal transition through the GLI transcription factors - **Natalia Riobo-Del Galdo et al**
- P.019** Collagen VIII: a promising target for anti-fibrotic treatment - **Olesya Plazyo et al**
- P.021** Genomic instability in systemic sclerosis is promoted by a PERK/FOXO1-dependent axis - **Mohammed Osman et al**
- P.023** Divergent Effects of Genetic and Diet-Induced Obesity on Dermal Adipose Tissue and Fibrosis - **Roberta Marangoni et al**

POSTER TOUR BASIC 2 EXPLORING MECHANISMS OF SSC PATHOGENESIS

Leader: **Yukie Yamaguchi (Japan)**

- P.006** S100A4 Regulated Genes are Differentially Activated in Systemic Sclerosis Skin Across Limited and Diffuse Cutaneous Subsets - **Medha Kanitkar et al**
- P.014** Common fibroblast subpopulations in skin and lung tissue in systemic sclerosis **Nikolaos Vlachogiannis et al**
- P.035** Primary cilia shortening of Systemic sclerosis dermal fibroblasts can be modulated by AURORA A kinase activity to reduce fibrotic phenotype **Begoña Caballero-Ruiz et al**
- P.044** Macrophage-Driven Osteogenic Differentiation of Mesenchymal Stem Cells in Systemic Sclerosis Calcinosis - **Kaushik Shetty et al**
- P.048** Lung NK Cells in SSC-ILD Exhibit a Paradoxical Activated-Exhausted State **Cristina Padilla et al**
- P.069** Human blood vessel organoids as a model of vasculopathy in SSC **Alexandru-Emil Matei et al**

POSTER TOUR TRANSLATIONAL ANTIBODIES AND BIOMARKERS IN SSC

Leader: **Rong Mu (China)**

- P.038** Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis - **Hanlin Yin et al**
- P.227** Identification of lipidomic biomarkers associated with disease progression in systemic sclerosis - **Rebecca Ross et al**
- P.240** Deciphering Synovitis in Systemic Sclerosis - **Muriel Elhai et al**
- P.245** Serum Type I Interferon Activity as a Biomarker of Morbimortality in Systemic Sclerosis Independent of Cutaneous Subset - **Veronica Batani et al**
- P.364** Site-specific cancer risks differ by autoantibody status and across time in patients with scleroderma - **Ami Shah et al**
- P.405** Clinical Characteristics and Ethnic Differences in Anti-Fibrillar Positive Systemic Sclerosis patients: An International Multicenter Cohort Study **Roberto D'Alessandro et al**

POSTER TOUR CLINICAL 1 SCLERODERMA CLINICAL RESEARCH SHOWCASE

Leader: **Zsuzsanna McMahan (USA)**

- P.301** Defining the symptom severity and palliative care needs of patients with systemic sclerosis - **Julie McDonald et al**
- P.317** Significant unmet needs and treatment preferences concerning patients' orofacial needs in systemic sclerosis: Results from a large international survey **Eleni Deligianni et al**
- P.346** Concomitant Sjögren's syndrome as a marker for severe visceral disease in systemic sclerosis - **Janet Pope et al**
- P.373** Travel distance to tertiary healthcare reflects disease severity and medication access in systemic sclerosis patients: insights from the Italian SPRING registry of the Italian Society of Rheumatology - **Carmilla Teresa Magnanimiti et al**
- P.408** Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment - **Blaz Burja et al**



POSTER TOUR CLINICAL 2 EMERGING TREATMENT STRATEGIES IN SSC


Leader: **Silvia Bellando Randone (Italy)**

- P.051** Fc-gamma-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T-cell therapy
Wolfgang Merkt et al
- P.252** BCMAxCD3 bispecific antibody therapy with teclistamab induces profound B- and plasma cell depletion with preliminary clinical efficacy in the treatment of refractory systemic sclerosis - a case series - **Elise Siegert et al**
- P.257** RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Dinesh Khanna et al
- P.277** Rituximab in Patients with Systemic Sclerosis Non-responsive to csDMARDs Preliminary Results of a Prospective Observational Monocentric Study over 36 Months - **Zavada Daniel et al**
- P.282** Impact of updated treatment paradigms on clinical trial referral in diffuse cutaneous systemic sclerosis - **Kimberly Lakin et al**
- P.285** Safety And Effectiveness Of Tocilizumab In Systemic Sclerosis: A Multicenter French-Italian Study - **Corrado Campochiaro et al**

POSTER TOUR CLINICAL 3 CARDIOVASCULAR AND IMAGING ADVANCES IN SSC: EMERGING TOOLS AND INSIGHTS

Leader: **John Pauling (UK)**

- P.065** Quantitative T2* magnetic resonance imaging for the detection of iron deposition in the fingers of patients with systemic sclerosis
Nikolaos Vlachogiannis et al
- P.131** Characterization of early pulmonary arterial hypertension in systemic sclerosis: a Canadian Scleroderma Research Group cohort study - **Chloé Jessen et al**
- P.141** Primary heart disease in patients with systemic sclerosis and myocardial iron deposition detected by T2* magnetic resonance - **Petros P Sfikakis et al**
- P.146** Magnetic resonance cardiopulmonary tissue characteristics in a systemic sclerosis cohort: a pilot study - **Sieiro Santos Cristiana et al**
- P.206** Cutaneous telangiectasia quantification as a predictive marker of vascular complications of Systemic Sclerosis - **Matthew Wells et al**
- P.386** Radiographic hand assessment of acro-osteolysis in systemic sclerosis provides novel insights into pathogenesis and evolution of disease burden over time - **Michael Hughes et al**



PRE-CONGRESS WORKSHOPS & COURSES

Pre-congress Workshops and Courses will be held on **Thursday, March 5**, for registered participants only.
Reservation is requested.

PRE-CONGRESS WORKSHOPS

09:00-10:30 First slot pre-congress Workshops
10:30-11:00 Coffee break
11:00-12:30 Second slot pre-congress Workshops

PRE-CONGRESS WORKSHOP 1 Room MC 3.2, level -1
Fibrotic skin manifestations - new diagnostic and therapeutic approaches
Convenor: **Thomas Krieg (Germany)**

09:00-9:10 / 11:00-11:10
Introduction: Challenges in diagnosis and therapy
Thomas Krieg (Germany)

09:10-9:25 / 11:10-11:25
Sclerosing skin diseases - how to reach a correct diagnosis and balance therapies?
Pia Moinzadeh (Germany)

09:25-09:35 / 11:25-11:35
Discussion

09:35-9:50 / 11:35-11:50
New developments in the management of patients with linear scleroderma
Kathryn Torök (USA)

09:50-10:00 / 11:50-12:00
Discussion

10:00-10:15 / 12:00-12:15
How to treat skin manifestations in SSc and other sclerosing systemic diseases
Franco Rongioletti (Italy)

10:15-10:25 / 12:15-12:25
Discussion

10:25-10:30 / 12:25-12:30
Conclusion

PRE-CONGRESS WORKSHOP 2 Room MC 3.4, level -1
Digital ulcers in SSc - A comprehensive approach to the assessment and management of digital ulcers in SSc
Convenor: **Michael Hughes (UK)**

09:00-09:05 / 11:00-11:05
Introduction and objectives
Michael Hughes (UK)

09:05-09:20 / 11:05-11:20
Clinical overview and burden of DUs
Tracy Frech (USA)

09:20-09:35 / 11:20-11:35
Assessment of Dus: definition, categorisation, and classification
Corrado Campochiaro (Italy)

09:35-09:55 / 11:35-11:55
Local management of DUs
Begonya Alcacer-Pitarch (UK)

09:55-10:15 / 11:55-12:15
Pharmacological management of DUs
Dilia Giuggioli (Italy)

10:15-10:25 / 12:15-12:25
Current challenges and future perspectives
Michael Hughes (UK)

10:25-10:30 / 12:25-12:30
Summary and closing remarks
Michael Hughes (UK)

PRE-CONGRESS COURSES

PRE-CONGRESS COURSE 1 Room MC 2, level -1
Capillaroscopy

Convenor: **Vanessa Smith (Belgium)**
 Chairs: **Ariane Herrick (UK), Maurizio Cutolo (Italy),
 Vanessa Smith (Belgium)**

08:30 - 08:50
 State of the art on capillaroscopy
Maurizio Cutolo (Italy)

08:50 - 09:10
 Pro and con of existing devices
Francesca Ingegnoli (Italy)

09:10 - 10:00
 Standardised interpretation of capillaroscopy
Vanessa Smith (Belgium)

10:00 - 10:20
 How to discern a scleroderma pattern from a non-scleroderma
 pattern: the fast track algorithm
Madelon Vonk (The Netherlands)

10:20 - 10:50
 Examination of the attendees
 Technical support by **Rosanna Campitiello (Italy)**
 and **Ramona Govender (South Africa)**

10:50- 11:00 • Coffee break

11:00 - 11:20
 Automated reading of capillaroscopy: research versus applicability
 in daily practice
Ariane Herrick (UK)

11.20 - 11.40
 Central reading of capillaroscopy and organ involvement
Claudia Ickinger (South Africa)

11:40 - 12:00
 Dermatoscopy versus nailfold video capillaroscopy
Genesis Maldonado Velez (USA) and Mislav Radic (Croatia)

12:00 - 12:20
 Standardised interpretation of capillaroscopy in children
Clare Pain (UK)

12:20 - 13:00
 6 stations of hand-on immersion in nailfold videocapillaroscopy,
 dermatoscopy, USB capillaroscopy
 Trainers: **Maurizio Cutolo, Ariane Herrick, Claudia Ickinger,
 Genesis Maldonado Velez, Clare Pain, Mislav Radic,
 Vanessa Smith, Madelon Vonk**

13:00 - 13:20
 Red flags in capillaroscopy
Maurizio Cutolo (Italy)

13:20 - 13:30
 Closure
**Ariane Herrick (UK), Maurizio Cutolo (Italy),
 Vanessa Smith (Belgium)**


PRE-CONGRESS COURSE 2 Room MC 3, level -1
 WSF/SCTC mRSS-training and standardization
 Convenor: **Dinesh Khanna (USA)**
 Teachers: **Marco Matucci-Cerinic (Italy),
 Francesco Del Galdo (UK), Yannick Allanore (France),
 Chris Denton (UK)**

- 08:30 - 09:00 - Registration
- 09:00 - 10:00 - Lecture on mRSS and demo on 2 patients
- 10:00 - 12:00 - Practice on at least 3 patients with scleroderma
- 12:00 - 12:30 - Evaluation for each attendee and reassess patients

Come and join us at the BMS Symposium

Beyond Immunosuppression: CAR T Cell Therapy - A New Era of Investigation in the Treatment of SSc

- Friday, March 6, 2026, 2026 | 14:25 – 15:25 EET
- Megaron International Conference Centre | Trianti Hall
- Systemic Sclerosis World Congress 2026 | Athens, Greece



Speakers



Dinesh Khanna, MD, MSc

Frederick G L Huetwell
Professor of Rheumatology
Professor of Internal Medicine
University of Michigan
United States



Oliver Distler, MD

Professor and Chair
Department of Rheumatology
University Hospital Zurich
Switzerland



**Claire Roddie, MD, PhD,
FRCPath, MRCP**

Consultant Hematologist &
Associate Professor in Hematology
University College London
United Kingdom

Objectives



Discuss the complexities of SSc and the unmet needs that persist in diagnosis and treatment



Understand the potential applicability of CAR T cell therapy to B cell-driven autoimmune disease



Examine recent findings with CD19 CAR T cell therapy in SSc

Agenda

Time (EET)	Presentation Title	Speaker
14:25 – 14:30	Welcome and Introductions	Dinesh Khanna
14:30 – 14:40	Unmet needs and B cell pathology in SSc	Oliver Distler
14:40 – 14:50	Evolution of CAR T cell therapy - from hematology to investigating autoimmune diseases	Claire Roddie
14:50 – 15:07	Emerging evidence for CAR T cell therapy in SSc, deep B cell depletion, and immune reset	Dinesh Khanna
15:07 – 15:15	Potential of CAR T cell therapy in SSc	Oliver Distler
15:15 – 15:25	Panel Discussion and Q&A	All

CAR, chimeric antigen receptor; CD, cluster of differentiation; CME, continuing medical education; SSc, systemic sclerosis.

This program is developed and offered by Bristol Myers Squibb and does not qualify as CME or any other type of accreditation. This is not an official program of the Systemic Sclerosis World Congress 2026.

The safety and efficacy of investigational therapies and/or uses have not been established.

SATELLITE SYMPOSIA

THURSDAY, MARCH 5

ASTRAZENECA SATELLITE SYMPOSIUM

TRIANTI HALL

16:00-16:30

FROM MECHANISMS TO MEDICINE: THE ROLE OF THE TYPE I INTERFERON PATHWAY IN SSC

Chair: **Dinesh Khanna (USA)**

• 16:00-16:05

Welcome and introductions - **Dinesh Khanna (USA)**

• 16:05-16:15

Understanding the disease burden and unmet needs in SSC
Gabriela Riemekasten (Germany)

• 16:15-16:25

Exploring Type I interferon as a driver of SSc pathology
Francesco Del Galdo (UK)

• 16:25-16:30

Delegate Q&A and close

THURSDAY, MARCH 5

MSD SATELLITE SYMPOSIUM

TRIANTI HALL

16:30-17:30

SYSTEMIC SCLEROSIS-ILD AND TL1A: BRIDGING PATHOGENESIS, POSSIBILITY, AND PATIENT CARE

Chair: **Petros Sfikakis (Greece)**

• 16:30-16:35

Welcome and Introductions - **Petros Skifakis (Greece)**

• 16:35-16:50

Beyond the Surface: Tackling the Multisystem Burden of Systemic Sclerosis - **Elizabeth Volkmann (USA)**

• 16:50-17:05

TL1A/DR3: A new pathway in autoimmune conditions
Dinesh Khanna (USA), Giorgos Bamias (Greece)

• 17:05-17:25

Multidisciplinary team in SSc- Moderation to the panel
Petros Sfikakis (Greece), Vincent Cottin (France), Elizabeth Volkmann (USA), Dinesh Khanna (USA), Giorgos Bamias (Greece)

• 17:25-17:30

Q&A from Audience and close

FRIDAY MARCH 6

BOEHRINGER INGELHEIM SATELLITE SYMPOSIUM

TRIANTI HALL

11:50-13:20

IMPROVING THE PATIENT JOURNEY IN SSC: FROM EARLY DIAGNOSIS TO TREATMENT AND ONGOING CARE

• 11:50-11:55

Introduction and welcome - **Dinesh Khanna (USA)**

• 11:55-12:35

Optimizing treatment approaches for patients with SSc: now and in the future - **Dinesh Khanna (USA), Francesco Del Galdo (UK), Zsuzsanna McMahan (USA), Vanessa Smith (Belgium)**

• 12:35-13:15

Working together to deliver best practice multidisciplinary care for patients with SSc - **Dinesh Khanna (USA), Francesco Del Galdo (UK), Zsuzsanna McMahan (USA), Vanessa Smith (Belgium)**

• 13:15-13:20

Wrap-up and close - **Dinesh Khanna (USA)**

FRIDAY MARCH 6

BRISTOL-MYERS SQUIBB SATELLITE SYMPOSIUM

TRIANTI HALL

14:25-15:25

BEYOND IMMUNOSUPPRESSION: CAR T CELL THERAPY, A NEW ERA OF INVESTIGATION FOR THE TREATMENT OF SSC

• 14:25-14:30

Welcome & Introductions - **Dinesh Khanna (USA)**

• 14:30-14:40

Unmet needs and B cell pathology in SSc
Oliver Distler (Switzerland)

• 14:40-14:50

Evolution of CAR T cell therapy - from haematology to investigating autoimmune diseases - **Claire Roddie (UK)**

• 14:50-15:07

Emerging evidence for CAR T cell therapy in SSc, deep B cell depletion and immune reset - **Dinesh Khanna (USA)**

• 15:07-15:15

Potential of CAR T cell therapy in SSc
Oliver Distler (Switzerland)

• 15:15-15:25

Panel Discussion and Q&A
Dinesh Khanna (USA, moderator), Oliver Distler (Switzerland) and Claire Roddie (UK)

SATURDAY, MARCH 7

BOEHRINGER INGELHEIM ROUND TABLE

TRIANTI HALL

11:50-12:35
**FROM DIAGNOSIS TO FOLLOW-UP: PAVING A TWO-WAY
STREET IN PATIENT-PHYSICIAN COMMUNICATIONS**

- 11:50-11:55
Introduction and welcome - **Sue Farrington (UK)**
- 11:55-12:30
Paving a two-way street in patient-physician communications
**Sue Farrington (UK), Madelon Vonk (The Netherlands),
Ilaria Galletti (Italy)**
- 12:30-12:35
Wrap-up and close - **Sue Farrington (UK)**

SATURDAY, MARCH 7

ARGENX SATELLITE SYMPOSIUM

TRIANTI HALL

13:50-14:20
**ESCAPING THE MAZE: CLUES TO THE FUTURE
OF SYSTEMIC SCLEROSIS MANAGEMENT**
Chair: **Marco Matucci-Cerinic (Italy)**

- 13:50-13:53
Welcome - **Marco Matucci-Cerinic (Italy)**
- 13:53-14:03
Choosing a path: How autoantibodies inform our understanding of
SSc - **Marie-Elise Truchetet (France)**
- 14:03-14:13
eSScape the maze: Emerging therapeutic solutions in SSc
Dinesh Khanna (USA)
- 14:13-14:20
Finding the way out together: Audience discussion on the future of
SSc management - **Marco Matucci-Cerinic (Italy),
Marie-Elise Truchetet (France), Dinesh Khanna (USA)**

PATIENT CONGRESS

Through the work of patient advocacy, patients, survivors, and caregivers, aim to amplify the voices of those affected, ensuring their rights and well-being are protected within the healthcare system. This can encompass groups that develop patient centric policies, government bodies crafting legislation to enhance healthcare systems, or patients taking an active role, resulting in a collective effort aspiring to a healthcare system that adequately addresses the diverse needs of individuals dealing with health challenges.

Drawing on their lived experience and a deep understanding of their disease, healthcare systems, and engagement with healthcare professionals, patients can assume responsibility and advocate as informed, competent representatives of their peers, on an equal footing with other stakeholders. This is particularly true for those patients who have undergone specialised training in key areas such as healthcare systems, research and development, or HTA.

However, patient advocacy extends beyond a merely passive, advisory role in the interplay between those stakeholders and their respective interests.

As an integrative, driving and enriching force, patient advocates can make significant contributions in the field of research, bringing their lived experience and refined expertise to visibly step forward as representatives of an entire patient community. For instance, at the 9th Systemic Sclerosis Patient World Congress, held this year in Athens.

This congress, hosted by the Federation of European Scleroderma Associations (FESCA), is part of the larger Systemic Sclerosis World Congress, organised by the

World Scleroderma Foundation. Both events feature renowned experts and opinion leaders from the field of scleroderma - with the fundamental, yet crucial difference that the Systemic Sclerosis Patient World Congress is designed by patients, for patients.

The 9th Systemic Sclerosis Patient World Congress offers an extensive and balanced agenda, providing attendees the chance to learn from leading scleroderma experts and patient advocates in an open and welcoming environment. Interactive sessions provide opportunities for questions, discussions, and practical takeaways to support those affected by scleroderma, addressing topics such as drug development, clinical practice, the latest research, and the often-overlooked topic of mental health.

With patient experts embedded throughout the programme, the Congress elevates lived experience, putting patient expertise centre stage, while with its scientific component, building a bridge to the World Scleroderma Congress. This synergy invites mutual understanding, perspective shifts, and exploration of diverse viewpoints.

Consequently, many of the sessions of the 9th Systemic Sclerosis Patient World Congress are designed to foster networking and the direct exchange of experience, ideas and knowledge, emphasising the importance of collaboration, and that only together, with effective patient engagement, can a real difference be made for all those affected by systemic sclerosis.

PROGRAMME

FRIDAY, MARCH 6 • BANQUETING ROOM, LEVEL -2

TIME	TITLE	SPEAKERS
09:00 09:30	Opening and welcome	Sue Farrington Christina-Maria Kravvari Marco Matucci-Cerinic Katy Antonopoulou
09:30 10:30	ROUNDTABLE Accelerating Access: Breaking Barriers to Therapies	Spyros Sapounas Annie Gilbert Mary Wheatley Moderator: Ilaria Galetti
10:30 11:00	Coffee break	
11:00 12:00	Keep on Moving: Prehab & Rehab	Maria Koulopoulou Michael Oeschger Alain Lescoat Kyriaki Keramiotou Moderator: Henrik Pettersson
12:00 13:00	Lunch break	
13:00 14:00	VEDOSS: The Present and the Future of Early SSc Diagnosis	Marco Matucci-Cerinic Monica Holmner Moderator: Beata Garay
14:00 14:15	Coffee break	
14:15 15:15	Taking Control: Self-Management of calcinosis and digital ulcers	Tanaka Ngcozana Mercè Piñero Michael Hughes Moderator: Luna Toppenberg
15:15 16:15	Breaking the silence: Intimacy living with SSc	Cosimo Bruni Maria Grazia Lazzaroni Anne Schouffoer Kim Fligelstone Moderator: Linda Schraven



SATURDAY, MARCH 7 • BANQUETING ROOM, LEVEL -2

PATIENT CONGRESS

TIME	TITLE	SPEAKERS
09:00 10:00	Navigating GI complications: Funduplication, fecal incontinence and GERD	Zsuzsanna McMahan Catarina Leite Yannick Allanore Moderator: Ilaria Galetti
10:00 11:00	Eat better, feel better: Understanding the role of diet in managing the disease	Susanna Proudmann Annelise Roennow Elizabeth Volkmann Moderator: Kristofer Andreasson
11:00 11:30	Coffee break	
11:30 12:15	Understanding CAR-T: Opportunities and challenges for Scleroderma Patients	Corrado Campochiaro Michael Oeschger Moderator: Maureen Mayes
12:15 13:15	Artificial Intelligence in SSc: Empowering Patient Support	John Pauling Janet Pope Edith Brown Moderator: Annelise Roennow
13:15 14:15	Lunch break	
14:15 15:15	ROUNDTABLE What's new In SSc treatment	Brian Lee Michael Oeschger Moderator: Sue Farrington
15:15 16:15	Feel better to live better	Rita Shrimer Janet Poole Moderator: Catarina Leite
16:15 16:30	Closing	Ilaria Galetti
16:30	Farewell reception	



From diagnosis to follow-up: paving a two-way street in patient–physician communications

Date:

Saturday, 7 March 2026, 11:50–12:35 (EET)

Venue:

Trianti Auditorium, Megaron Athens International
Conference Centre, Athens, Greece

Join and share your insights at the Boehringer Ingelheim-sponsored roundtable discussion.

During this roundtable, the panelists will discuss their perspectives on the key communication challenges faced by patients and physicians, providing strategies to enhance education and facilitate truly informed patient–healthcare professional dialogue throughout the care pathway.

Agenda

Speakers: Sue Farrington (**Moderator**, Chief Executive of SRUK and President of FESCA), Madelon Vonk (Associate Professor and Rheumatologist at Radboud University Medical Center), Ilaria Galetti (Patient Advocate, Vice President of FESCA and GILS)

Time (EET)	Session	Speaker/s
11:50–11:55	Introduction and welcome	Sue Farrington
11:55–12:30	Paving a two-way street in patient–physician communications	All
12:30–12:35	Wrap-up and close	Sue Farrington

We look forward to welcoming you to our roundtable discussion!

Visit Boehringer Ingelheim at Booth 04 for more information and resources.

POSTER SESSION

Poster session will take place on:

- **Friday, March 6 from 13:20 to 14:25** and
- **Saturday, March 7 from 12:35 to 13:50**

in the Poster Area 1 at level 0 (from P.001 to P.125) and Poster Area 2 at level 1, balcony, (from P.126 to P.418)

Authors have been given a number and must be fixed on the poster board marked with the same number.

Poster panel height is cm 250 and the maximum usable surface, portrait orientation is **cm. 95 (width) and cm. 235 (height)**.

Posters can be hanged on:

- **Thursday, March 5 from 11:00 to 16:00**
- **Friday, March 6 from 08:00 to 13:00**

and removed within 16:00 of Saturday, March 7.

Authors are kindly requested on Friday March 6 and Saturday March 7 to stand by their poster during the Poster Session time for discussion with delegates. Otherwise please hang a note to inform when you will be available.

All presentations, discussions and questions will be in English.

Tape to hang posters will be distributed at the poster information desk in the Poster Area 1.

Authors must strictly respect the above-mentioned timing for hanging and removing posters.

Posters not removed by the scheduled time will be removed by the Organizing Secretariat and thrown away. The Organizing Secretariat cannot be addressed for any responsibility in posters' loss.

Poster Tour information at page: 16

01.PATHOGENESIS - GENETICS, ENVIRONMENTAL TRIGGERS, AND THE INFLUENCE OF GENDER

P.001 Identification and Functional Characterization of Cell Type-Specific Causal Variants in Systemic Sclerosis

Honglin Zhu

P.002 The contrasting associations of ERAP1 and HLA class I regions between Systemic Sclerosis and Psoriasis

Ishikawa Yuki, Allanore Yannick, Yuki Nishio, Issei Imoto, Hachulla Eric, Mouthon Luc, Truchetet Marie-Elise, Stephanie Debette, Chikashi Terao

P.003 Analysis of mosaic chromosomal alteration in systemic sclerosis identifies phenotype-specific associations

Yuki Nishio, Shunsuke Uchiyama, Yuki Ishikawa, Xiaoxi Liu, Seiya Takada, Tomoki Kuroshima, Keitaro Matsuo, Yasushi Kawaguchi, Masataka Kuwana, Issei Imoto, Yuki Yamaguchi, Chikashi Terao

P.004 Impact of active and passive exposure to tobacco on Systemic Sclerosis manifestations, disability and quality of life- Data from a Tertiary Centre

Sara Amaro Lopes, Mariana Diz-Lopes, Carlos Marques-Gomes, Marina Oliveira, Bárbara Fernandes Esteves, Miguel Correia Natal, Ana da Rocha Sá, Bruno Miguel Fernandes, Georgina Terroso, Lúcia Costa, Raquel Miriam Ferreira

P.005 Clinical features and autoimmune profile in systemic sclerosis patients of Jewish origin from a single rheumatology center in Israel

Irena Litinsky, Yifat Alkalai, Dafna Capelusnik, Sara Pel, Julia Berman, Ori Elkayam

P.006 S100A4 Regulated Genes are Differentially Activated in Systemic Sclerosis Skin Across Limited and Diffuse Cutaneous Subsets

Medha Kanitkar, Philip Yee, Stefano Rodolfi, Kristina Clark, Voon Ong, Christopher Denton

P.007 Impact of Occupational Pollutant Exposure on Clinical and Serological Phenotypes in Systemic Sclerosis

Carrión-Barberà Irene, Sanhuja I Sanz Martina, Tió Laura, Triginer Laura, Lee María, Guillén-Del Cast Alfredo, Ribes Anna, Valencia Muntalà Lidia, Galarza David, Monfort Jordi, Salman-Monte Tarek Carlos, Narváez Javier, Simeón-Aznar Carmen Pilar, Pros Anna

P.008 Evaluation of the History of Trauma in Systemic Sclerosis: Prevalence and Patient Characteristics

Nahal Ghanoongooi, Samuel Good, Ju Young Lee, Arissa Young, Elizabeth Volkman

P.009 Antecedent Ambient PM2.5 and Constituent Exposure Associations with Scleroderma-Associated Autoantibodies

Samantha Branton, Gillian Goobie, Sharon Kim, Maureen Laffoon, Robert Lafyatis, Robyn Domsic

02.PATHOGENESIS - FIBROSIS

- P.010 Mitochondrial DNA escape from Ca²⁺-overload-mitochondria provokes fibrosis via cGAS-STING pathway activation in skin fibroblasts of SSC**
Xiaoyun Zhang, Yingyu Wang, Weiguo Wan, Hejian Zou, Xue Yang
- P.011 EZH2 Promotes Lung Fibrosis by Disrupting the Balance Between Profibrotic and Pro-resolving Alveolar Macrophages**
Qiming Meng, Shasha Xie, Bingying Dai, Sijia Liu, Hui Luo, *Honglin Zhu*
- P.012 Non-muscle myosin II isoforms (NMII) are involved in Systemic Sclerosis skin fibrosis and collagen deposition**
Barbara Russo, Fanny Noulet, Xuewei Jian, Elisa Burri, Jeremy Kessler, George Radu Romanescu, Nicolo Brembilla, Bernard Wehrle-Haller, Maria Shutova, Wolf-Henning Boehncke
- P.013 The stromal vascular fraction mitigates bleomycin-induced fibrosis in mice**
Jiucun Wang, Zonghao Liu, Ziyu Wang, Mengqi Shi, Yahui Chen, Xiangguang Shi
- P.014 Common fibroblast subpopulations in skin and lung tissue in systemic sclerosis**
Nikolaos Vlachogiannis, Kleio-Maria Verrou, Konstantinos Kontodimas, Eleftherios Zormpas, Oliver Distler, Xaralabos Varelas, Petros P. Sfikakis
- P.015 A pathogenic role of microvasculopathy-related hemorrhagic deposition of iron in the skin: ex vivo results in systemic sclerosis**
Nikolaos Vlachogiannis, Aikaterini Avdi, Kleio-Maria Verrou, Eleftherios Zormpas, Petros P. Sfikakis
- P.016 Tryptophan metabolism dysregulation and its pathogenic roles in systemic sclerosis**
Takehiro Takahashi, Takuya Takahashi, Masahiro Watanabe, Yuichiro Segawa, Kenta Oka, Toshiya Takahashi, Masamitsu Maekawa, Yoshihide Asano
- P.017 The PIM and ATK kinases cooperatively support lung myofibroblast activation in SSC by regulating energy and protein metabolism**
Ioannis Papaioannou, Xu Shiwen, Ping Kang, Voon Ong, Christopher P. Denton, Elizabeth Renzoni, Markella Ponticos, *Jan-Willem Taanman*, David Abraham
- P.018 TGF β and Shh induce endothelial-to-mesenchymal transition through the GLI transcription factors**
Natalia Riobo-Del Galdo, Esther Perez-Barreiro, Francesco Del Galdo
- P.019 Collagen VIII: a promising target for anti-fibrotic treatment**
Olesya Plazyo, Poulami Dey, Jake Erba, Rachael Bogle, William Brodie, Alexander Cai, Lam Tsoi, Eliza Tsoi, Dinesh Khanna, John Varga, Johann Gudjonsson
- P.020 Crystalline silica as an aetiological factor of systemic sclerosis: from epidemiological data to mechanistic considerations in mouse models**
Salomé Patry, Laura Morin, Lelong Marie, Alice Ballerle, Erwan Dumontet, Francois Huaux, Catherine Cavalin, Valerie Lecureur, Alain Lescoat
- P.021 Genomic instability in systemic sclerosis is promoted by a PERK/FOXO1-dependent axis**
Lamia Khan, Junqin Wang, Charmaine van Eeden, Carmanah Hunter, Lisa Willis, Caylib Durand, Jan Storek, Janet Pope, Benjamin Korman, Jan Willem Cohen Tervaert, Robert Gniatecki, *Mohammed Osman*
- P.022 Contribution of mitochondrial DNA to the onset and maintenance of inflammation in systemic sclerosis patients**
Martina Orlandi, Sinigalia Giorgia, Amelia Spinella, Marco De Pinto, Isabella Martuscello, Giorgia Roveta, Luca Keller, Marcello Pinti, Dilia Giuggioli
- P.023 Divergent Effects of Genetic and Diet-Induced Obesity on Dermal Adipose Tissue and Fibrosis**
Roberta Marangoni, Gaochan Wang, Stacey Dummel, Benjamin Korman
- P.024 Generating IL-17B and IL-17D specific antibodies to investigate their potential role in driving Systemic Sclerosis**
Avneet Kaur Manghara, Alastair Lawson, Voon Ong, David Abrahams
- P.025 CLEC3B is a Key Regulator and Potential Therapeutic Target in Skin Fibrosis**
Qianqian Ma, Qingmei Liu, Weilin Pu, *Jiucun Wang*, Yuhong Liu
- P.026 Treprostinil, a Prostacyclin Analog, Mitigates Profibrotic Signaling in Scleroderma Fibroblasts via the EP2-PPARG-SMARCA4 Pathway**
Bashar Kahaleh, Yongqing Wang
- P.027 Molecular markers for disease progression in Systemic Sclerosis – Exosomes and CX3CR1 T cell subsets**
Josna Joseph, Abarna R, Manna Sera Jacob, Sandhya Rani B, Reka K, Phaneendra Datari, John Mathew
- P.028 Interleukin-19 is related to systemic sclerosis, especially interstitial lung disease**
Yuki Ichimura, Hikaru Hirose, Tomoaki Higuchi, Akiko Tochimoto, Yasushi Kawaguchi
- P.029 The PD-1 pathway as a new treatment target in systemic sclerosis**
Maitri Aspari, Voon Ong, Klaus Søndergaard, Esben Næser, Malene Hvid, Angela Tam, Shiwen Xu, Xinyue Bian, Henry Lopez, Christopher Denton, David Abraham, Bent Deleuran, *Stinne Greisen*
- P.030 Evaluation of the altered miRNA and mRNA levels and their biological functions in peripheral blood mononuclear cells of systemic sclerosis patients**
Dóra Csige, Szilárd Pólska, János Rózsa, Sára Lipták-Lukácsik, Monika Bodoki, Dóra Tari, Szilvia Szamosi, Zoltán Szekanez, Gabriella Szűcs, Levente Bodoki
- P.031 Distinct Temporal Dynamics of Inflammation and Fibrosis in A Prolonged Experimental Model of Systemic Sclerosis**
Aurora Collet, Manel Jendoubi, Thomas Guerrier, Alexis Largy, Farah Mana, Silvia Speca, Sylvain Dubucquoi, David Launay
- P.032 Evaluation of Serum Bromodomain-4 Levels in patients with systemic sclerosis and its association with disease characteristics**
Erhan Kupcuk, Emine Busra Ata, Ezgi Cimen Gunes, Omer Faruk Kirlangic, Taner Ozgurtas, Emre Tekgoz, Sedat Yilmaz, *Seda Colak*
- P.033 BAG3 as a possible therapeutic target and biomarker in systemic sclerosis**
Iannone Claudia, Margot De Marco, Antonina Minniti, Angela D'Ardia, Paola Manzo, Antonia Falco, Liberato Marzullo, Alessandra Rosati, Roberto Caporali, Maria Caterina Turco, Nicoletta Del Papa

02.PATHOGENESIS - FIBROSIS

- P.034 Navigating the single-cell landscape of colonic disease in systemic sclerosis**
Kristina Clark, Moustafa Attar, Matthias Friedrich, Charles Murray, Alexander Clarke, Christopher Denton
- P.035 Primary cilia shortening of Systemic sclerosis dermal fibroblasts can be modulated by AURORA A kinase activity to reduce fibrotic phenotype**
 Rebecca A. Wells, Begoña Caballero-Ruiz, Panji Mulipa, Alex J. Timmis, Ioanna Ch. Georgiou, Colin A. Johnson, Francesco Del Galdo, Rebecca L. Ross, Natalia A. Riobo-Del Galdo
- P.036 The involvement of pDC and ER stress in systemic sclerosis-associated fibrosis**
 Beatriz H Ferreira, Mariana D Machado, Carolina Mazedo, Catarina R Silva, Eduardo Dourado, Camila Castro, Fátima Leite-Pinheiro, Andreia Mendes, Luis Mendes, Adrienne W Paton, James C Paton, Philippe Pierre, Catarina R Almeida

03.PATHOGENESIS - IMMUNE DYSREGULATION, INCLUDING AUTOANTIBODIES

- P.037 Anti-protein arginine methyltransferase 5 (PRMT5) antibodies in the assessment of patients with systemic sclerosis**
Marco Binda, Anna Ghirardello, Beatrice Moccaldi, Anna Cuberli, Andrea Benini, Marta Tonello, Roberta Ramonda, Elisabetta Zanatta
- P.038 Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis**
Hanlin Yin, Wanyi Lin, Zhangyi Zhao, Chenhan Jia, Fenglin Wu, Xuesong Liu, Liangjing Lu
- P.039 The occurrence of vitamin D deficiency and insufficiency in patients with systemic sclerosis**
Ewa Wielosz, Magdalena Dryglewska, Natalia Siedlecka, Bozena Targonska-Stepniak
- P.040 Closing the seronegative gap in systemic sclerosis with immunoprecipitation-mass spectrometry: a multicentric international study**
 Birthe Michiels, Jean-Baptiste Vulsteke, Marie Vanthuyne, May Choi, Tikly Mohammed, Carole Lacout, Antoine Brochard, Frédéric Coutant, Katja Lakota, Ellen De Langhe, Doreen Dillaerts, Tom Dehaemers, Jonas De Leeuw, Sasa Cucunik, Nicole Fabien, Emeline Vinatier, Neil McHugh, Sarah Tansley, Marvin J Fritzel, Frédéric Houssiau, Xavier Bossuyt

- P.041 Demographic and Clinical Features of Systemic Sclerosis Patients With Anti-U1RNP Antibodies: a European Scleroderma Trials and Research (EUSTAR) Analysis**
Madeleine Venables, Wanlong Wu, Rucsandra Dobrota, Oliver Distler, Eric Hachulla, Paolo Airò, Marco Matucci-Cerinic, Francesca Cozzi, Yannick Allanore, Peter Carreira, Andra Balanescu, Ivan Castellvi, Alberto Cauli, Christopher Denton, Michele Iudici David Launay, Ulf Mueller-Ladner, Elena Rezus, Valeria Riccieri, Gabriela Riemekasten, Bojana Stamenkovic, Elisabetta Zanatta, Shuang Ye, Suzana Jordan, Marie-Elise Truchetet, Masataka Kuwana, Francesco Del Galdo
- P.042 Coexistence of All Three Major Systemic Sclerosis-Specific Autoantibodies in a Single Patient**
 Stavroula Magaliou, Nikolaia Zioga, Arriana Gkouvi, Vasiliki Syrmou, Maria Karapli, Eleni Patrikiou, Christina Katsiari, Dimitrios Bogdanos, Theodora Simopoulou
- P.043 Predictive Value of Classical and Emerging Autoantibodies for Cardiac Dysfunction in Systemic Sclerosis: Systematic Review**
Mislav Radic, Petra Simac Prizmic, Tina Becic, Hana Dogas, Ivana Jukic, Damir Fabijanic, Josipa Radic
- P.044 Macrophage-Driven Osteogenic Differentiation of Mesenchymal Stem Cells in Systemic Sclerosis Calcinosis**
Kaushik Shetty, Sandra Lopez Garces, Bahja Ahmed Abdi, Kaifeng Liang, Zestranjyan Kannan, Henry Lopez, Clayton Yates, Voon Ong, Christopher Denton, Peter Butler, David Abraham, Richard Stratton
- P.045 Autoantibodies targeting the angiotensin II type 1 receptor contribute to endothelial dysfunction in systemic sclerosis**
Carolin Schmidt, Benedikt Fels, Alexander Hackel, Antje Müller, Jens Y. Humrich, Kristina Kusche-Vihrog, Gabriele Riemekasten, Reza Akbarzadeh
- P.046 Impact of genetic background on topoisomerase immunization in mouse model**
Salomé Patry, Laura Morin, Marie Lelong, Erwan Dumontet, David Launay, Alain Lescoat, Valerie Lecreur
- P.047 Cytokine profile of individuals with raynaud's phenomenon with and without systemic sclerosis**
Pinja Parmanne, Antti Kuuliala, Alexandra Häme, Kari Eklund, Pia Isomäki, Riitta Luosjärvi, Marjatta Leirisalo-Repo, Krista Kuuliala
- P.048 Lung NK Cells in SSC-ILD Exhibit a Paradoxical Activated-Exhausted State**
Cristina Padilla, John Sembrat, Tracy Tabib, Robert Lafyatis
- P.049 Oxygen-Transport-Cascade and dysregulated interferon signals are associated with Severe Fatigue in patients with Systemic Sclerosis**
 Charmaine van Eeden, Janet Pope, Udo Mulder, Desiree Redmond, Erin Reynolds, Murray Baron, Robert Gniadecki, Maggie Larché, May Choi, Sabrina Hoa, Carter Thorne, Elena Netchiporouk, Laura Ross, Jan Willem Cohen Tervaert, Mohammed Osman
- P.050 The role of anti-G protein-coupled receptors antibodies in the assessment of systemic sclerosis-primary heart involvement**
Beatrice Moccaldi, Giovanni Civieri, Annagrazia Cecere, Marco Binda, Marta Vadori, Laura Iop, Marta Tonello, Anna Cuberli, Andrea Benini, Emanuele Cozzi, Roberta Ramonda, Francesco Tona, Elisabetta Zanatta

03. PATHOGENESIS - IMMUNE DYSREGULATION, INCLUDING AUTOANTIBODIES

- P.051 Fc-gamma-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T-cell therapy**
Merle Freitag, Philipp Kolb, Pauline Schröder, Lea Rodon, Franca Deicher, Ayla Stütz, Georg Schett, [Wolfgang Merkt](#)
- P.052 The Role of TLR7 and TLR9 in the pathogenesis of Systemic Sclerosis**
[Takashi Matsushita](#), Chenyang Wang, Yasuhiro Hamaguchi
- P.053 Clinical and Serological Expression of Scleroderma in Jewish vs. Arab Patients in Israel**
[Yair Levy](#), Hitam Hagog Natour, Aiman Natour, Abdullah Asli, Izabella Elgardt
- P.054 Anti-NOR-90 autoantibodies and clinical associations in systemic sclerosis: an international retrospective cohort study**
Cheng Shen, Marie Hudson, Susanna Proudman, Jenny Walker, Wendy Stevens, Mandy Nikpour, Shervin Assassi, Maureen Mayes, Mianbo Wang, Valerie Leclair, Yves Troyanov, [Maggie Larche](#), Murray Baron, May Choi, Mohammed Osman, Janet Pope, Carter Thorne, Canadian Scleroderma Research, Australian Scleroderma Interest, Genetics vs Envnt in Scleroderma Outcome, Marvin Fritzer, Sabrina Hoa
- P.055 Clinical manifestations and long-term outcomes of systemic sclerosis patients with various combinations of RNA polymerase I, II and III antibodies**
[Maureen Laffoon](#), Leah Wunsch, Namitha Nair, Kwonho Jeoung, Lan Yu, Robert Lafyatis, Robyn Domsic
- P.056 Serum concentrations of Peroxiredoxin-4 (PRDX4) and -6 (PRDX6) are associated with disease progression in patients with systemic sclerosis (SSc).**
[Otylia Kowal-Bielecka](#), Krzysztof Krajewski, Krzysztof Kowal, Natalia Szymanska
- P.057 Revisiting Anti-Nucleolar Antibody Associations in Systemic Sclerosis by Organ and Disease Subset**
[Medha Kanitkar](#), Christopher Denton, Voon Ong
- P.058 Dual Role of Extracellular Vesicle Size and Concentration as Inverse Correlates in Autoantibody Profiling and Organ Involvement Prediction in Systemic Sclerosis**
[Alexander Hackel](#), Precious Bonney, Moritz Jägermann, Hanna Grasshoff, Sebastian Jendrek, Reza Akbarzadeh, Gabriela Riemekasten
- P.059 Anti-SSA, Anti-SSB and Anti-Ro52 in Systemic Sclerosis: More Than Just Sicca?**
[Carlos Gomes](#), Mariana Diz-Lopes, Miguel Natal, Bárbara Esteves, Sara Lopes, Ana Sá, Marina Oliveira, Mariana Sebastião, Miguel Bernardes, Raquel Ferreira, Georgina Terroso, Lúcia Costa
- P.060 Interleukin-6 as a marker of pulmonary involvement in systemic sclerosis**
[Ljudmila Garzanova](#), Lidia Ananyeva, Olga Koneva, Olga Ovsyannikova, Oxana Desinova, Mayya Starovoytova, Rushana Shayakhmetova, Anna Khelkovskaya-Sergeeva, Anastasiya Avdeeva, Mikhail Diatrotov

- P.061 Triple-negative systemic sclerosis: epidemiological profile and implications for pathogenesis from the spring registry**
[Veronica Batani](#), Ilaria Cavazzana, Martina Orlandi, Corrado Campochiaro, Silvia Bosello, Fabio Cacciapaglia, Francesca Ingegneri, Veronica Codullo, Valeria Ricceri, Franco Franceschini, Dilia Giuggioli, Lorenzo Dagna, Rossella De Angelis, Clodoveo Ferri, Marco Matucci-Cerinic, Giacomo De Luca
- P.062 Antinuclear antibodies from systemic sclerosis patients enter cells via a clathrin-mediated endocytosis mechanism and interact with their intracellular antigen.**
[Aurélien Chepy](#), Martel Marie-Elise, Vivier Solange, Tardivel Meryem, Bongiovanni Antonino, Mistretta Marie, Secq Maxime, Guilbert Lucile, Hachulla Eric, Dubucquoi Sylvain, Launay David, Sobanski Vincent
- P.063 Innate lymphoid cell alterations and enhanced intestinal fibrosis in systemic sclerosis: evidence for an immune contribution to gastrointestinal involvement**
[Louis Bébéar](#), Alexis Jean, Pauline Riviere, Damien Brisou, Isabelle Douchet, Nathalie Senant, Edouard Forcade, Estibaliz Lazaro, Christophe Richez, Cécile Bordes, Marie-Elise Truchetet
- P.064 Isolated changes as clinical markers in systemic sclerosis**
[Svetlana Agachi](#), Liliana Groppa, Lucia Andries, Larisa Rotaru, Oxana Bujor, Maria Lungu

04. PATHOGENESIS - VASCULOPATHY

- P.065 Quantitative T2* magnetic resonance imaging for the detection of iron deposition in the fingers of patients with systemic sclerosis**
[Nikolaos Vlachogiannis](#), Artemis Galani, Vassilis Koutoulidis, Georgia Lymperepoulou, Thomas G Maris, Vasiliki Bourmia, Stylianos Panopoulos, Maria Tektonidou, Lia Angela Mouloupoulos, Petros P. Sfikakis
- P.066 Dynamic OCT of the skin reveals microvascular pathology of clinically unaffected skin in patients with Very Early Diagnosis of SSc**
[Duygu Temiz Karadag](#), Alp Eren Aydin, Marco Minerba, Ayse Cefle, Francesco Del Galdo
- P.067 Anti-endothelial cell antibodies as biomarkers of endothelial dysfunction in Systemic sclerosis (SSc) patients**
Chiara Pellicano, [Annalisa Villa](#), Giancarlo D'ippolito, Gabriella Cusa, Valeria Carnazzo, Federica Laterza, Umberto Basile, Antonietta Gigante, Edoardo Rosato
- P.068 Optical coherence tomography angiography: a window on Systemic Sclerosis microangiopathy**
[Martina Orlandi](#), Tommaso Verdina, Filippo Santoro, Mohammed El Alouani, Matteo Gibertini, Giorgia Roveta, Amelia Spinella, Marco De Pinto, Dilia Giuggioli
- P.069 Human blood vessel organoids as a model of vasculopathy in SSc**
Yanhua Xiao, Xuezi Hong, Langxian Zhi, Yi-Nan Li, Martin Regensburg, Franz Marxreiter, Boris Görg, Sarah Koziel, Andrea-Hermina Györfi, Tim Filla, Peter-Martin Bruch, Philipp Tripal, James Adjaye, Sascha Dietrich, Jürgen Winkler, Jörg H.W. Distler, [Alexandru-Emil Matei](#)

04. PATHOGENESIS - VASCULOPATHY

- P.070** **Prevalence of Venous Thromboembolism in Patients with Scleroderma: A Comparative Study**
Yair Levy, Hitam Hagog Natour, Aiman Natour, Siwar Shekh Yusuf, Izabella Elgardt
- P.071** **Endothelial-Specific Deletion of RIPK3 Reduces Lung Inflammation and Fibrosis in a Sex-Dependent Manner in a Murine Model of Systemic Sclerosis-Associated Interstitial Lung Disease**
Charmain Johnson, Courtney Griffin
- P.072** **Acute Kidney Injury and its implication on kidney function in patients with Systemic Sclerosis**
Katya Dolnikov, Alexandra Balbir-Gurman, Kochava Toledano, Yonit Tavor, Sami Giryes, Suheir Assady, Yolanda Braun-Moscovici
- P.073** **Neutrophil extracellular traps and thromboinflammatory markers in limited systemic sclerosis: non-specific correlation with clinical and serological phenotype**
Aiki Venetsanopoulou, Maria Ntinopoulou, Nikolaos Koletsos, Paraskevi Voulgari, Akrivi Chrysanthopoulou
- P.074** **Prognostic value of telangiectasia score in systemic sclerosis: a retrospective cohort study from a tertiary center**
Filipa Canhão André, João Oliveira, Margarida Coutinho, Sara Costa, Maria Joao Cadorio, Fabiana Gouveia, Mariana Rodrigues, Fernando Albuquerque, Marcelo Neto, Tania Santiago, Maria Joao Salvador
- P.075** **Analysis of the dynamics of clinical parameters and serum angiogenic factors in systemic sclerosis patients undergoing tocilizumab treatment**
Yuichiro Segawa, Takehiro Takahashi, Takuya Takahashi, Kenta Oka, Yumi Kambayashi, Toshiya Takahashi, Yoshihide Asano
- P.076** **Micro-and macro-vascular damage in systemic sclerosis: an observational prospective cohort study (VASSC study)**
Vincenzo Zaccone, Silvia Agarbatì, Silvia Contegiacomo, Chiara Paolini, Carolina Clementi, Matteo Mozzicafreddo, Silvia Svegliati Baroni, Lorenzo Falsetti, Devis Benfaremo, Gianluca Moroncini

05. INTERSTITIAL LUNG DISEASE

- P.077** **Preclinical lung volume loss in Very Early Diagnosis of Systemic Sclerosis (VEDOSS): characterization of early forced vital capacity (fvc) decline and clinical evolution**
Fiammetta Danzo, Martina Iacobino, Lorenzo Beretta, Marta Mozzo, Antonella Arcadu, Silvia Dellafiora, Marco Mantero, Letizia Morlacchi, Francesco Blasi, Francesco Del Galdo, Chiara Bellocchi
- P.078** **Survival and Mortality Risk Factors in Patients with Systemic Sclerosis Associated Interstitial Lung Disease from a Single Referral Center**
Burak Gultekin, Shirkhan Amikshiyev, Zuleyha Bingol, Bahar Artim-Esen, Ahmet Gul, Gulfer Okumus, Murat Inanc, Yasemin Yalcinkaya
- P.079** **Investigating the role of fibroblast trained immunity in the pathogenesis of systemic sclerosis associated pulmonary fibrosis**
Julie Worrell

- P.080** **Keratinocyte-targeting functional autoantibodies in systemic sclerosis are associated with interstitial lung disease**
Jacqueline Wax, Gabriela Riemekasten, Frank Petersen, Xinhua Yu
- P.081** **Airway disease; an underrecognized pulmonary manifestation of systemic sclerosis**
Marloes Verstappen, M. Voortman, A.D.M. Vorselaars, J. Spierings
- P.082** **Serum proteins reflecting vascular processes associate with interstitial lung disease development in patients with systemic sclerosis**
Emiel Marges, Katherine van der Wouden, Marieke Overbeek, Jeska de Vries-Bouwstra
- P.083** **Efficacy and safety of nintedanib in Systemic Sclerosis-associated Interstitial lung disease: one-year results from the REMSCL cohort**
Claudia Codina, Laura Triginer Gil, Ana Argibay Filgueira, Adela Marin Ballve, Jose Luis Callejas Rubio, Mayka Freire, Maria Martin Armada, Nuria Vilanova Anducas, Clara Itziar Soto Abanades, Antonio Javier Chamorro, Cristina Lavilla Olleros, Raquel Aranega, Ignasi Rodriguez Pinto, Adriana Iriarte Fuster, Begoña Mari Alfonso, Antonio Castro Salomo, Alejandra Fernandez Luque, Ana Villar, Alfredo Guillen Del Castillo, Carmen Pilar Simeon Aznar
- P.084** **Baseline Nailfold Videocapillaroscopy and Its Prognostic Value in Pulmonary Decline and Disease Progression in Systemic Sclerosis**
Cristiana Sieiro Santos, Jose Ordas Martinez, Miriam Retuerto Guerrero, Laura Sierra Herranz, Elena Bollo De Miguel, Elvira Diez Alvarez
- P.085** **Serum KL-6 and IL-18 as Diagnostic and Prognostic Biomarkers in SSC-ILD: A 24-Month Cohort Study**
Cristiana Sieiro Santos, Jose Ordas Martinez, Miriam Retuerto Guerrero, Sara Calleja Antolin, Juan Garcia Herrero, Laura Sierra Herranz, Javier De La Calle Lorenzo, Elena Bollo De Miguel, Elvira Diez Alvarez
- P.086** **Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study**
Cristiana Sieiro Santos, Miriam Retuerto Guerrero, Jose Ordas Martinez, Sara Calleja Antolin, Juan Garcia Herrero, Laura Sierra Herranz, Javier De La Calle Lorenzo, Elena Bollo De Miguel, Goncalo Boletto, Vasco Romao, Elvira Diez Alvarez
- P.087** **Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis**
Miriam Retuerto-Guerrero, Clara Moriano Morales, Ivan Castellvi Barranco, Elvira Diez Alvarez
- P.088** **Mediastinal lymphadenopathy in SSC-ILD is associated with upper Gastrointestinal involvement and higher risk of ILD progression: a bicentric retrospective observational study**
Valeria Rella, Cinzia Rotondo, Raffaele Barile, Marco Minerba, Lucy Thornton, Adolorata Corrado, Francesco Paolo Cantatore, Francesco Del Galdo
- P.089** **Impact of disease characteristics and patient reported measures on exercise capacity in a prospective SSC-ILD cohort**
Mona-Lovise Ramsli, Torhild Garen, Phoung Phoung Diemp, Håvard Frøtheim, Henriette Didriksen, Emily Violette Langballe, Helena Andersson, Øyvind Molberg, Øyvind Midtvedt, Hilde Jessen Bjørkekjær, Michael Durheim, Anna-Maria Hoffmann-Vold

05.INTERSTITIAL LUNG DISEASE

- P.090 Deep-learning analysis of hrct images predicts progression and mortality in systemic sclerosis related interstitial lung disease**
Enrico De Lorenzis, Rosa D'abronzo, Pier Giacomo Cerasuolo, Lucio Calandriello, Giuseppe Cicchetti, Gerlando Natalello, Bruno Iovene, Francesco Varone, Giacomo Sgalla, Luca Richeldi, Anna Rita Larici, Maria Antonietta D'agostino, Silvia Laura Bosello
- P.091 Circulating levels of TL1A and DcR3 molecules and Systemic Sclerosis progression**
Vasiliki Poulia, Nikolaos I. Vlachoyiannis, Aikaterini Avdi, Vasiliki-Kalliopi Bournia, Maria G. Tektonidou, Petros P. Sfikakis, Stylios Panopoulos
- P.092 ENDOTHELIN-1 and severity of disease and interstitial lung disease in scleroderma patients**
Olga Ovsyannikova, Olga Koneva, Lidiya Ananyeva, Liudmila Garzanova, Rushana Shayachmetova, Anastasia Avdeeva, Michail Diatroptov
- P.093 Association th serum level of il-13 with interstitial lung disease in systemic sclerosis patients**
Olga Ovsyannikova, Olga Koneva, Liudmila Garzanova, Rushana Shayachmetova, Lidiya Ananyeva, Anastia Avdeeva, Michail Diatroptov
- P.094 Clinical characteristics of systemic sclerosis with interstitial lung disease, one center experience**
Hande Ogun, Serdal Ugurlu
- P.095 Antifibrotic and immunomodulatory properties of the PDE4B inhibitor nerandomilast in cell models relevant to systemic sclerosis, including intestinal fibrosis**
Daniel Schniertshauer, David Ebenezer, Daniela Schloesser, Barbara Kistler, Chang Zeng, Leslie Amador, Chantelle Simone-Roach, Kristen Hall, LeeAnne Daley, Jochen Schmitz, Kremena Simitchieva, Peter Nikolaus, Christian Hesslinger, Jörg Bergemann, Karim Christian El Kasmi
- P.096 Identifying predictors of lung function decline in patients with systemic sclerosis associated with ILD (SSC-ILD) - insights from the German Network for Systemic Sclerosis**
Pia Moinzadeh, Francesco Bonella, Jithmi Weliwitige, Gabriele Riemekasten, Joerg Henes, Norbert Blank, Marc Schmalzing, Gabriele Zeidler, Claudia Günther, Annette Alberding, Ilona Jandova, Jan Ehrchen, Gernot Keyszer, Margitta Worm, Alexander Kreuter, Ulf Müller-Ladner, Aaron Juche, Joerg Distler, Nicolas Hunzelmann, Michael Kreuter
- P.097 Quantitative CT phenotyping and biomarker signatures in systemic sclerosis-associated interstitial lung disease**
Davide Mohammad Reza Beigi, Giuseppe Ocone, Greta Pellegrino, Nicholas Landini, Ilaria Bisconti, Francesca Romana Di Ciommo, Marius Cadar, Jacopo Landro, Elena Platania, Martina Salerno, Beatrice De Girolamo, Simona Truglia, Fabrizio Conti, Loredana Frasca, Valeria Ricciari
- P.098 Pulmonary microbiome in patients with interstitial lung disease secondary to scleroderma and other connective tissue diseases: a pilot study Project funded by PNRR – NextGenerationEU PNRR-MCNT2-2023-1**
Gabriella Alonzi, Enrico De Lorenzis, Valentina Boni, Camilla Teresa Magnanini, Gaspare Davide Patti, Carlotta Pomini, Gerlando Natalello, Lucia Lanzo, Rocco Trisolini, Daniele Magnini, Flavio De Maio, Maurizio Sanguinetti, Maria Antonietta D'Agostino, Silvia Laura Bosello
- P.099 The Silent Clinical Impact of Systemic Sclerosis-Associated Interstitial Lung Disease Highlights Sclerod's Limitations in Early Fibrosis**
Groseanu Laura, Nita Cristina, Boromiz Catalina, Mardale Denise, Ilie Cristian, Mazilu Diana, Borangiu Andreea, Abobului Mihai, Bojinca Violeta, Opris-Belinski Daniela, Balanescu Andra
- P.100 Circulating angiogenic T cells are reduced in systemic sclerosis-associated interstitial lung disease and correlate with lung function and early vasculopathy: evidence from a case-control study**
Jergus Krc, Yehya Al-Adwi, Berber Doornbos-Van Der Meer, Alja Stel, Wayel Abdulahad, Harry Van Goor, Johanna Westra, Douwe Johannes Mulder
- P.101 Markers of alveolar epithelial injury in patients with systemic scleroderma and interstitial lung disease (SSC-ILD): clinical and laboratory associations**
Olga Koneva, Liudmila Garzanova, Rushana Shayachmetova, Anastasia Avdeeva, Michail Diatroptov, Olga Ovsyannikova, Lidia Ananyeva
- P.102 Association of interstitial lung disease (ILD) with markers of microvascular damage and fibrogenesis in systemic sclerosis (SSC)**
Olga Koneva, Rushana Shayachmetova, Liudmila Garzanova, Anastasia Avdeeva, Michail Diatroptov, Olga Ovsyannikova, Lidia Ananyeva
- P.103 Interstitial lung disease in systemic autoimmune rheumatic diseases: radiologic and histologic correlations**
Hyein Kim, Aidan Pye, Darya Jalaludin, Angela Chang, Navid Saleh, Saud Alhajer, Béatrice Daviault, Arusa Shah, Sabrina Hoa, Alec Yu, Robert Levy, Jennifer Wilson, Charles Poirier, James Choi, John Yee, Océane Landon-Cardinal, Kun Huang
- P.104 Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: Real-World Multicenter Cohort Study on Tolerability and Discontinuation**
Punchalee Kaenmuang, Nina R. Goldman, Arthihai Srirangan, Fiammetta Danzo, Yip Wing-Ho, Ali Taki, Shereen Boreland, Benedetta Vitri, Carmel JW. Stock, Christopher P. Denton, Athol U. Wells, Voon H. Ong, Piersante Sestini, Elisabetta A. Renzoni
- P.105 Quantitative Computed Tomography radiomic features as predictors of progression and mortality in Systemic Sclerosis-associated Interstitial Lung Disease**
Maria Iacovantuono, Nicholas Landini, Lisa Jungblut, Florian Käs, Rucsandra Dobrota, Sinziana Muraru, Muriel Elhai, Carmen-Marina Mihai, Mike Oliver Beker, Maria Sole Chimenti, Thomas Frauenfelder, Anna-Maria Hoffmann-Vold, Oliver Distler, Cosimo Bruni
- P.106 Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis**
Maria Iacovantuono, Nicholas Landini, Lisa Jungblut, Gesa Marie Sauer, Rucsandra Dobrota, Sinziana Muraru, Muriel Elhai, Carmen-Marina Mihai, Mike Oliver Beker, Maria Sole Chimenti, Thomas Frauenfelder, Anna-Maria Hoffmann-Vold, Oliver Distler, Cosimo Bruni
- P.107 Proteomic analysis of plasma extracellular vesicles in systemic sclerosis-associated interstitial lung disease reveals potential novel diagnostic biomarkers**
Stela Hrkac, Rudjer Novak, Grgur Salai, Josko Mitrovic, Lovorka Grgurevic

05. INTERSTITIAL LUNG DISEASE

P.108 Predicting progression of mild interstitial lung disease in systemic sclerosis: an international retrospective cohort study

Sabrina Hoa, Danick Goulet, Yumeko Kawano, Susanna Proudman, Wendy Stevens, Lorinda Chung, Amine Mohammed Maimoune, Raphael Hurtubise, Maggie Larché, May Choi, Mohammed Osman, Janet Pope, Carter Thorne, Murray Baron, Mandana Nikipour, Marie Hudson, Canadian Scleroderma Research, Australian Scleroderma Interest

P.109 Prognostic value of quantitative chest computed tomography for predicting progression of mild interstitial lung disease in systemic sclerosis: a multicentric nested case-control study

Sabrina Hoa, Marcelo Veiga Da Silva, Mathieu Rousseau, Catherine Faucher, Yi Cheng Mu, Jean Chalaoui, Patrick Bourgouin, Raphael Hurtubise, Maggie Larche, May Choi, Mohammed Osman, Janet Pope, Carter Thorne, Carl Chartrand-Lefebvre, Murray Baron, Canadian Scleroderma Research Group

P.110 Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Analysis

Navid Saleh, Angela Chang, Alec Yu, Darya Jaleedin, Sabrina Hoa, Robert Levy, Jennifer Wilson, Charles Poirier, James Choi, John Yee, Oceane Landon-Cardinal, Hyein Kim, Kun Huang

P.111 Association of systemic sclerosis-related interstitial lung disease with tumor-associated antigens and their autoantibodies

Jiayi Guo, Aiping Ma, Heqing Huang, Shaowei Lin, Biqi Fu, Anja Kerstein-Stähle, Frank Petersen, Xinhua Yu

P.112 Interstitial Lung Disease in Systemic Sclerosis: Clinical, Serological, and Instrumental Associations in a Ukrainian Patient Cohort

Marta Dzhus, Tatiana Karasevska, Ruslana Potoka, Hanna Novytska, Natiana Tkachuk, Kateryna Mulyk

P.113 Heterogeneity in Treatment Outcomes for Systemic Sclerosis with or Without Interstitial Lung Disease: A Systematic Literature Review

Emily Glowienka, Ian Steinfield, Kevin Coody, Carole Lunny, Florence R Wilson, Alicia N Pepper, Svetlana Nihtyanova, Roger A Levy, Elaine Irving, Daniel Moldaver, Cosimo Brucci

P.114 Multimodal Imaging Uncovers Concomitant Lung and Primary Cardiac Involvement in Systemic Sclerosis

Veronica Batani, Elisa Bruno, Corrado Campochiaro, Anna Palmisano, Davide Vignale, Antonio Esposito, Marco Matucci-Cerinic, Giacomo De Luca

P.115 Interstitial Lung Disease in Mixed Connective Tissue Disease: A Distinct Clinical Pattern Compared to Systemic Sclerosis and Myositis?

Filipa Costa, Inês Sopa, Khea Hasmmucrai, Manuel Silvério-António, Ana Teresa Melo, Joana Martinho, Bianca Paulo Correia, Nikita Khmelinski, Catarina Resende, Raquel Campanilho-Marques, Gonçalo Boletto

P.116 Analysis and validation of the different progressive pulmonary fibrosis (PPF) criteria in a cohort of patients with interstitial lung disease associated to systemic sclerosis (SSc-ILD)

Claudia Codina Clavaguera, Laura Triguera, Alejandra Fernández-Luque, Ana Villar, Iñigo Ojangueren, Marialbert Acosta, Javier Martín, Ivan Vollmer, Luis Del Carpio, Luis Alcalá-González, Janire Perurena, María Teresa Sanz-Martínez, Laura Viñas-Giménez, Carmen Pilar Simeón Aznar, Alfredo Guillén-Del-Castillo

P.117 Vasodilation with prostanoids influences progression systemic sclerosis-associated interstitial lung disease: a EUSTAR cohort study

Adela-Cristina Sarbu, Liubov Petelytska, Lorenzo Tofani, Gabriele Moroncini, Elisabetta Zanatta, Jorg Hanes, Paolo Airò, Marco Matucci-Cerinic, Ana-Maria Gheorghiu, Antonella Maccocchia, Branimir Anic, Jelena Colic, Daniel Furst, Julia Spierings, Alexandra Balbir, Britta Maurer, Anna-Maria Hoffmann-Vold, Oliver Distler, Cosimo Brucci

P.118 Detecting Interstitial Lung Disease and Identifying Extended Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implication

Nicholas Landini, Lisa Jungblut, Cecilia Strappa, Christian Bluethgen, Rucsandra Dobrota, Muriel Elhai, Carina Mihai, Sinziana Muraru, Martina Orlandi, Mariaelena Occhipinti, Khadija El Aoufy, Gemma Lepri, Valeria Panebianco, Anna Rita Larici, Anna Maria Hoffmann-Vold, Cosimo Nardi, Serena Guiducci, Silvia Bellando-Randone, Marco Matucci-Cerinic, Thomas Frauenfelder, Oliver Distler, Cosimo Brucci

P.119 Prognostic Value of an AI-Derived HRCT Score in Predicting Outcomes for Scleroderma-Related Interstitial Lung Disease

Itamar Vazina, Eyal Bercovich, Luda Goralnik, Katya Dolnikov, Sami Giryes, Yonit Tavor, Kochava Toledano, Aiman Arraf, Alexandra Balbir-Gurman, Yolanda Braun-Moscovici

P.120 Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease (SSc-ILD): results from an EUSTAR cohort study

Devis Benfaremo, Corrado Campochiaro, Gábor Kumánóvics, Christina Bergmann, Elisabetta Zanatta, David Launay, Serena Guiducci, Mickaël Martin, Carolina de Souza Müller, Carlomaurizio Montecucco, Luc Mouthon, Gabriella Szucs, Kastriot Kastrati, Marie-Elise Truchetet, Madelon Vonk, Francesco Del Galdo, Marco Matucci-Cerinic, Gianluca Moroncini, Yannick Allanore

P.121 Evaluation of the Living with Pulmonary Fibrosis Questionnaire in patients with Systemic Sclerosis associated interstitial lung disease: monocentric results

Claudia Barison, Elda Piovani, Eleonora Pedretti, Eleonora Pazzi, Liala Moschetti, Ilaria Cavazzana, Franco Franceschini, Maria Grazia Lazzaroni, Paolo Airò

P.122 Correlation between IL-6 polymorphisms and the presence and severity of ILD in patients with systemic sclerosis

Marko Baresic, Boris Karanovic, Miroslav Mayer, Branimir Anic

P.123 Ancillary HRCT features at baseline predict Progressive Pulmonary Fibrosis in Systemic Sclerosis-associated Interstitial Lung Disease: A Retrospective Cohort Study

Andrea Benini, Beatrice Moccaldi, Serena Bellani, Chiara Giraud, Elisabetta Coconcelli, Valeria Gilberti, Nicole Zizzari, Marco Binda, Gioele Castelli, Anna Cuberli, Francesco Carta, Roberta Ramonda, Elisabetta Balestro, Elisabetta Zanatta

P.124 Characteristics of scleroderma patients with lung involvement treated with biologic drugs, a single center experience

Balbir-Gurman Alexandra, Yaniv Dotan, Katya Dolnikov, Yonit Tavor, Sami Giryes, Luda Goralnik, Ana Solomonov, Jasmin Atalla, Yolanda Braun-Moscovici

P.125 Association between Thoracic Muscle and Fat Area and Density and Pulmonary Function in Systemic Sclerosis

Aradhna Agarwal, Niki Pradhan, James St. Clair, Dinesh Khanna, Elana Bernstein

06. PULMONARY HYPERTENSION

- P.126** **EZH2 Inhibits the Profibrotic Differentiation of ADH7⁺ Fibroblasts in Pulmonary Arterial Hypertension**
Xiaofang Zeng, Bingying Dai, Zhe Li, Hui Luo, Xiaoxia Zuo, Sijia Liu, Honglin Zhu
- P.127** **Targeting IL-13 signaling pathway as a potential therapeutic approach in experimental models of pulmonary arterial hypertension**
Jakia Khan, Lifang Wen, Christoph Hölscher, Jacqueline Wax, Alexandra Hölscher, Xinhua Yu, Gabriela Riemekatsen, Frank Petersen
- P.128** **Real-life effectiveness of Selexipag treatment in Systemic Sclerosis associated pulmonary arterial hypertension: long-term data from a multicentric Italian cohort**
Stefano Stano, Fabio Cacciapaglia, Mariangela Nivuori, Corrado Campochiario, Claudia Iannone, Marco Vicenzi, Maria Grazia Lazzaroni, Cinzia Rotondo, Marius Cadar, Angelo De Cata, Roberta Foti, Maria Iacovantuono, Elisabetta Zanatta, Maria De Santis, Nicoletta Del Papa, Roberto Caporali, Marco Matucci-Cerinic, Florenzo Iannone
- P.129** **Macitentan for Pulmonary Arterial Hypertension Associated with Systemic Sclerosis: results from the European Scleroderma Trials And Research Group (EUSTAR) database**
Maria-Grazia Lazzaroni, Corrado Campochiario, Paolo Airo, Tatsuya Atsumi, Andra Balanescu, Alexandra Balbir-Gurman, Cosimo Bruni, Francesco Paolo Cantatore, Maria De Santis, Oliver Distler, Michael Hughes, Dörte Huscher, Florenzo Iannone, Jacqueline Lemmers, Antonella Marcocchia, Britta Maurer, Liala Moschetti, Ignasi Rodriguez-Pinto, Tania Santiago, Carmen-Pilar Simeón-Aznar, Julia Spierings, Ulrich Andreas Walker, Elisabetta Zanatta, Marco Matucci-Cerinic, Marie-Elise Truchetet, Francesco Del Galdo, Madelon C. Vonk
- P.130** **Immunosuppressive therapy and risk of incident pulmonary arterial hypertension in systemic sclerosis: results from the Canadian Scleroderma Research Group**
Chloé Jessen, Mireille Schnitzer, Maggie Larché, May Choi, Mohammed Osman, Janet Pope, Carter Thorne, Murray Baron, Marie Hudson, Sabrina Hoa, Canadian Scleroderma Research Group
- P.131** **Characterization of early pulmonary arterial hypertension in systemic sclerosis: a Canadian Scleroderma Research Group cohort study**
Chloé Jessen, Claudie Berger, Maggie Larché, May Choi, Mohammed Osman, Janet Pope, Carter Thorne, Murray Baron, Marie Hudson, Sabrina Hoa, Canadian Scleroderma Research Group
- P.132** **Clinical and Echocardiographic Profile of Pulmonary Hypertension in Systemic Sclerosis: Experience from a Tertiary Care Center in India**
Manna Jacob, Jesu Krupa, Ruchika Goel, Ashish Mathew, Nithin Koshy, John Mathew
- P.133** **Change in DLCO Over Time as a Predictor of Mortality in SSc-PAH**
Håvard Frøtheim, Hilde Bjørkekjær, Øyvind Midtvedt, Thao Nguyen, Yi Hu, Arne Andreassen, Phuong Phuong Diep, Torhild Garen, Emily Langballe, Øyvind Molberg, Anna-Maria Hoffmann-Vold
- P.134** **Improvement of survival in patients with Pulmonary Arterial Hypertension associated with Systemic Sclerosis**
Giovanna Cuomo, Carlo Iandoli, Fiorina Tulipano, Gennaro Porcelli, Caterina Naclerio, Giorgia Lo Faso, Ciro Romano

- P.135** **Clinical and Hemodynamic profile of Patients with SSc-PAH with and without Pulmonary Veno-occlusive Disease: A Single-Center Study**
Anna Cuberli, Michele Strosio, Alessandro Magi, Beatrice Moccaldi, Marco Binda, Andrea Benini, Andrea Doria, Martina Perazzolo Marra, Giulia Famoso, Laura De Michieli, Elisabetta Zanatta
- P.136** **Concentration of anti-centromere-antibodies associates with and may predict development of pulmonary arterial hypertension**
Kristofer Andréasson, Maria Frida Bengtsson, Marie Wildt, Christine Am Möller Westerberg, Anna Katherina Svanqvist, Johan Kristian Rönnelid

07. HEART

- P.137** **Longitudinal changes in high-Sensitivity cardiac troponin T and their association with clinical outcomes in systemic sclerosis: a cohort study**
Attapon Chotmanee, Chingching Foocharoen, Burabha Pussadhamma, Tippawan Onchan, Patnarin Pongkulkiat, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Wilaiphorn Thinkhamrop, Nathaphop Chaichaya
- P.138** **Heart Rate Variability Reflects Subclinical Atherosclerosis in Patients with Systemic Sclerosis**
Daniel Zavada, Sabina Oreska, Aneta Prokopcova, Hana Wunsch, Jaroslav Kudlicka, Vladimir Tuka, Ondrej Mikes, Zdislava Krupickova, Martin Satry, Eva Chytilova, Jan Kvasnicka, Maja Spiritovic, Barbora Vala, Petr Cesak, Marian Rybar, Karel Pavelka, Ladislav Senolt, Radim Becvar, Jiri Vencovsky, Michal Vrablik, Michal Tomcik
- P.139** **Myocarditis in systemic sclerosis patients with positive anti-PM/ Scl-100 antibodies: two cases treated with combination therapy of mycophenolate mofetil and rituximab**
Monika Gosz, Anna Wojteczek, Michal Chmielewski
- P.140** **24-hour Holter-derived heart rate variability and heart rate turbulence in systemic sclerosis: links with severe vasculopathy, interstitial lung involvement and arrhythmic risk**
Cristina Andreea Vrancianu, Dragos Emanuel Popa, Silvia Toma, Bianca Budu, Ethem Isa Demirkol, Adriana Ilesiu, Mihai Bojinca, Ana Ciobanu, Ana Maria Gheorghiu
- P.141** **Primary heart disease in patients with systemic sclerosis and myocardial iron deposition detected by T2* magnetic resonance**
Petros P. Sfikakis, Stylianos Panopoulos, Vassiliki Poulia, Nikolaos Vlachogiannis, Maria G. Tektonidou, Sophie I. Mavrogeni
- P.142** **Naifold capillaroscopy improves cardiovascular risk stratification in systemic sclerosis: an adjustment to the SCORE2 algorithm**
Carlos Valera Ribera, Javier Narvaez, Joaquin Lacasa Molina, Adrian Mayo-Juanatey, Paula Mencio-Viana, Patricia León-Torralba, Juan José Alegre-Sancho
- P.143** **Unusual severe cardiac manifestation of diffuse cutaneous Systemic Sclerosis**
Kamal Solanki, Kamal Solanki, Magdalena Budziakowska, Vijay Anand Dhakshinamurthy

07.HEART

P.144 Subclinical myocardial tissue changes in Systemic Sclerosis associate with progressive nailfold capillaroscopy patterns

Cristiana Siero Santos, Raluca Bianca Dimitru, Lesley-Anne Bissel, Bara Erhayiem, Graham Fent, Giuseppina Abignano, John Greenwood, John Biglands, Sven Plein, Francesco Del Galdo, Maya Buch

P.145 Common proteomic biomarkers of vascular and myocardial tissue abnormalities in systemic sclerosis and rheumatoid arthritis

Rudresh Shukla, Amr Mohammed, Raluca Dumitru, Lesley-Anne Bissell, Bara Erhayiem, Graham Fent, Christopher Miller, Francesco Del Galdo, Sven Plein, Darren Plant, Maya Buch

P.146 Magnetic resonance cardiopulmonary tissue characteristics in a systemic sclerosis cohort: a pilot study

Rushab Shah, Nicholas Black, John Farrant, Hashem Cheema, Jyotin Singh, Cristiana Siero Santos, Josephine Naish, Christopher Miller, Maya Buch

P.147 Prevalence and Associated Factors of Resting Electrocardiogram Abnormalities in Systemic Sclerosis: A Single-Centre Study

Catarina Rua, Tiago Beirão, Catarina Silva, Mariana Patela, Tiago Meirinhos, Flavio Costa

P.148 Usefulness of vascular imaging as a complement to classic methods for estimating cardiovascular risk in systemic sclerosis

Carmen Riesco Bárcena, Elena Grau Garcia, Jose Andrés Román Ivorra

P.149 Don't count your chickens before they hatch! Analysis of cardiovascular definitions in studies on systemic sclerosis: a Systematic Literature Review

Laura Pezzoni, Silvia Sirotti, Georgios Filippou, Piercarlo Sarzi Puttini, Greta Pellegrino

P.150 Analysis of mortality and risk factors in Systemic Sclerosis: the role of cardiac and vascular involvement

Andres Perez Hurtado, Elena Grau Garcia, Patricia Anton Enguidanos, Marta De La Rubia Navarro, Carmen Riesco Barcena, Alba Maria Torrat Noves, Daniel Ramos Castro, Iago Alcántara Alvarez, Belen Villanueva Mañes, Miguel Simeó Vinaixa, Belen Diaz Mora, Jose Andres Roman Ivorra

P.151 Peri-myocarditis Leading to Cardiac Tamponade in Systemic Sclerosis Overlap

Pawikorn Nampisaj, Siraphop Suwannarop, Tippawan Onchan, Patnarin Pongkulkiat, Chingching Foocharoen, Ajanee Mahakkanu

P.152 Heart involvement in patients with systemic sclerosis – from electrocardiographic changes and laboratory abnormalities to clinical symptoms: a preliminary study

Aleksandra Nadel, Maciej Nadel, Olga Brzezinska, Bartosz Stepień, Karolina Michno, Jakub Gajdecki, Kinga Gajdecka, Anna Lewandowska-Polak, Joanna Makowska

P.153 Differentiating Active vs. Chronic Systemic Sclerosis-Primary Heart Involvement: Clinical and Prognostic Implications

Beatrice Moccaldi, Anna Cuberli, Alessandro Parodi, Marco Binda, Andrea Benini, Laura De Micheli, Anna Baritussio, Andrea Silvio Giordani, Martina Perazzolo Marra, Alessia Pepe, Alida Caforio, Roberta Ramonda, Barbara Bauce, Elisabetta Zanatta

P.154 Arrhythmias and Conduction System Abnormalities among Patients with Systemic Sclerosis

Susana Matias, Catarina Abreu, Ana Cordeiro, Maria José Santos

P.155 The Liver's Impact on Cardiac Fibrosis in a Liver-Cardiac Multi-Organ-on-a-Chip System

Lukas Minder, Astrid Hofman, Ellen Kossmann, Amela Hukara, Ievgeniia Kocherova, Andrea Laimbacher, Lisa Hölting, Tamara Häfeli, Oliver Distler, Przemyslaw Blyszczuk, Gabriela Kania

P.156 Monocyte chemoattractant protein-1 (MCP-1): association with the progression of skin and cardiovascular manifestations of systemic sclerosis (SSc)

Olga Koneva, Liudmila Garzanova, Rushana Shayachmetova, Anastasia Avdeeva, Michail Diatropov, Olga Ovsyannikova, Lidia Ananyeva

P.157 Left Atrial Strain Reveals Early Myocardial Involvement in Systemic Sclerosis

Martina Iacubino, Chiara Bellocchi, Emma Lentini, Silvia Tamanini, Giuseppe Locatelli, Marta Mozzo, Alessandro Quarenghi, Maria De Santis, Nicoletta Del Papa, Giacomo De Luca, Lorenzo Beretta, Marco Vicenzi

P.158 Heart involvement in systemic sclerosis and prescleroderma measured by electrocardiogram, PRO-BNP, and troponin T

Marta De La Rubia Navarro, Borja Guerrero, Elena Grau Garcia, Alba Maria Torrat Noves, Daniel Ramos Castro, Iago Alcántara Álvarez, Belén Villanueva Mañes, Andrés Pérez Hurtado, Miguel Simeó Vinaixa, José Andrés Román Ivorra

P.159 Early Myocardial Involvement in Patients with Systemic Sclerosis

Ana Da Rocha Sá, Carlos Marques Gomes, Mariana Diz Lopes, Bárbara Esteves, Marina Oliveira, Miguel Natal, Sara Helena Amaro Lopes, Georgina Terroso, Raquel Miriam Ferreira, Lúcia Costa, Salomé Garcia

P.160 First non-Raynaud's phenomenon sign/symptom predicts MACE occurrence in systemic sclerosis: a monocentric long-term analysis

Eugenio Capparelli, Eleonora Zaccara, Greta Pellegrino, Francesco Lapia, Daniela Bompiane, Laura Castelnovo, Antonio Tamburello, Maria Sole Chimenti, Antonino Mazzone, Paola Faggioli

P.161 Severe cardiac involvement in Systemic Sclerosis: Two cases of Scleroderma cardiac crisis

Maria Boutel, Vasiliki Dimitriadou, Konstantinos Tsafts, Elpidia Skouvakliadou, Evdokia Papadimitriou, Vasileios Skepastianos, Dimitrios Deligeorgakis, Nikolaos Kougkas, Christina Adamichou, Sofia Anastasia Mouratoglou, Theodoros Dimitroulas

08. GI SYSTEM

- P.162 Assessment of the Effectiveness of Intravenous Immunoglobulin Therapy in Gastrointestinal Manifestations of Systemic Sclerosis**
Milica Markovic Vlaisavljevic, Natasa Miketic, Milan Bogojevic, Rifat Medjedovic, Giulia Bandini, Marco Matucci-Cerinic
- P.163 Acid reflux triggers type I interferon and cause epithelial-mesenchymal transition in oesophageal epithelial cells may contribute to the pathogenesis of oesophageal involvement in systemic sclerosis**
Safoura Zahed Mohajerani, Ala Altaie, Marco Minerba, Kin Man Suen, Christopher Black, Lesley-Anne Bissell, Monique Hinchcliff, John E Ladbury, Rebecca L Ross, Francesco Del Galdo
- P.164 Evaluating Gastrointestinal Involvement in Systemic Sclerosis Using the GIT 2.0 Instrument and the Impact of Immunosuppressive Therapy in a Chinese Cohort**
Shihan Xu, Haochen Huang, Bo Yu, Lu Yuan, Xiaofeng Zeng, Mengtao Li, Dong Xu
- P.165 Prevalence and Characterization of Liver Disease in Systemic Sclerosis: a multicentric Cohort Study**
Carolina Vilafanha, Maria João Cadório, Cláudia Pinto Oliveira, Pedro Miguel Teixeira, Maria João Salvador, Tânia Santiago, José António Pereira da Silva, Carolina Mazedo, Anabela Barcelos, Ana Rita Prata
- P.166 High prevalence of antimitochondrial antibodies and association with gastrointestinal vascular involvement in systemic sclerosis**
Antonio Tonutti, Francesca Motta, Natasa Isailovic, Carlo Selmi, Angela Ceribelli, Maria De Santis
- P.167 Breaking the Barrier: Intestinal Permeability, Malnutrition, and Serological Profiles in Systemic Sclerosis**
Bartosz Stepień, Olga Brzezinska, Aleksandra Opinc-Rosiak, Jakub Gajdecki, Kinga Gajdecka, Aleksandra Nadel, Joanna Sarnik, Joanna Makowska
- P.168 Prevalence and Risk Factors for Oesophageal Strictures in Systemic Sclerosis**
Alannah Quinlivan, Dylan Hansen, Kathleen Morrisroe, Wendy Stevens, Nava Ferdowsi, Susanna Proudman, Jennifer Walker, Joanne Sahhar, Gene-Siew Ngian, Diane Apostolopoulos, Lauren V Host, Chamara Basnayake, Laura Ross, Mandana Nikpour
- P.169 The Usefulness of Eating Assessment Tool-10 (EAT-10) in Patients with Systemic Sclerosis (SSc) for detecting swallowing at risk of aspiration**
Tatsuaki Naganawa, Ayako Kuwabara, Risa Ohara, Naoki Dosoden, Kodai Ito, Marika Sawada, Natsuko Watanabe, Yumi Ito, Ai Umeda, Konomi Akamatsu, Megumi Kurumizawa, Takako Hashimoto, Shusaku Fukaya, Seiko Shibata, Yohei Otaka, Hidekata Yasuoka
- P.170 Digesting the data: tracking GI manifestations in SSc over time**
Cosimo Bruni, Jasmin Klöti, Aurora Tatu, Lea Stamm, Rucsandra Dobrota, Muriel Elhai, Mike Oliver Becker, Sinziana Muraru, Gesa Sauer, Anna Maria Hoffmann-Vold, Oliver Distler, Carina Mihai
- P.171 Watermelon stomach in patients with systemic sclerosis: A single center experience**
Nektarios Marios Liapis, Arriana Gkouvi, Fotios Fytsilis, Christina Katsiari, Ioannis Alexiou, Andreas Kapsoritakis, Dimitrios Bogdanos, Theodora Simopoulou
- P.172 Real world diagnosis and treatment of small intestinal bacterial overgrowth in systemic sclerosis: results from a multicenter retrospective descriptive study**
Marie-Laurence Laliberté, Hao Cheng Shen, Ariel Masetto, Genevieve Gyger, Marie Hudson, Sabrina Hop
- P.173 The prevalence of dysphagia among patients with systemic sclerosis using the EAT-10 questionnaire**
Arriana Gkouvi, Eleni Pardali, Nektarios Marios Liapis, Theodora Simopoulou, Christina Katsiari, Dimitrios Bogdanos, Maria Grammatikopoulou
- P.174 Primary Biliary Cholangitis associated with Sistemik Sclerosis: does the diagnostic time sequence matters?**
Francesco Girelli, Alarico Ariani, Elisa Maria Montebelli, Stefano Ruggiero, Ilaria Plate', Elena Bravi, Eugenio Arrigoni, Marica Trevisani, Massimo Reta, Gianluigi Bajocchi, Emanuele Cocchiara, Martina Orlandi, Amelia Spinella, Marco De Pinto, Marcello Govoni, Andrea Lo Monaco, Giorgio Galoppini, Pierugi Cataleta, Fabio Mascella, Alessandra Bezzi, Paola Sambo, Marco Bruschi, Francesca Martelli, Dilia Giuglioli
- P.175 Gastrointestinal worsening correlates to body composition, mediterranean diet and physical activity**
Mislav Radic, Hana Dogas, Andrea Gelemanovic, Dijana Perkovic, Josipa Radic
- P.176 The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort**
Francesca Romana Di Ciommo, Subhash Kulkarni, Aidan Strother, Ashish Balar, Michael Hughes, Brian Skaug, Maureen Mayes, Shervin Assassi, Ali Ayla Yazig, Zsuzsanna Mcmahon
- P.177 Gastrointestinal symptoms, dietary intake, malnutrition and mortality in systemic sclerosis**
Lucas Denardi Dória, Vanessa Hax, André Luiz Silveira Mallmann, Rafael Nascimento Silva, Lucas Pereira Cruz, Pedro Manzke Gianzel, Emily Caroline Lopes, Bruno Eduardo Lara Da Silva, Stephanie Pilott, Daniel Nóbrega De Moraes, Helena Calegato Beheregaray, Roberta Ramos De Araujo, Daniel Do Nascimento Silva, Amanda Marques Francisco, Agnes Rivera Palmeiras, Ricardo Machado Xavier, Rafael Mendonca Da Silva Chakr
- P.178 Impaired Postprandial Mesenteric Vascular Reserve in Systemic Sclerosis: Preliminary Evidence from a Pilot Study**
Francesco Bonomi, Silvia Peretti, Aura Tricomi, Elisa Martinelli, Martina Spini, Khadija El Aoufy, Silvia Bellando Randone, Marco Matucci-Cerinic, Alberto Moggi Pignone, Giulia Bandini
- P.179 Benchmarking gastrointestinal involvement in systemic sclerosis: practical insights and unmet needs from a tertiary referral centre**
Millie Bensimon, John McLaughlin, Melissa Mandzuk, Muditha Samaranyaka, Elizabeth Wragg, Ariane Herrick, Graham Dinsdale, Michael Hughes

08.GI SYSTEM

- P.180 Self-reported oropharyngeal dysphagia and swallowing-related quality of life in people with systemic sclerosis: preliminary results of a cross-sectional study**
Devis Benfaremo, Nikla Pacenti, Federica Lucia Galli, Andrea Colangelo, Gianluca Moroncini
- P.181 Vascular disease burden predicts gastrointestinal manifestations in systemic sclerosis: longitudinal analysis from the EUSTAR cohort**
 Stefano Di Donato, Louis Bébear, Michael Hughes, Zsuzsanna McMahan, Elizabeth Volkmann, Gabriela Riemekasten, Marco Maticci-Cerinic, Masataka Kuwana, Yannick Allanore, Francesco Del Galdo, Marie-Elise Truchetet
- P.182 SCLEROGUT: Description of micronutrient deficiencies, identification of risk factors and correlation with digestive involvement in systemic sclerosis**
Louis Bébear, Julien Seneschal, Florian Poullenet, Pauline Rivière, Thomas Barnette, Estibaliz Lazaro, Thierry Schaevebeke, Christophe Richez, Nicolas Poursac, Nadia Mehnen, Marie-Elise Truchetet
- P.183 Evaluation of the Relationship Between Sarcopenia, Gastrointestinal Involvement and Malnutrition in Systemic Sclerosis**
 Aysegül Avcu, Zeynep Dilara Selcuk, Haner Direskeneli, Fatma Alibaz-Oner
- P.184 Autoantibodies targeting the cellular subsets in the ENS correlate with small bowel dysmotility patterns in patients with Systemic Sclerosis**
Luis Alcalá, Alfredo Guillen-Del-Castillo, Francisco Felix-Tellez, Claudia Codina, Carolina Malagelada, Carmen P Simeon-Aznar, Laura Triginer, Janire Perurena, Laura Viñas, Maite Sanz, Subhash Kulkarni, Zsuzsanna McMahan

09.RAYNAUD AND DIGITAL ULCERS

- P.185 Impact of immunosuppressive therapy on burden of recurrent digital ulcers in scleroderma vasculopathy**
 Sheh Yi Yeap, Stefano Rodolfi, Annalyn Nunag, Michela Maio, Medha Kanitkar, Voon H. Ong, Christopher P. Denton
- P.186 Clinical risk factors for the development of lower limb ulcers in patients with systemic sclerosis: A cohort study of 239 patients**
Tomoya Watanabe, Izumi Moteki, Yukari Hamamura, Haruka, Arakawa, Hisho Kawamura, Yasushi Ototake, Miwa Kanaoka, Yukie Yamaguchi
- P.187 Influence of BMI, fibromyalgia and migraine on symptom characteristics in people with primary Raynaud's phenomenon**
Reshma Seomore, Matthew Wells, Urszula Tymoszuk, Christopher P. Denton, Francesco Del Galdo, Sue Farrington, Nick Jeffries-Owen, Mithi Ahmed-Richards, Ariane Herrick, Michael Hughes, John D Pauling
- P.188 Optimising the assessment and novel mechanistic insights into digital ulcers in systemic sclerosis: Design of the International '100 DU' Study**
Ashley Seepujak, John Pauling, Marina Anderson, Ami Shah, Rosalind Benson, Francesco Del Galdo, Christopher Denton, Graham Dinsdale, Karen Douglas, Tracy Frech, Jessica Gordon, Monique Hinchcliff, Laura Hummers, Dinesh Khanna, Kimberly Lakin, Génessis Maldo Vélez, Andrea Murray, Mohamed Osman, Susanna Proudman, Lesley Ann Saketkoo, Michael Hughes
- P.189 Filmed Interviews Elucidate Diverse Patient Experiences with Digital Ulcers**
Tani Ngcozana, Sue Woodward, Jackie Sturt, Chris Denton
- P.190 Sensitivity Analysis of Thermal Imaging in Systemic Sclerosis (SATISS)**
Andrea Murray, Sophie Blaise, Jean-Luc Cracowski, Christopher Denton, Graham Dinsdale, Alicia Guigui, Kevin Howell, Michael Hughes, Joanne Manning, Elizabeth Marjanovic, Douwe Johannes Mulder, Paul New, John Pauling, Matthieu Roustit, Muditha Samaranyaka, Rita Schriemer, Annie van Roon, Arie van Roon, Saskia van de Zande, Jack Wilkinson, Sarah Wilkinson, Ariane Herrick
- P.191 Digital Artery Thickening in Systemic Sclerosis Correlates with Reduced Finger Blood Flow Independent of Nailfold Capillary Patterns: A High-Resolution Ultrasound Study**
 Anne Van Gessel, Ruby Welman, Mohammed Osman, Alja Stel, Arie Van Roon, Douwe Johannes Mulder
- P.192 Capillaroscopic Features in Systemic Sclerosis: A Comparative Study of Patients positive for Anti-Centromere and for Anti-topoisomerase I Antibodies from the CAPRAS Registry**
Susana Matias, Tomás Novais, Rodrigo Rei, Catarina Abreu, Vanessa Fraga, Alice Castro, Ana Cordeiro, Maria José Santos
- P.193 Refractory digital ulcers and chronic osteomyelitis complicating diffuse systemic sclerosis: a real-life case**
Sara Amaro Lopes, Mariana Diz-Lopes, Carlos Marques-Gomes, Marina Oliveira, Bárbara Fernandes Esteves, Miguel Correia Natal, Ana da Rocha Sá, Bruno Miguel Fernandes, Lúcia Costa, Raquel Miriam Ferreira, Georgina Terroso
- P.194 Raynaud's phenomenon in the setting of Immune Checkpoint Inhibitors: a case series and possible implications**
 Jeff Li, Maryam Buni, Huifang Lu, Jean Tayar, Shervin Assassi
- P.195 Non-pharmacological management of Raynaud's phenomenon in systemic sclerosis: a systematic review**
Kirmiti Kumar, Jai Ethan Paris, Emma Hocking, Kim Griggs, Laura Ross, Jenny Walker, Susanna Proudman
- P.196 Clinical and laboratory associations of TNF-alfa in patients with systemic scleroderma**
Olga Koneva, Rushana Shayachmetova, Liudmila Garzanova, Anastasia Avdeeva, Michail Diatroptov, Olga Ovsyannikova, Lidia Ananyeva
- P.197 An Audit of Iloprost Delivery in a Tertiary Scleroderma Specialist Centre**
Medha Kanitkar, Helen Quah, Myat Noe Oo, Annalyn Nunag, Aoife Tynan, Tanaka Ngcozana, Christopher Denton, Voon Ong
- P.198 Seasonal Variation in Public Interest in Raynaud's Phenomenon: A Search Trend Analysis in South Korea and a Cross-National Comparison**
 Bon San Koo, Bora Nam, Jae-Bum Jun
- P.199 Specialist Wound Care Services Provision and Sharp Debridement Practices for Digital Ulcers (DU) Management in Systemic Sclerosis (SSc): An International Survey**
 Rúben Duarte-Fernandes, Fernando Estevez-Lopez, Michael Hughes, Francesco Del Galdo, Begonya Alcacer-Pitarch

09. RAYNAUD AND DIGITAL ULCERS

- P.200** **The validity of Nailfold Capillaroscopy in the assessment of Raynaud's Phenomenon**
 Mahima Charan, Khin Aung, Shaza Obaid, Batsi Chikura
- P.201** **Photoelectric Plethysmography Reveals Distinct Digital Artery Recovery Patterns in Secondary Raynaud's Phenomenon: A 262-Patient Study with Systemic Sclerosis Subanalysis**
 Jesse Cappelle, Saskia C Van De Zande, Anne I Van Gessel, Alja J Stel, Arie M Van Roon, Udo Dj Mulder
- P.202** **Raynaud's phenomenon and systemic sclerosis : differences in microcirculatory adaptive changes to cold exposure**
 Joana Caetano, Marisa Nicolai, Elisabete Silva, Clemente Rocha, José Alves, Luis Rodrigues
- P.203** **The burden of calcinosis cutis on peripheral vascular involvement in systemic sclerosis: data from the Italian spring registry**
 Marius Cadar, Greta Pellegrino, Fabrizio Conti, Clodoveo Ferri, Marco Matucci-Cerinic, Rossella De Angelis, Valeria Riccieri
- P.204** **Mycophenolate mofetil in limited scleroderma reduces the risk of vascular complication leading to treatment escalation: emulation of a target trial using time-dependent propensity score-matching**
 Valentina Boni, Silvia Laura Bosello, Fabio Cacciapaglia, Rossella De Angelis, Edoardo Cipolletta, Gerlando Natalello, Maria Antonietta D'agostino, Veronica Codullo, Giacomo De Luca, Dilia Giuggioli, Francesca Ingegnoli, Valeria Riccieri, Clodoveo Ferri, Marco Matucci-Cerinic, Enrico De Lorenzis

10. SKIN AND LOCALIZED SCLERODERMA

- P.205** **Spatial Insights into Melanocyte Niches in Salt-and-Pepper Dyspigmentation of Systemic Sclerosis**
 Zhangyi Zhao, Chanhan Jia, Wanyi Lin, Chaoyu Gu, Fenglin Wu, Zhe Ding, Yuankai Sun, Hanlin Yin, Liangjing Lu
- P.206** **Cutaneous telangiectasia quantification as a predictive marker of vascular complications of Systemic Sclerosis**
 Matthew Wells, Theresa Smith, Aishwarya Anilkumar, Tracy M Frech, Ariane L Herrick, Laura K Hummers, Ami A Shah, Christopher P Denton, Dinesh Khanna, Robyn T Domsic, John D Pauling
- P.207** **"Two of the kind, yet with a differing course -The tale of heterogeneity within!"**
 Kamal Solanki, Kamal Solanki, Karen Koch, Alistair Brown
- P.208** **Rethinking skin assessment: analysis of individual Rodnan skin sites scores in early diffuse systemic sclerosis using the EUSTAR cohort**
 Tania Santiago, Cristiano Matos, Alain Lescoat, Michael Hughes, Dinesh Khanna, José António Pereira Da Silva, Eustar Collaborators

- P.209** **Enrichment criteria for skin progression in future trials: a preliminary analysis of skin progression in limited cutaneous systemic sclerosis and sine scleroderma patients using the EUSTAR cohort**
 Tania Santiago, Cristiano Matos, Michael Hughes, Dinesh Khanna, Alain Lescoat, Eustar Collaborators
- P.210** **Skin tissue parameters and CEMIP: promising candidate biomarkers in systemic sclerosis**
 Pauline Salpétier, Zoe Gendebien, Joan Somja, Genevieve Paulissen, Beatrice Andre, Zeld Plener, Marie-Elise Truchetet, Dominique De Seny, Clio Ribbens, Celine Deroyer
- P.211** **Ruxolitinib Therapy in Pansclerotic Morphea refractory to Autologous Stem-Cell Transplantation**
 Alexandros Panagiotopoulos, Ourania Kosta, Ioanna Eleftheriadou, Stylianos T. Panopoulos, Petros P. Sfikakis
- P.212** **From Normal to Active Scleroderma Pattern: Nailfold Videocapillaroscopy as a Mirror of Disease Progression in Systemic Sclerosis**
 Miguel Natal, Mariana Diz-Lopes, Carlos Marques Gomes, Bárbara Esteves, Marina Oliveira, Catarina Rua, Sara Amaro Lopes, Ana Rocha Sá, Lúcia Costa, Raquel Miriam Ferreira, Georgina Terroso
- P.213** **Comparison of localized scleroderma assessment tools, telethermography and ultrasound in the evaluation of juvenile localized cutaneous scleroderma: preliminary data of a monocentric study**
 Caterina Matucci-Cerinic, Saverio La Bella, Gianmaria Viglizzo, Luca Basso, Marco Gattorno, Clara Malattia
- P.214** **Current insights and Future Directives in Calcinosis Cutis Associated with Systemic Sclerosis**
 Luna Toppenberg Lazar, Mette Mogensen, Anne Braae Olesen
- P.215** **Impact of Skin Fibrosis on Quality of Life in Systemic Sclerosis: A Comparative Analysis of Clinical Measures and Patient-Reported Outcomes**
 Groseanu Laura, Nita Cristina, Boromiz Catalina, Mardale Denis, Bojinca Violeta, Mazilu Diana, Ilie Cristian, Opris-Belinski Daniela, Cobilinschi Claudia, Balanescu Andra
- P.216** **Immunosuppressive drug use in limited systemic sclerosis: an international survey**
 Sabrina Hoa, Yi Cheng Mu, Marie Hudson, Janet Pope
- P.217** **Features of patients with morphea: A single center 15-year experience**
 Ariana Gkovi, Nektarios Marios Liapis, Ioannis Alexiou, Christina Katsiari, Lazaros Sakkas, Dimitrios Bogdanos, Theodora Simopoulou
- P.218** **Changes of interleukin-4 in systemic sclerosis during immunosuppressive therapy**
 Liudmila Garzanova, Lidia Ananyeva, Olga Koneva, Olga Ovsyannikova, Oxana Desinova, Mayya Starovoytova, Rushana Shayakhmetova, Anna Khelkovskaya-Sergeeva, Anastasiya Avdeeva, Mikhail Diatroptov
- P.219** **The Effect of Autologous Fat Transfer on Skin Stiffness, Functional Parameters and Visual Appearance Perception in Systemic Sclerosis: Preliminary Results of a Prospective Study**
 Aysegul Avcu, Seyda Guray, Halit Delibalta, Onur Bugdayci, Tulin Ergun, Haner Direskeneli, Fatma Alibaz-Oner

10. SKIN AND LOCALIZED SCLERODERMA

- P.220 Morphea Across the Gulf Region: Largest Multicenter Cohort Highlights Disease Patterns and Therapy**
Rajaie Namas, [Sarah Al Qassimi](#), Moza Alzaabi, Waleed Hafiz, Maria Alsulami, Heba Nasef, Fawaz Aljehani, Mazin Aljabri, Fatima Abdulla, Farah Soukieh, Ahlam Almarzooqi, Mohammed Gamal, Noura Zamani, Aishwariya Padmakumari, Karima Becetti, Samar Alemadi, Rowaida Abou Hamdy, Ela Memisoglu, Ahmed Al Dhaheri, Asia Mubashir, Mohamed Elarabi
- P.221 Clinical Characteristics, Burden, and Outcomes of Calcinosis Cutis in Systemic Sclerosis: A Multicenter Cohort from the United Arab Emirates**
[Sarah Al Qassimi](#), Mohammed Gamal, Noura Zamani, Rajaie Namas
- P.222 Ex vivo calcinosis cutis analysis from patients with systemic sclerosis and dermatomyositis**
[Laura Agerley Rørsgaard](#), Søren Risom Kristensen, Henrik Lauridsen, Jesper Skovhus Thomsen, Luna Lazar, Anne Braae Olesen

11. PRECISION MEDICINE - INCLUDING MOLECULAR AND IMAGING STUDIES

- P.223 Comparison of Artificial Intelligence and Rheumatologists in Nailfold Capillaroscopic Evaluation**
[Nese Cabuk Celik](#), Elif Altunel Kilinc
- P.224 Metabolomic and lipidomic profiling in patients with systemic sclerosis**
[Cecilia Overdahl](#), Antonio Orlando, Roberto Giacomelli, Rille Pullerits, Yuan Zhang, Cristina Maglio
- P.225 The Role of Artificial Intelligence in Detecting Systemic Sclerosis Distinctive Facial Features**
[Yossra Suliman](#), Michal Torcick, John Antowan, Esraa Talaat, Jerry Wu, Thomas Winkler, Amyn Rajan, Daniel E Furst
- P.226 Unfolded protein response and binding immunoglobulin protein in Systemic Sclerosis-associated muscle disease**
[Elise Siegert Siegert](#), Andreas Hentschel, Udo Schneider, Gerhard Krönke, Werner Stenzel, Andreas Roos, Corinna Preube
- P.227 Identification of lipidomic biomarkers associated with disease progression in systemic sclerosis**
Sunhwa Kim, Yingtao Bi, Vishal Kakkar, [Rebecca Ross](#), Francesco Del Galdo
- P.228 Formulation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial**
[Stefano Rodolfi](#), Kristina Klark, Bahja Ahmed Abdi, Elen Roblin, Medha Kanitkar, Voon H Ong, Alexandre E Voskuyl, Jeska K. De Vries-Bouwstr, Jacob M Van Laar, Christopher P Denton, Julia Spierings

- P.229 Neutrophil-to-Lymphocyte Ratio as a Biomarker for Disease Onset and Severity in Systemic Sclerosis – Real-world data from a large healthcare provider in Israel**
[Doron Rimar](#), Shlomit Yaari, Gleb Slobodin, Shiri Keret
- P.230 Soluble immune checkpoints reflect immune activation and treatment response in high-risk systemic sclerosis patients**
[Judith Potjewijd](#), Rachid Tobal, Daan P.C. Van Doorn, Leon J. Schurgers, Peter Heeringa, Jan G.M.C. Damoiseaux, Pieter Van Paassen
- P.231 Exploring potential vegf receptor 2 inhibitors: a molecular modeling and pharmacophore-based screening approach**
[Matteo Mozzicafreddo](#), Devis Benfaremo, Silvia Agarbati, Carolina Clementi, Chiara Paolini, Silvia Svegiati Baroni, Gianluca Moroncini
- P.232 Early diagnosis of SSC-ILD progression: a comparative study of high-resolution chest CT assessment with visual and artificial intelligence-assisted scoring**
Francesca Motta, [Antonio Tonutti](#), Federica Catapano, Gianluca Sellaro, Francesco Amati, Anna Stainer, Calogero Messana, Stefano Aliberti, Marco Francone, Carlo Selmi, Maria De Santis
- P.233 Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis**
[Ji Soo Kim](#), Zixing Liu, Adrienne Woods, Julie Paik, Laura Hummers, Scott Zeger, Ami Shah
- P.234 Hand dexterity assesment in systemic sclerosis using an engineered glove: correlations with clinical features, high frequency skin ultrasonography and nailfold videocapillaroscopy**
Alberto Sulli, Elvis Hysa, Paolo Ciini, Emanuele Gotelli, Tamara Vojinovic, Carmen Pizzorni, Ali Jaffal, Sabrina Paolino, [Rosanna Campitiello](#), Vanessa Smith, Maurizio Cutolo
- P.235 Novel biomarkers of type vii collagen turnover are associated with interstitial lung disease and prognostic of pulmonary and skin outcomes**
[Signe Holm Nielsen](#), Pei-Suen Tsou, Marzieh Jamali, Johann E. Gudjonsson, Suiyuan Huang, Olesya Plazyo, Anne-Christine Bay-Jensen, John Varga, Dinesh Khanna
- P.236 Biomarkers of fibroblast activity and tissue destruction are associated with diffuse systemic sclerosis, and prognostic of pulmonary and cardiovascular outcomes**
[Signe Holm Nielsen](#), Pei-Suen Tsou, Marzieh Jamali, Johann E. Gudjonsson, Suiyuan Huang, Olesya Plazyo, Anne-Christine Bay-Jensen, John Varga, Dinesh Khanna
- P.237 Nailfold videocapillaroscopy in patients with suspected systemic sclerosis: a comparison of one-finger method versus eight-finger method**
[Dieneke Haverkort](#), Madelon Vonk
- P.238 A Novel Single Time Point Prediction Tool for Systemic Sclerosis-Associated Interstitial Lung Disease based on High Resolution Computed Tomography**
[Kim Grace Hyun](#), Jonathan Goldin, Donald Tashkin, Pangyu Teng, Bianca Villegas, Elizabeth Volkmann

11. PRECISION MEDICINE - INCLUDING MOLECULAR AND IMAGING STUDIES

- P.239 Clinical correlations of 18F-NaF PET/CT in the Assessment and Follow-up of Subcutaneous Calcinosis in Patients with Systemic Sclerosis. A 12-months' prospective study**
Bodor Gergely, Kristóf Apró, Tamás Czékus, Eszter Makai, Dávid Kurszán Jász, Dóra Tari, Gábor Kumánovics, László Czirják, Gabriella Szűcs, Zoltán Szekanez, László Kovács, Ilona Polyák, Zsuzsanna Besenyi
- P.240 Deciphering Synovitis in Systemic Sclerosis**
 Celina Geiss, Miranda Houtman, Camino Calvo Cebrían, Raphael Micheroli, Melpomeni Toitou, Anne Cauvet, Yannis Djéffal, Alexandra Khmelevskaya, Mojca Frank Bertoncelj, Sam Edalat, Thomas Rauer, Kristina Bürki, Chantal Pauli, Michael Bonelli, Thomas Karonitsch, Yannick Allanore, Oliver Distler, Caroline Ospelt, Muriel Elhaji
- P.241 Serum Biomarker Components Align with Lung and Cardiac Phenotypes in Systemic Sclerosis Through Principal Component Analyses (PCA)**
David Galarza, Francisco Maldonado, Laura Tío, Irene Carrión-Barberá, Laura Triginer, Alfredo Guillén-del Castillo, Anna Ribes, Lidia Valencia Muntalá, Jordi Monfort, Tarek Carlos Salman-Monte, Javier Narváez, Carmen Pilar Simeón-Aznar, Anna Pros
- P.242 Distinct Serum Metabolomic Profiles Differentiate Systemic Sclerosis with ILD From Idiopathic Pulmonary Fibrosis: An Untargeted Metabolomic Analysis**
James Dunne, Young Woong Kim, Liang Li, Shuang Zhao, Beth Whalen, Basak Sahin, Pearce Wilcox, Christopher Ryerson, Scott Tebbutt, Kevin Keen, Amrit Singh
- P.243 Identification of Distinct Phenotypes in Systemic Sclerosis Through Clustering Algorithm and Proteomic Analysis: Data from the PRECISESADS Study**
Santiago Dans Caballero, Rafaela Ortega Castro, Chary López Pedrera, Alejandro Escudero Contreras, Carlos Pérez Sánchez, Clementina López Medina
- P.244 Validation of strong candidate RNA biomarkers for Systemic Sclerosis**
Paraskevi P. Chairta, Savvas Psarelis, Sofia Symeonidou, Marios Tomazou, Nestoras Karathanasis, Styliana Menelaou, George M. Spyrou, Paschalis Nicolaou, Kyroula Christodoulou
- P.245 Serum Type I Interferon Activity as a Biomarker of Morbimortality in Systemic Sclerosis Independent of Cutaneous Subset**
Veronica Batani, Stefano Di Donato, Rebecca Ross, Marco Minerba, Enrico De Lorenzis, Vishal Kakkar, Christopher P. Denton, Francesco Del Galdo
- P.246 FTIR spectroscopy analysis and Machine Learning Approaches for Clinical Subtyping in Systemic Sclerosis: current and future perspectives**
Miziolek Bartosz, Miszczyk Justyna, Paja Wieslaw, Bultrowicz Monika, Pieczyrak Robert, Kucharz Eugeniusz, Depciuch Joanna

12. INNOVATIVE THERAPIES, INCLUDING CELL THERAPIES

- P.247 Multi-omic Profiling of Patients with Progressive Systemic Sclerosis Undergoing CD19 CAR-T Cell Therapy**
Hanlin Yin, Zhangyi Zhao, Chenhan Jia, Wanyi Lin, Fenglin Wu, Zhe Ding, Xuesong Liu, Liangjing Lu
- P.248 Anti-CD19 CAR T cell therapy in systemic sclerosis - Update on seven patients from Tuebingen**
Luisa Schneider, Ann-Christin Pecher, Wolfgang Bethge, Claudia Lengerke, Jörg Henes
- P.249 Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Diffuse Cutaneous Systemic Sclerosis: A Case Series Linking Outcomes to Patient Age and Conditioning Regimen**
Sithavarat Uthaiaphan, Chinadol Wanitpongpun, Tippawan Onchan, Patnarin Pongkulkiat, Siraphop Suwannaroj, Ajanee Mahakkanukrauh, Chingching Foocharoen
- P.250 Role of hematopoietic stem cell transplantation on microvasculature in systemic sclerosis**
Alba Maria Torrat Noyes, Elena Grau Garcia, Marta De La Rubia Navarro, Carmen Riesco Barcena, Daniel Ramos Castro, Iago Alcántara Alvarez, Belen Villanueva Mañes, Andres Perez Hurtado, Miguel Simeon Vinaixa, Patricia Anton Enguidanos, Belen Diaz Mora, Jose Andres Roman Ivorra
- P.251 Are we Putting the 'CART' before the Horse in Systemic Sclerosis? A review of the CAR-T studies in scleroderma**
Carlos Enrique Toro Gutierrez, Nader Khalidi, Janet Pope
- P.252 BCMAxCD3 bispecific antibody therapy with teclistamab induces profound B- and plasma cell depletion with preliminary clinical efficacy in the treatment of refractory systemic sclerosis - a case series**
 Elpidia Phithak, Robert Biesen, Fredrik Albach, Ioanna Minopolou, Arnd Kleyer, Edgar Wiebe, Marie Rehm, Qingyu Cheng, Arne Sattler, Stefano Bianco, Anja Fleischmann, Gerhard Krönke, Tobias Alexander, David Simon, Elise Siegert
- P.253 Unveiling the storm: prevalence and risk factors for cytokine release syndrome in systemic sclerosis patients undergoing autologous hematopoietic stem cell transplantation**
Charlotte Schimmel, Eva Hoekstra, Maaike Koops, Jacopo Ciaffi, Anna van Rhenen, Peter van dem Borne, Tom Huizinga, Jacob van Laar, Jeska de Vries-Bouwstra, Julia Spierings
- P.254 CAR-T Therapy for Relapsed Systemic Sclerosis After Autologous Hematopoietic Stem Cell Transplantation**
Doron Rimar, Abraham Avigdor, Shiri Keret, Paula David, Merav Lidar
- P.255 An innovative approach to the treatment of systemic sclerosis: the Cryopreserved autologous adipose tissue bank aka LIPOBANK, preliminary results from an Italian Scleroderma referral center**
Martina Orlandi, Valentina Pinto, Luca Contu, Amelia Spinella, Marco De Pinto, Massimo Pinelli, Dilia Giuglioli

12. INNOVATIVE THERAPIES, INCLUDING CELL THERAPIES

- P.256** **Persisting CD19-CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 3 years**
Wolfgang Merkt, Manuel Röhrich, Eleni Mavriopoulou⁵, Ayla Stütz, Anita Schmitt, Markus Polke, Claus Peter Heußel, Michael Schmitt, Hanns-Martin Lorenz
- P.257** **RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis**
Dinesh Khanna, Monalisa Ghosh, Ankoor Shah, Sonali Bracken, George Georges, Carrie Richardson, Benjamin Korman, Elena Bernstein, PS Tsou, Charles Ross, Carleigh Zahn, Courtney Little, Mikaela Raymond, Adreeja GuhaRay, Jenell Volkov, Daniel Nunez, Thomas Furmanak, Jason Stadanlick, Larissa Ishikawa, Zachary Vorndran, Alexandra Ellis, Jazmean Williams, Steve Flanagan, Quynh Lam, Domenico Braccia, Fatemeh Hadi-Nezhad, Dan Thompson, Raj Tummala, Samik Basu, David Chang
- P.258** **Reduction of TH2 overexpression after stem cell transplantation is associated with clinical response**
Olschner Johannes, Pecher Ann-Christin, Klein Reinhild, Henes Jörg
- P.259** **Advancing drug development for systemic sclerosis by prioritising findings from human genetic association studies**
Michael Hughes, Zsuzsanna McMahan, Shervin Assassai, Christopher Denton, Rui Providencia
- P.260** **A Phase IIb, open label, Randomised Trial within Cohort (TWiC) of IV Anifrolumab in Adults with Systemic Sclerosis. The REASCENT study**
Collette Hartley, Enrico De Lorenzis, Lesley-Anne Bissell, Marco Minerba, Francesco Del Galdo
- P.261** **The efficacy and safety of divozilimab, anti-cd20 monoclonal antibody in patients with systemic sclerosis**
Lidia Ananyeva, Liudmila Garzanova, Inna Gaydukova, Mayya Starovoytova, Galina Lukina, Diana Abdulganieva, Elena Zonova, Larisa Eliseeva, Gulshat Fatkhullina, Anton Lutsyky, Arina Zinkina-Orikhan, Yulia Linkova, Ekaterina Fokina, Anastasia Porozova, Anna Ereemeeva, Polina Pukhtinskaia
- P.262** **Impact of autoantibodies specific for systemic sclerosis in disease course on anti-B-cell therapy**
Liudmila Garzanova, Lidia Ananyeva, Olga Koneva, Olga Ovsyannikova, Oxana Desinova, Mayya Starovoytova, Rushana Shayakhmetova, Anna Khelkovskaya-Sergeeva
- P.263** **Safety and efficacy of four years aminaphtone administration in systemic sclerosis patients**
Rosanna Campitiello, Sabrina Paolino, Emanuele Gotelli, Elvis Hysa, Carmen Pizzorni, Elisa Alessandri, Arlin Lysha, Antonio Maggio, Giulia Bernardi, Gianluca Mairone, Tamara Vojinovic, Maurizio Cutolo, Alberto Sulli
- P.264** **M10 as a Novel Drug Candidate for Skin Fibrosis**
Galina Bogatkevich, Iliia Atanelishvili, Dilyn Clarke, Richard Silver

- P.265** **Development of gastrointestinal symptoms in patients with diffuse cutaneous systemic sclerosis after CD19-targeting CAR T cell therapy**
Janina Auth, Andrea Zoli, Panagiotis Garantziotis, Andreas Wirsching, Melanie Hagen, Fabian Müller, Michael Aigner, Sascha Kretschmann, Soraya Kharboubti, Simon Völkl, Armin Atzinger, Sebastian Böltz, Carlo Tur, Maria Gabriella Raimondo, Ricardo Grieshaber-Bouyer, Andreas Mackensen, Georg Schett, Christina Bergmann

13. RANDOMIZED CLINICAL TRIALS

- P.266** **Effects of a Self-Management Telehealth Program on Improving Strength and Hand Function in Systemic Sclerosis Patients: A Randomized Controlled Trial**
Orathai Wantha, Ajane Mahakkanukrauh, Siraphop Suwannaroj, Kwankaew Tuydaung, Nonglak Methakanjanasak, Kannika Srichomphu, Jinnaphat Kraipoj, Chingching Foocharoen
- P.267** **TibuSURE: A Phase 2, Global, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Tibulizumab in Systemic Sclerosis**
Christopher Denton, Brandon Walsh, Vaishali Moulton, Shelly Shirkey, Kate Lindsell, Marjan Sepassi, Kiran Nistala, Dinesh Khanna
- P.268** **Efficacy and Safety Results From a Phase 2b Trial of Fipaxalparant in Patients With Diffuse Cutaneous Systemic Sclerosis**
Dinesh Khanna, Yannick Allanore, Masataka Kuwana, Janet Pope, Krischan Hudson, Arati Kiran Kanchi, Yang Song, Zhan Ye, Christopher P. Denton
- P.269** **Screening failure in systemic sclerosis randomized trials: reporting, rates, causes, and trends over time**
 Delphine Courvoisier, Barbara Russo, Iulia-Simona Chirica, Michele Iudici
- P.270** **Efficacy and Safety of Nerandomilast in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the FIBRONEER-ILD trial**
Anna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, Michael Kreuter, Claudia Valenzuela, Marlies S. Wijsenbeek, Hui Gu, Ivana Ritter, Susanne Stowasser, Gerrit Weimann, Toby M. Maher, Hao Li
- P.271** **MTX-474 appears safe and well tolerated, engages its target, EphrinB2, and impacts pharmacodynamic biomarkers in healthy volunteers**
Jeffrey Bornstein, Pablo Zertuche, Rezi Zawadski, Colleen Graham, Chris Espelin, Kelly Regal, Daniel Beal, Paul Yaworski
- P.272** **Efgartigimod PH20 Subcutaneous in Adults With Systemic Sclerosis: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study (eSScape)**
Dinesh Khanna, Francesco Del Galdo, Christopher P. Denton, Oliver Distler, Masataka Kuwana, Despoina Papadopoulou, Bas Van Der Woning, Erica Falkenbach, Agna Neto, Piotr Zabrocki, Marco Matucci-Cerinic
- P.273** **SHARP dEbridement of Digital ulcer in Systemic Sclerosis (SHED SSc): a multicenter Randomised Control Trial feasibility study**
Begonya Alcaccer-Pitarch, Ruben Duarte-Fernandes, Caroline Fairhurst, Annalyn Nunag, Jude Watson, Maisie Martland, Medha Kanitkar, Daniel Gallo, Philip Laws, Anthony C. Redmond, Christopher P. Denton, Adam Martin, Chris Bojke, David Torgerson, Andrea Nelson, Francesco Del Galdo

14. STANDARD OF CARE THERAPIES

- P.274 Hospitalizations in Systemic Sclerosis: Causes, Duration, and Outcomes in a One-Year Retrospective Study**
 Nikoleta Zioga, Theodora Simopoulou, Dimitrios Bogdanos
- P.275 The Effect of Empagliflozin on Skin Fibrosis in a Bleomycin-Induced Scleroderma Model and Comparison of Different Routes of Administration**
 Seyma Yilmaz, Seda Duman Ozturk, Cuneyt Ozer, Ozgur Cakir, Andac Komac, Ayten Yazici, Ayse Cefle, Duygu Temiz Karadag
- P.276 Immunosuppressive therapy persistence in systemic sclerosis: the role of anti-centromere antibodies**
 Martina Salerno, Marius Cadar, Ilaria Bisconti, Francesca Romana Di Ciommo, Elena Platania, Jacopo Landro, Beatrice De Girolamo, Davide Mohammad Reza Beigi, Simona Truglia, Fabrizio Conti, Valeria Riccieri
- P.277 Rituximab in Patients with Systemic Sclerosis Non-responsive to csDMARDs – Preliminary Results of a Prospective Observational Monocentric Study over 36 Months**
 Oreská Sabina, Daniel Zavada, Aneta Jirankova, Anna Bobrova, Katerina Bobrova, Eliska Sudkova, Emma Polouckovs, Barbora Hermankova, Hana Wünc, Karel Pavelka, Ladislav Senolt, Jiri Vencovsky, Radim Becvar, Michal Tomcik
- P.278 Effects of non-pharmacological therapies in systemic sclerosis: A longitudinal observational study**
 Nicole Nyfeler, Frank Behrendt, Corina Schuster-Amft, Ulrich Gerth, Zorica Suica
- P.279 Development of a Multidisciplinary Dutch Clinical Practice Guideline for the Treatment of Secondary Raynaud's Phenomenon and Related Digital Ulcers in Secondary and Tertiary Care**
 Amaal Eman Abdule, Anniëk Van Roon, Femke Bonte-Mineur, Zana Brkic, Jamy Pullen, Mike Ruetterman, Ben Saleem, Sanne Van Schaik-Mast, Anne Schouffoer, Rita Schriemer, Julia Spierings, Sanne Van Wissen, Mariska Tuut, Douwe Johannes Mulder
- P.280 Evaluation of skin involvement and disease activity in Greek patients with systemic sclerosis treated with bosentan during a 18-month follow-up period: results from the CURE clinical study**
 Katerina Laskari, Dimitrios Vassilopoulos, Theodoros Dimitroulas, Dimitrios Daoussis, Paraskevi Voulgari, Gkikas Katsifis, George Bertisias, Argiro Repa, George Katsikas, Nikolaos Papadopoulos, Theofanis Karageorgas, Polyanthi Papanastasiou, Georgios Tsioumas, Theodora Simopoulou, Dimitrios Bogdanos, Petros P Sfikakis
- P.281 Real-life observational study to evaluate Raynaud's severity and the change in digital ulcers in Greek patients with systemic sclerosis treated with bosentan. The CURE study**
 Katerina Laskari, Dimitrios Vassilopoulos, Theodoros Dimitroulas, Dimitrios Daoussis, Paraskevi Voulgari, Gkikas Katsifis, George Bertisias, Argiro Repa, George Katsikas, Nikolaos Papadopoulos, Eleni Pagkopoulou, Theofanis Karageorgas, Alexandros Ginis, Georgios Tsioumas, Theodora Simopoulou, Dimitrios Bogdanos, Petros Sfikakis

- P.282 Impact of updated treatment paradigms on clinical trial referral in diffuse cutaneous systemic sclerosis**
 Kimberly Lakin, Robert Spiera, Antonia Valenzuela, Deanna Jannat-Khah, Kelsey Gripp, Oshmita Golam, John Pauling, Jessica Gordon
- P.283 Randomized controlled trials of drug interventions in limited cutaneous systemic sclerosis: a systematic literature review**
 Minh-Duc Ngo, Sasha Bernatsky, Sabrina Hoa
- P.284 Safety of Rituximab Combined with Mycophenolate Mofetil Versus Rituximab Monotherapy in Patients with Systemic Sclerosis – A Single-Center Real-Life Retrospective Study**
 Anna Cuberli, Beatrice Moccaldi, Marco Binda, Maria Favaro, Elisabetta Zanatta, Andrea Doria
- P.285 Safety And Effectiveness Of Tocilizumab In Systemic Sclerosis: A Multicenter French-Italian Study**
 Corrado Campochiaro, Giulia Buonsante, Elena Marazzi, Fabio Cacciapaglia, Maria Grazia Lazzaroni, Marco De Pinto, Devis Benfaremo, Valentina Longo, Carlo Iandoli, Giovanna Cuomo, Anna Cuberli, Elisabetta Zanatta, Alain Lescoat, Silvia Bellando Randone, Georgia Trignani, Serena Guiducci, Lorenzo Beretta, Gianluca Moroncini, Dilia Giuggioli, Paolo Airo, Florenzo Iannone, Veronica Codullo, Silvia Laura Bosello, Nicoletta Del Papa, Giacomo De Luca, Marie-Elise Truchetet, Jerome Avouac, Lorenzo Dagna, Marco Matucci-Cerinic, Yannick Allanore
- P.286 Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses**
 Francesco Bonomi, Ilaria Bisconti, Ilenia Mallia, Greta Pellegrino, Gabriele Ciuti, Gloria Muolo, Martina Salerno, Simona Truglia, Cristiano Barbetta, Silvia Peretti, Serena Guiducci, Valeria Riccieri, Silvia Bellando Randone

15. PATIENT PERSPECTIVE, INCLUDING PATIENT-REPORTED OUTCOMES

- P.287 Predictors of work disability in systemic sclerosis**
 Ekaterina Mikheeva, Alesya Klimenko, Natalia Babadayeva, Tatiana Kargaeva
- P.288 Incorporating User Research into AI-Guided Nailfold Capillaroscopy Software to Support Early Diagnosis of Systemic Sclerosis**
 Sarah Wilkinson, Chelsea Sawyer, Sarah Groves, Andrea Murray, Edith Brown, Michael Berks, Chris Taylor, Ariane Herrick, Lamiece Hassan
- P.289 Cannabis oil in systemic sclerosis: exploratory evaluation of subjective pain outcomes in a placebo-controlled trial**
 Orathai Wantha, Siraphop Suwanaroj, Chingching Foocharoen, Ajane Mahakkankurath
- P.290 Disease features and patients reported outcomes: data from a Peruvian systemic sclerosis cohort**
 Alberto Miguel Vicente Perez, Samira Garcia-Hirsh, Manuel F. Ugarte-Gil, Denisse Toledo-Neira, Jesus Sime-Diaz, Victor Pimentel-Quiroz, Rocio V, Gamboa-Cardenas

15. PATIENT PERSPECTIVE, INCLUDING PATIENT-REPORTED OUTCOMES

- P.291 Regional Differences in Mental Health Burden and Support in Systemic Sclerosis: Patient and Physician Perspectives From a Multinational Real-World Survey**
Dan Twigg, Isabel Truman, Nicola Massey
- P.292 Multifactorial explanatory model of fatigue in patients with systemic sclerosis: a structural equation approach**
 Ana Francisca, Pedro Matos, Eduardo Santos, Anabela Silva, Paula Vicente, JAP Da Silva, Maria João Salvador, Tânia Santiago
- P.293 Correlation between functional disability, systemic burden and presence of depressive symptoms in a cohort of patients with systemic sclerosis**
Carmen Riesco Bárcena, Elena Grau Garcia, Jose Andrés Román Ivorra
- P.294 Activity limitations and quality of life in persons with systemic sclerosis**
Henrik Pettersson, Karin Pettersson, David Byström, Susanne Pettersson, Marie Holmqvist, Malin Regardt
- P.295 EULAR Systemic Sclerosis Impact of Disease (SclerID): a tool to assess patient-reported disease burden and organ damage: evidence from an Italian multicenter cross-sectional and longitudinal study**
 Eleonora Pedretti, Liala Moschetti, Elda Piovani, Claudia Barison, Eleonora Pazzi, Emma Manzoni, Elena Platania, Ilaria Bisconti, Francesco Bonomi, Carmela Coccia, Silvia Peretti, Veronica Batani, Valeria Riccieri, Silvia Bellando-Randone, Corrado Campochiaro, Giacomo De Luca, Marco Matucci-Cerinic, Fabio Cacciapaglia, Ilaria Cavazzana, Franco Franceschini, Maria-Grazia Lazzaroni, Paolo Airo
- P.296 clinical and functional correlates of the ABILHAND-SSC score in a Portuguese systemic sclerosis cohort**
João Oliveira, Filipa Canhão André, Paula Vincente, Tânia Santiago, Maria João Salvador
- P.297 Face to face scleroderma family day patient feedback**
Tani Ngcozana, Rachel Ochiel, Christopher Denton, Voon Ong, Deborah Akinsulire
- P.298 High frequency of miscarriages in diffuse cutaneous form of systemic sclerosis**
Dóra Nemes-Tömöri, Julianna Janka Marien, Gyöngyike Emese Majai, Melinda Nagy-Vincze
- P.299 Adaptation and validation of the scleroderma skin patient-reported outcome questionnaire into Hungarian**
 Panna Pytel, Ágnes Ágoston-Szabó, Attila Szabó, Gábor Kumánovics, Gabriella Nagy
- P.300 Validity of translation and cross-cultural adaptation for the Scleroderma Skin Patient- Reported Outcome in Thai systemic sclerosis patients**
Kamonwan Mulalin, Chingching Foocharoen, Orathai Wantha, Siraphop Suwannaroj, Patnarin Pongkulkiat, Tippawan Onchan, Ajane Mahakkankurauh
- P.301 Defining the symptom severity and palliative care needs of patients with systemic sclerosis**
Julie McDonald, Laura Ross
- P.302 Comparing the symptom severity and specialist palliative care needs in systemic sclerosis with incurable cancer**
Julie McDonald, Laura Ross
- P.303 The power of an engaged and empowered patient**
Melissa Marquis
- P.304 Artificial Intelligence-Based Prediction of Organ Involvement in Systemic Sclerosis**
Nune Manukyan, Valentina Vardanyan, Vahan Mukuchyan, Anna Sargsyan, Syuzanna Vardanyan, Sona Mardoyan
- P.305 Do patients reported outcomes overlap with disease activity indices and severity scores in systemic sclerosis?**
Groseanu Laura, Boromiz Catalina, Nita Cristina, Opris-Belinski Daniela, Bojnic Violeta, Mardale Denis, Ilie Cristian, Mazilu Diana, Borangiu Andreea, Alexandra Boromiz, Balanescu Andra
- P.306 Comparative analysis of systemic sclerosis in Indian and us cohorts: insights from two national registries**
Puneet Kapoor, Sean Lim, Shufeng Li, Swarna Swarna, Uma Ayachit, Anna C Das, Padmanabha Shenoy, Joicy Jose, Virginia Steen, John M. Vanburen, Shervin Assassi, Elana J. Bernstein, Flavia V. Castellino, Luke B Evnin, Tracy M. Frech, Jessica K. Gordon, Faye N. Hant, Ami A. Shah, Ashima Makol, Jerry A. Molitor, Carrie Richardson, Dinesh Khanna, Nora Sandorfi, Ankoor Shah, Elizabeth R. Volkman, Andreea Bujor, Vineeta Shobha, Rita Popat, Lorinda Chung
- P.307 Validation of the SCTC-AI in a U.S. systemic sclerosis cohort**
 Ayush Kalia, Sophia Ruser, Morgan Emokpae, Bindu Koyi, Abhijeet Danve, Michael Zamani, Bashar Kadhim, Ilayda Gunes, Mandana Nikpour, Monique Hinchcliff
- P.308 The consumption of medical health services by systemic sclerosis patients up to five years prior to diagnosis: a population -based case control study**
Helana Jerjes, Ariel Israel, Eugene Marzon, Mohammad E. Naffaa
- P.309 Patient perspective of hand function impairment in daily life with systemic sclerosis**
Mark Greveling, Stefano Rodolfi, Nora El Bardai, Chris Denton, Rita Schriemer, Nick Jeffries-Owen, Voon Ong, Lieke Tweehuisen, Julia Spierings
- P.310 Greek adaptation of the VENUS questionnaire: Rheumatologists' perspectives on nutrition in patients with systemic sclerosis**
Arriana Gkouvi, Eleni Pardali, Elisavet Efthymiou, Theodora Simopoulou, Dimitrios Bogdanos, Maria Grammatikopoulou
- P.311 Structured assessment of patients with Raynaud's phenomenon- a way to follow patients with signs of very early diagnosis of systemic sclerosis**
Ingrid Gerhardson, Malin Regardt, Marie Holmqvist, Susanne Pettersson

15. PATIENT PERSPECTIVE, INCLUDING PATIENT-REPORTED OUTCOMES

- P.312 Hand disability, dyspnea and fatigue are associated with Quality of Life (QoL) in Systemic Sclerosis patients: Report from the Peruvian Almenara Scleroderma Cohort**
Rocio V Gamboa-C, Samira Garcia-Hirsh, Alberto-M Vicente-Perez, Denisse Toledo-Neyra, Jesus-M Sime-Veliz, Victor-R Oimentel-Quiroz, Manuel-F Ugarte-G
- P.313 Hand function impairment in Systemic Sclerosis: determinants through investigations of clinical, radiographic and ultrasonographic features**
Giulia Franchi, Elena Marazzi, Alain Lescoat, Sophie Hecquet, Sandrine Carves, Guillaume Coiffier, Marine Tas, Veronica Codullo, Carlomaurizio Montecucco, Jerome Avouac, Yannick Allanore
- P.314 Determinants of Functional Disability in Systemic Sclerosis: Insights from the Scleroderma Health Assessment Questionnaire (SHAQ)**
Bárbara Fernandes Esteves, Carlos Marques-Gomes, Mariana Diz-Lopes, Miguel Correia Natal, Marina Oliveira, Ana Rocha Sá, Sara Amaro Lopes, Georgina Terroso, Lúcia Costa, Raquel Miriam Ferreira
- P.315 Arabic Translation and Validation of the EULAR Systemic Sclerosis Impact of Disease (SclerID) Questionnaire**
Rahma Elziaty, Maha Elgaafary, Mary Wadie, Walaa Elwakil, Safaa Mahran, Yasser Elmiedany
- P.316 Validity and Reliability of the Rosenberg Self-Esteem Scale - Short Form in Turkish in Patients with Systemic Sclerosis**
Özlem Dogan Agbuga, Betül Dikkanoglu Demirok, Ayse Cefle, Esmâ Eseroglu, Abdulsamet Erden, Gezmis Kimyon, Esra Genc, Mehmet Engin Tezcan, Mücteba Enes Yayla, Murat Turgay, Gülsah Yamancan, Ahmet Karatas, Süleyman Serdar Koca, Mehmet Akif Baltacı, Alper Sari, Arif Babayigit, Ali Sahin, Serdar Can Güven, Orhan Küçükşahin, Sükran Erten, Fatih Albayrak, Orhan Zengin, Mustafa Erdogan, Murat Inanc, Merih Birlik, Ali Akdogan, Duygu Temiz Karadag
- P.317 Significant unmet needs and treatment preferences concerning patients' orofacial needs in systemic sclerosis: Results from a large international survey**
Eleni Deligianni, Lee Shapiro, Zsuzsanna H. McMahan, Michael Hughes
- P.318 Cross validation and sensitivity to change of EULAR SclerID as a measure of function and impact of disease in patients with Systemic Sclerosis**
Seda Colak, Stefano Di Donato, Riccardo Bixio, Lesley-Anne Bissell, Theresa Barnes, Muhammad Nisar, Vishal Kakkur, Christopher Denton, Francesco Del Galdo
- P.319 Comparative Sensitivity to Change of SclerID and UCLA GIT Score in a Lower GI Predominant SSC Cohort**
Maylen Nordgaard Carstens, Torhild Garen, Håvard Halland Fretheim, Hilde Jessen Bjørkekjær, Emily Eng Langballe, Øyvind Midtvedt, Øyvind Molberg, Anna-Maria Hoffmann-Vold
- P.320 Beyond the White Coat: Patient Education Initiative**
Amy Gietzen, Hannah Bowen, Lee Shapiro, Steve Rosenblum

- P.321 Exploring the Subjective Burden of Upper Gastrointestinal Involvement in Systemic Sclerosis: Are Current Activity Scores Reflective Enough?**
Catalina-Anamari Boromiz, Cristian-Mihai Ilie, Cristina-Elena Nita, Alexandra Boromiz, Claudia-Oana Cobilinschi, Daniela Opris-Belinski, Andra-Rodica Balanescu, Laura-Maria Groseanu
- P.322 Profiling Fatigue in Systemic Sclerosis: Clinical Predictors and Implications for Disease Monitoring**
Francesco Bonomi, Silvia Peretti, Veronica De Silvestri, Giulia Bandini, Ilenia Mallia, Khadija El Aoufy, Serena Guiducci, Zsuzsanna H McMahan, Alberto Moggi Pignone, Cosimo Bruni, Marco Matucci-Cerinic, Michael Hughes, Silvia Bellando Randone
- P.323 Anxiety and depression in Hispanic patients with systemic sclerosis**
Juan Pablo Gonzalez Morales, Joselyn Aracely Alvarez Meza, Ana Cecilia Bardan Inchaustegui, Gisela Garcia Arellano, Valeria Cantu Martinez, Diana Paola Flores Gutierrez, Paola Fernanda Martinez Valencia, Pablo Emmanuel Meza Lugo, Maximiliano Miranda Velazquez, Miguel Angel Villarreal Alarcon, Jesus Alberto Cardenas de la Garza, Dionicio Angel Galarza Delgado
- P.324 Yoga Therapy for Digestive Health: Case Series Highlighting Patient-Centered Approaches in Scleroderma**
Cheryl Albright, Alexis Harrison, Irene Gallagher
- P.325 Adaptation and validation of the Brief-Satisfaction With APpearance scale questionnaire into Hungarian**
Ágnes Agoston-Szabó, Attila Szabó, Panna Pytel, Gabriella Nagy, Gábor Kúmánovics
- P.326 Muscle involvement in systemic sclerosis**
Antónia Nikolett Ács, Máté Palancsa, Zsófia Bálint, Franciska Kiss, Cecilia Varjú
- P.327 Impact of Systemic Sclerosis on Work, Family, and Couple Life: Insights from a North African Patients Group**
Houssein Abida, Salem Fekih, Emna Ben Hnia, Lamia Moati

16. PEDIATRIC SCLERODERMA

- P.328 Physiotherapy of Hand Function in Juvenile Systemic Sclerosis: A Case Study Using the MediTutor Robotic Glove**
Maja Spiritovic, Natalie Kleistnerova, Vojtech Spet, Ales Prihoda, Leos Navratil
- P.329 Pediatric systemic sclerosis and localized scleroderma - a systematic review of clinical presentation and management in published original articles**
Paul Levannier, Sophie Martchenko, Véronique Despert, Claire Cazalets, François Robin, Nicolas Belhomme, Ninon Le Goaziou, Alain Dupuy, Catherine Droitcourt, Alain Lescoat
- P.330 Case of Nailfold Capillaroscopy in Juvenile Systemic Sclerosis: From Very Early Detection to Treatment Response Monitoring**
Hyun-Sook Kim, Seung-Jae Hong

16. PEDIATRIC SCLERODERMA

P.331 Age of onset effect on the clinical manifestations of patients with Juvenile Systemic Sclerosis

Ivan Foeldvari, Jens Klotsche, Kathryn Torok, Ozgur Kasapcopur, Brian Feldman, Flavio Sztajn bok, Maria Teresa Terreri, Raju Khubchandani, Jordi Anton, Gülcan Özomay Baykal, Sindhu Johnson, Dieneke Schonenberg-Meinema, Valda Stanevicha, Ekaterina Alexeeva, Maria Katsicas, Sujata Sawhney, Vanessa Smith, Sima Abu Al-Saoud, Eslam Al-Abadi, Simone Appenzeller, Natalia Cabrera, Stefanie Hajek, Siri Opsahl Hetlevik, Suzanne Li, Edoardo Marrani, Clare Pain, Anjali Patwardhan, Bertntson Lillemor, Jorge M López Benítez, Nicola Helmus

P.332 Anticentromere antibodies are occurring only in 6% of juvenile systemic sclerosis patients but correlate with more severe pulmonary involvement

Ivan Foeldvari, Jens Klotsche, Kathryn Torok, Maria Teresa Terreri, Sindhu Johnson, Flavio Sztajn bok, Jordi Anton, Brian Feldman, Raju Khubchandani, Gülcan Özomay Baykal, Dieneke Schonenberg-Meinema, Ekaterina Alexeeva, Maria Katsicas, Vanessa Smith, Sima Abu Al-Saoud, Simone Appenzeller, Stefanie Hajek, Siri Opsahl Hetlevik, Mikhail Kostik, Suzanne Li, Hana Malcova, Edoardo Marrani, Anjali Patwardhan, W-Alberto Sifuentes-Giraldo, Natalia Vasquez-Canizares, Natalia Cabrera, Jorge M López Benítez, Nicola Nicola

P.333 Is anti-Scl70 positivity associated with a more severe disease in juvenile systemic scleroderma?

Ivan Foeldvari, Jens Klotsche, Kathryn Torok, Ozgur Kasapcopur, Brian Feldman, Flavio Sztajn bok, Maria Teresa Terreri, Sindhu Johnson, Jordi Anton, Raju Khubchandani, Valda Stanevicha, Gülcan Özomay Baykal, Dieneke Schonenberg-Meinema, Ekaterina Alexeeva, Maria Katsicas, Sujata Sawhney, Vanessa Smith, Sima Abu Al-Saoud, Eslam Al-Abadi, Simone Appenzeller, Stefanie Hajek, Siri Opsahl Hetlevik, Mikhail Kostik, Suzanne Li, Edoardo Marrani, Anjali Patwardhan, Natalia Vasquez-Canizares, Natalia Cabrera, Jorge M López Benítez, Nicola Helmus

P.334 Patient and physician reported outcomes of juvenile systemic sclerosis patients significantly improve over 12 months observation period in the juvenile systemic scleroderma inception cohort

Ivan Foeldvari, Jens Klotsche, Ozgur Kasapcopur, Brian Feldman, Maria Teresa Terreri, Kathryn Torok, Sindhu Johnson, Jordi Anton, Gülcan Özomay Baykal, Flavio Sztajn bok, Valda Stanevicha, Maria Katsicas, Raju Khubchandani, Simone Appenzeller, Tadey Avcin, Mikhail Kostik, Edoardo Marrani, W-Alberto Sifuentes-Giraldo, Dieneke Schonenberg-Meinema, Dana Nemcova, Nicola Helmus

P.335 A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease

Ivan Foeldvari, Jens Klotsche, Kathryn Torok, Ozgur Kasapcopur, Flavio Sztajn bok, Maria Teresa Terreri, Jordi Anton, Raju Khubchandani, Sindhu Johnson, Gülcan Özomay Baykal, Brian Feldman, Dieneke Schonenberg-Meinema, Sujata Sawhney, Vanessa Smith, Eslam Al-Abadi, Simone Appenzeller, Stefanie Hajek, Maria Katsicas, Mikhail Kostik, Suzanne Li, Hana Malcova, Anjali Patwardhan, W-Alberto Sifuentes-Giraldo, Natalia Vasquez-Canizares, Nicola Helmus

P.336 Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?

Ivan Foeldvari, Jens Klotsche, Kathryn Torok, Ozgur Kasapcopur, Brian Feldman, Flavio Sztajn bok, Maria Teresa Terreri, Jordi Anton, Sindhu Johnson, Raju Khubchandani, Gülcan Özomay Baykal, Dieneke Schonenberg-Meinema, Eslam Al-Abadi, Maria Katsicas, Sujata Sawhney, Sima Abu Al-Saoud, Simone Appenzeller, Natalia Cabrera, Stefanie Hajek, Siri Opsahl Hetlevik, Suzanne Li, Edoardo Marrani, Clare Pain, Vanessa Smith, Mikhail Kostik, Hana Malcova, Patricia Costa Reis, Jorge M López Benítez, Mihaela Sparchez, Nicola Helmus

P.337 Emotional and Social Impact of Juvenile Systemic Sclerosis: Insights from PedQL Outcomes

Elena deRosas, Kathryn Torok

P.338 Nailfold Videocapillaroscopy in the Assessment of Juvenile Connective Tissue Diseases

Marco Binda, Beatrice Moccaldi, Francesca Tirelli, Anna Cuberli, Andrea Benini, Alessandra Meneghel, Roberta Ramonda, Francesco Zulian, Elisabetta Zanatta

17. OVERLAP SYNDROMES

P.339 Upadacitinib in a Rare Systemic Sclerosis-Ankylosing Spondylitis Overlap

Milan Bogojevic, Milica Markovic Vlaisavljevic, Rifat Medjedovic, Natasa Miketic, Marco Matucci-Cerinic

P.340 Histopathological clinical correlation of juvenile systemic sclerosis and overlap syndrome: report of two cases. national hospital dos de mayo, lima - Peru

Janeth Edalina Villegas Guzmán, Ingrid Yanina Saavedra Carcausto, Nancy Lourdes Mayo Simón, Roxana Maybor Lipa Chancolla

P.341 Triple Threat: A rare case of Systemic Sclerosis, Psoriatic Arthritis, and Inflammatory Myopathy

Daniele Tragni, Angelo Simone, Donatello Marziliano, Silvia Novielo, Carolina Marasco, Sebastiano Cicco, Roberto Ria, Angelo Vacca

P.342 The prognosis for pulmonary hypertension in systemic sclerosis complicated by Sjögren's syndrome is favorable

Kae Takagi, Yuki Ichimura, Akiko Tochimoto, Tomoaki Higuchi, Yasushi Kawaguchi

P.343 Overlap of Systemic Sclerosis and Sjögren's Disease: insights from an Italian case-control study

Stefano Stano, Fabio Cacciapaglia, Maria Morrone, Simone Perniola, Marco Capodiferro, Marco Fornaro, Laura Coladonato, Giuseppe Lopalco, Florenzo Iannone

P.344 Recalcitrant tumorous symptomatic calcifications in PM-Scl Scleroderma Overlap patient

Kamal Solanki, Kamal Solanki, Rajesh Kumar

P.345 Mediastinal lymphadenopathy in SSC patients

Theodora Simopoulou, Dimitrios Bogdanos, Christina Katsirli

17. OVERLAP SYNDROMES

- P.346 Concomitant Sjögren's syndrome as a marker for severe visceral disease in systemic sclerosis**
Tatiana Nevskaya, Maggie Larche, Murray Baron, Sabrina Hoa, May Choi, Mohammed Osman, Carter Thorne, [Janet Pope](#), Canadian Scleroderma Research Group
- P.347 Clinical and Serological Profile of Systemic Sclerosis-Primary Biliary Cholangitis Overlap (Reynolds Syndrome): A Matched Case-Control Analysis**
[Miguel Natal](#), Mariana Diz-Lopes, Carlos Marques-Gomes, Bárbara Esteves, Marina Oliveira, Catarina Rua, Ana Rocha Sá, Sara Amaro Lopes, Lúcia Costa, Raquel Miriam Ferreira, Georgina Terroso
- P.348 Delayed Seroconversion and Pulmonary Involvement in SLE-Systemic Sclerosis Overlap Syndrome: A Case Report**
[Ana Da Rocha Sá](#), Carlos Marques Gomes, Mariana Diz Lopes, Bárbara Esteves, Marina Oliveira, Miguel Natal, Sara Helena Amaro Lopes, Salomé Garcia, Raquel Miriam Ferreira, Lúcia Costa, Georgina Terroso
- P.349 Systemic Sclerosis-Systemic Lupus Erythematosus Overlap: A Rare Subgroup With Distinct Renal and Clinical Features**
[Helena Codes Méndez](#), Jose Luis Tandaiapan, Guillem Verdaguer, Montse Diaz, Helena Marco, Anna Dominguez, Berta Magallares, Patricia Moya, Cesar Diaz-Torné, Hye-Sang Park, Luis Sainz, Julia Bernardez, Ana Laiz, Hector Corominas, Ivan Castellvi
- P.350 Stability of Systemic Sclerosis-Overlap Autoantibodies (Anti-Ku, PM-Sci75 and PM-Sci100) During the COVID-19 Pandemic: A Cross-Sectional Study in a Hispanic Cohort**
Hector Teodoro Rios Bazaldua, Valeria Cantu Martinez, Pablo Gamez Siller, Eglá Samantha Sanchez Peralta, John Robert Edminister, Angel Kevin Garza Elizondo, Rosa Icela Arvizu Rivera, [Ana Cecilia Bardan Inchaustegui](#), Gisela Garcia Arellano, Jesus Alberto Cardenas de la Garza, Miguel Angel Villarreal Alarcon, Angel Dionicio Galarza Delgado
- P.351 Clinical and serological characteristics of anti-Ku autoantibodies in a Hispanic cohort**
Hector Teodoro Rios Bazaldua, Valeria Cantu Martinez, Emmanuel Dominguez Chapa, Angel Kevin Garza Elizondo, Karina Deciderio Pavon, Rosa Icela Arvizu Rivera, [Ana Cecilia Bardan Inchaustegui](#), [Gisela Garcia Arellano](#), Jesus Alberto Cardenas de la Garza, Miguel Angel Villarreal Alarcon, Angel Dionicio Galarza Delgado

18. MISCELLANEOUS

- P.352 From Crisis to Chronicity: A Real-World Study of Renal Dysfunction in Systemic Sclerosis**
[Stefano Stano](#), Fabio Cacciapaglia, Giorgia Campanale, Simone Perniola, Mariangela Nivuroi, Angelica Napoletano, Marco Fornaro, Florenzo Iannone
- P.353 Economic Burden of Diffuse Cutaneous Systemic Sclerosis in Canada**
Tatiana Nevskaya, Benjamin G. Cohen, Francine Chingcuanco, Paul Steel, Isabelle Poirier, Vanita Sharma, [Janet E. Pope](#)

- P.354 Peripheral Nervous System Complications in Systemic Sclerosis: Association Between Polyneuropathy and Neuropathic Pain**
[Kristine Ivanova](#), Natalja Kurjane, Viktorija Kenina
- P.355 Pulmonary function decline in very early diagnosis of systemic sclerosis (VEDOSS): a retrospective longitudinal single-center study**
[Eugenio Capparelli](#), Greta Pellegrino, Eleonora Zaccara, Elisabetta Ricciuti, Giorgio Bonardi, Daniele Colombo, Maria Sole Chimenti, Paola Faggioli, Antonino Mazzone
- P.356 Digital ischaemia associated with paraneoplastic systemic sclerosis**
[Anna Wojteczek](#), Monika Gosz, Michal Chmielewski
- P.357 Risk factors for cancer in systemic sclerosis, impact on disease phenotype and prognosis, and exploration of machine learning algorithms for personalized screening strategies: an EUSTAR study**
[Antonio Tonutti](#), Francesca Motta, Liala Moschetti, Nicoletta Del Papa, Stefano Stano, Elisabetta Zanatta, Gabor Kumanovics, Luca Idolazzi, Oliver Distler, Gabriella Szucs, Valeria Ricciari, Masataka Kuwana, Gonçalo Boletto, Rossella De Angelis, Radim Becvar, Serena Guiducci, Gianluca Moroncini, Duygu Temiz Karadag, Alejandro Brigante, Maurizio Cutolo, Britta Maurer, Massimiliano Limonta, Roberto Giacomelli, Yasser El Miedany, Fabiola Atzeni, Lilian Maria Lopez Nunez, Roberta Foti, Francesco Benvenuti, Carlo Selmi, Maria De Santis
- P.358 Elderly-onset systemic sclerosis is associated with a distinct clinical phenotype and increased mortality: an analysis from the Italian SPRING-SIR registry**
[Antonio Tonutti](#), Francesca Motta, Valeria Ricciari, Silvia Laura Bosello, Fabio Cacciapaglia, Veronica Codullo, Giacomo De Luca, Francesca Ingegnoli, Dilia Giuglioli, Clodoveo Ferri, Marco Matucci-Cerinic, Maria De Santis, Rossella De Angelis
- P.359 Association of Vaginal Mucosa and Wall Thickness with Sexual Dysfunction in Women with Systemic Sclerosis**
Irem Demirtas, Hayal Simsek, Andac Komac, Ayten Yazici, Ayse Cefle, [Duygu Temiz Karadag](#)
- P.360 Two of a kind – rare but not to be forgotten – Systemic Sclerosis with ANCA Vasculitis**
[Kamal Solanki](#), Kamal Solanki, Mark Ford
- P.361 An unusual yet a rare appendage manifestation of Systemic Sclerosis**
[Kamal Solanki](#), Kamal Solanki, Karen Koch
- P.362 A rare presentation in limited cutaneous systemic sclerosis –“Like in looks, so in the eyes”**
[Kamal Solanki](#), Kamal Solanki, Stephen Guest
- P.363 Uncommon but important presentation in Systemic Sclerosis - Sensorineural Hearing Loss (SNHL)**
[Kamal Solanki](#), Magdalena Budziakowska
- P.364 Site-specific cancer risks differ by autoantibody status and across time in patients with scleroderma**
Laura Cappelli, Takeru Igusa, Christopher Mecoli, Ji Soo Kim, Adrienne Woods, Laura Gutierrez-Alamillo, Laura Hummers, Fredrick Wigley, Kala Visvanathan, Leigh Freno, Maureen Laffoon, Antony Rosen, Robyn Domsic, Livia Casciola-Rosen, [Ami Shah](#)

18. MISCELLANEOUS

P.365 Disease outcome during the postpartum period in Systemic Sclerosis and VEDOSS patients: a retrospective multicentre study

Elda Piovani, Eleonora Pazzi, Liala Moschetti, Claudia Barison, Eleonora Pedretti, Cristiana Siero Santos, Carla Martins, Paolo Semeraro, Luca Ongaro, Fatma Alibaz-Oner, Angela Tincani, Laura Andreoli, Maria Grazia Lazzaroni, Ilaria Cavazzana, Franco Franceschini, Paolo Airò

P.366 Risk Score for Early Mortality to stratify for Intensive SSc Therapy. The RESIST score

Ann-Christin Pecher, Marouane Boubaya, Allanore Yannick, Vanessa Smith, Jeska De Vries-Bouwstra, Radim Becvar, Gianluca Moroncini, David Launay, Maria De Santis, Kamal Solanki, Carlomaurizio Montecucco, Luca Idolazzi, Nihal Fathi, Kotyla Przemyslaw, Marie-Elise Truchetet, Masataka Kuwana, Francesco Del Gado, Distler Oliver, Muriel Elhai, Jörg Henes

P.367 Lung cancer risk is highly increased in female patients with systemic sclerosis: data from an inception cohort and meta-analysis of published studies

Anastasios Makris, Vasiliki Poulia, Vasiliki-Kalliop Bournia, Kalliopi Fragiadaki, Maria G. Tektonidou, Petros P. Sfikakis, Stylianos Panopoulos

P.368 Gynecological health and ultrasound evaluation among fertile women affected by Systemic sclerosis

Martina Orlandi, Sofia Gambigliani Zoccoli, Mariagrazia Nuara, Amelia Spinella, Marco De Pinto, Carlo Alboni, Antonio La Marca, Dilia Giuggioli

P.369 Clinical features and outcomes of anti-ribonucleoprotein antibody positive systemic sclerosis patients

Tippawan Onchan, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Patnarin Pongkulkiat, Anawat Ratchatorn, Chingching Foocharoen

P.370 Pregnancy and Obstetric History in Women with Systemic Sclerosis: A Retrospective Study from a Single Tertiary Centre

Marina Oliveira, Carlos Marques Gomes, Mariana Diz Lopes, Bárbara Esteves, Miguel Natal, Ana Sá, Sara Lopes, Georgina Terroso, Lúcia Costa, Raquel Miriam Ferreira

P.371 Correlation Between Indirect Immunofluorescence Assay on HEp-2 Cells Patterns and Specific Autoantibodies by Line Blot in Systemic Sclerosis Patients

Pedro Matos, Gerson Dierley Keppeke, Silvia Helena Rodrigues, Trischna Martins, Claudia Pratas, Luis Eduardo C. Andrade, Cristiane Kayser

P.372 The Lip in Scleroderma: Variability, Assessment, and Clinical Gaps

Mustafa Mahmood, Michael Hughes, Zsuzsanna McMahan, Lee Shapiro

P.373 Travel distance to tertiary healthcare reflects disease severity and medication access in systemic sclerosis patients: insights from the Italian spring registry of the Italian society of rheumatology

Camilla Teresa Magnanini, Enrico De Lorenzis, Gerlando Natalello, Fabio Cacciapaglia, Rossella De Angelis, Edoardo Cipolletta, Maria Antonietta D'agostino, Veronica Codullo, Giacomo De Luca, Dilia Giuggioli, Francesca Ingegnoli, Valeria Riccieri, Lorenzo Dagna, Fiorenzo Iannone, Clodoveo Ferri, Marco Matucci-Cerinic, Silvia Laura Bosello

P.374 Characteristics and outcomes of males in the Australian Scleroderma Cohort Study (ASCS)

Emily Lin, Dylan Hansen, Maryam Tabesh, Laura Ross, Mandana Nikpour, Susanna Proudmán, Jenny Walker, Gabor Major, Lauren Host, Nava Ferdowsi, Alannah Quinlivan, Wendy Stevens, Gene-Siew Ngian, Diane Apostolopoulos, Joanne Sahhar

P.375 Defining VEDOSS (Very early Diagnosis of Systemic sclerosis) and pre-systemic sclerosis : A scoping literature review on applied definitions in original articles

Alain Lescoat, Yannick Allanore, Francesco Del Galdo, Masataka Kuwana, Christopher P. Denton, Dinesh Khanna, Marco Matucci-Cerinic, Silvia Bellando-Randone

P.376 Prevalence and incidence of skin telangiectasia and their association with clinical features: analysis of the European Scleroderma Trials and Research (EUSTAR) cohort

Gemma Lepri, Lorenzo Tofani, Silvia Bellando-Randone, Veronica Batani, Paolo Airò, Patricia Carreira, Joerg Henes, Alexandra Balbir Gurman, Florenzo Iannone, Antonella Marcoccia, Luc Mouthon, Branimir Anic, Carolina De Souza Müller, Armine Haroyan, Ana Cristina Cordeiro, Serena Guiducci And Eust

P.377 Increased frequency of anti-RNA Polymerase 3 antibodies in patients with Systemic Sclerosis and Silicone Breast Implants: a multicentre study from the international EUSTAR cohort

Maria Grazia Lazzaroni, Yolanda Braun-Moscovici, Elda Piovani, Claudia Barison, Liala Moschetti, Veronica Batani, Michal Tomcik, Sabina Oreska, Francesca Motta, Maria De Santis, Petros P. Sfikakis, Masataka Kuwana, Kamal Solanki, Brigitte Granel, Roberta Foti, Virginia Berlingiero, Joana Caetano, Yannick Allanore, Elisabetta Zanatta, Luca Idolazzi, Juan-José Alegre-Sancho, Devis Benfaremo, Gianluca Moroncini, Marco Matucci-Cerinic, Franco Franceschini, Alexandra Balbir-Gurman, Paolo Airò

P.378 Spontaneous intracranial hypotension: an underdiagnosed condition in Systemic Sclerosis?

Lucia Lanzo, Silvia Laura Bosello, Gerlando Natalello, Gabriella Alonzi, Pier Giacomo Cerasuolo, Silvia Fiore, Andrea Zoli, Stefano Di Murro, Valentina Boni, Camilla Teresa Magnanini, Davide Gaspare Patti, Maria Antonietta D'agostino, Enrico De Lorenzis

P.379 The involvement of the temporomandibular joint in patients with Systemic Sclerosis: a clinical and ultrasound study

Alessia Laneri, Giovanni Ciancio, Gabriele Amati, Beatrice Maranini, Amelia Spinella, Marco De Pinto, Martina Orlandi, Maria Grazia Malandra, Ottavio Secchi, Benedetta Bongiovanni, Gilda Sandri, Stefano Mandrioli, Andrea Lo Monaco, Marcello Govoni, Dilia Giuggioli

P.380 Microvascular involvement in idiopathic inflammatory myositis: capillaroscopic study in a single-center cohort of patients with dermatomyositis and antisynthetase syndrome

Jacopo Landro, Davide Mohammad Reza Beigi, Ilaria Bisconti, Marius Cadar, Francesca Romana Di Ciommo, Elena Platania, Martina Salerno, Beatrice De Girolamo, Simona Truglia, Fabrizio Conti, Valeria Riccieri

P.381 Clinical differences in systemic sclerosis patients with and without sicca symptoms

Nikolaos Koletsos, Konstantinos Trentzidis, Nafsika Gerolymatou, Paraskevi Voulgari

18. MISCELLANEOUS

- P.382 Mapping the journey to diagnosis in systemic sclerosis: A real-world cluster-based analysis**
Dinesh Khanna, Mario Ehlers, Lizette Moros, Arpit Misra, Hyemin Song, Isabel Truman, Liane Gillespie-Akar, Francesco Del Galdo
- P.383 Unveiling Cryofibrinogenemia in Systemic Sclerosis: Novel Links to Lung Disease and Pulmonary Hypertension**
Luca Keller Sarmiento, Caterina Vacchi, Gabriele Amati, Benedetta Bongiovanni, Amelia Spinella, Patrizia Natali, Daria Debbia, Martina Orlandi, Ottavio Secchi, Marco De Pinto, Dilia Giuglioli
- P.384 Clinical, immunological and treatment profile of male systemic sclerosis patients from India**
Sankar Jayaprakash, Puneet Saxena, Nidhi Goel, Ramakant Singh, Avneet Gupta, Kunal Kishore, Harsh Jain, Abhishek Kumar, Kartik Sivasami, Vivek Vasdev
- P.385 Clinical characteristics of “non-severe” scleroderma patients with physical frailty: An analysis using a Japanese single-center cohort**
Kodai Ito, Tatsuki Naganawa, Ryuto Hobo, Kaho Kondo, Risa Ohara, Naoki Dosoden, Toshihide Kimura, Marika Sawada, Yumi Ito, Natsuko Watanabe, Ai Umeda, CHIAI NAKADA, KONOMI Akamatsu, Megumi Kurumizawa, Machiko Tachibana, Takako Hashimoto, Shusaku Fukaya, Hidekata Yasuoka
- P.386 Radiographic hand assessment of acro-osteolysis in systemic sclerosis provides novel insights into pathogenesis and evolution of disease burden over time**
Michael Hughes, Graham Dinsdale, Aayushi Agnihotri, Joanne Manning, Muditha Samaranyaka, Jonathan Harris, Ariane Herrick
- P.387 Distinct Systemic Sclerosis Phenotypes Related to Race/Ethnicity: An Opportunity to Personalize Care?**
Danick Goulet, Camille Guertin, Maggie Larché, Marie Hudson, Isabelle Ferdinand, May Y. Choi, Mohammed Osman, Janet Pope, Carter Thorne, Murray Baron, Sasha Bernatsky, Sabrina Hoa, Scleroderma Research Group
- P.388 Imaging techniques for assessing the hand in systemic sclerosis: a systematic review**
Mark Greveling, Veerle Koerselman, Simon Mastbergen, Julia Spierings
- P.389 Educational online webinars of European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET): 6 years’ results of the systemic sclerosis disease group**
Emanuele Gotelli, Rosanna Campitiello, Eric Hachulla, Vanessa Smith, Marco Matucci-Cerinic, Ilaria Galetti, Sue Farrington, Wiebke Laurre, Monica Testoni, Diana Marinello, Rosaria Talarico, Marta Mosca, Maurizio Cutolo
- P.390 Salivary Gland Ultrasound in Systemic Sclerosis: Overlap with Sjögren’s Disease or Just a Look-Alike?**
Carlos Gomes, Mariana Diz-Lopes, Bárbara Esteves, Miguel Natal, Sara Lopes, Ana Sá, Marina Oliveira, Mariana Sebastião, Miguel Bernardes, Raquel Ferreira, Georgina Terroso, Lúcia Costa
- P.391 Exploring the Link: Systemic Sclerosis and Peripheral Arterial Disease – data from a tertiary center**
Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis and vasculopathy
Carlos Gomes, Diogo Domingues, Mariana Diz-Lopes, Bárbara Esteves, Sara Lopes, Ana Sá, Marina Oliveira, Mariana Sebastião, Miguel Natal, Miguel Bernardes, Raquel Ferreira, Georgina Terroso, Lúcia Costa, Joana Ferreira, Armando Mansilha
- P.392 LL37 as a Biomarker of Vascular and Pulmonary Involvement in Systemic Sclerosis**
Sami Gyires, Shani Peretz Bardan, Naomi Yeshurun Finkelstein1, Marielle Kaplan, Vika Shataylo, Rita Erlich, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman
- P.393 External Validation of Deep Learning Models for 5-Year Mortality in Systemic Sclerosis**
Kittikorn Duangkum, Wilaiphorn Thinkhamrop, Nathapob Chaichaya, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Pimchanok Tantiwong, Thida Phungtaharn, Chingching Foocharoen
- P.394 Patient perspectives and satisfaction following a short-term singing intervention in systemic sclerosis patients: a cross-sectional study**
Pasinnee Srinithiwat, Chingching Foocharoen, Ajanee Mahakkanukrauh, Tippawan Onchan Patnarin Pongkulkiat, Orathai Wantha, Siraphop Suwannaroj
- P.395 Hospital-based first diagnoses of systemic sclerosis: defining initial clinical presentations and diagnostic pathways**
Chingching Foocharoen, Teerapat Luengthanapol, Tippawan Onchan, Patnarin Pongkulkiat, Ajanee Mahakkanukrauh, Siraphop Suwannaroj
- P.396 Artificial Intelligence Distinguishes Edematous Phase of Systemic Sclerosis from Mimickers: A Video-Based Diagnostic Study**
Chingching Foocharoen, Tippawan Onchan, Patnarin Pongkulkiat, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Supachoke Somsilphong, Wanida Kanakard
- P.397 CT-Based Assessment of Thoracic Wall Muscle Mass and Its Association with FVC and FVC Test Quality in Systemic Sclerosis**
Busra Firlatan-Yazgan, Gul Sandal Uzun, Alper Sari, Mustafa Utku Ugur, Esra Akcicek, Selin Ardali Duzgun, Gamze Durhan, Elif Naz Sancar, Oguz Karcioglu, Gozde Sevgi Kart Bayram, Mustafa Ekici, Erdinc Unaldi, Levent Kilic, Ali Akdogan
- P.398 Systemic Sclerosis as a sign of malignancy: a case report**
Bárbara Fernandes Esteves, Carlos Marques-Gomes, Mariana Diz-Lopes, Miguel Correia Natal, Marina Oliveira, Ana Rocha Sá, Sara Amaro Lopes, Georgina Terroso, Lúcia Costa, Raquel Miriam Ferreira
- P.399 Fundus Examination versus Optical Coherence Tomography to assess for Retinal Microvascular Changes in Systemic Sclerosis**
Rahma Elziaty, Maha Elgaafary, Reem Mohsen, Mary Wadie, Walaa Elwakil, Yasser El Miedany
- P.400 The National Landscape of Systemic Sclerosis in Egypt: A Comprehensive EUSTAR database study**
Rahma Elziaty, Maha Elgaafary, Walaa Elwakil, Waleed Hassan, Mohamed Hassan Abu.Zaid, Mary Wadie, Samar Tabra, Sherif Ismail, Yasser Elmiedany


18. MISCELLANEOUS

- P.401** **The prevalence of interstitial lung disease in diagnosed cases of rheumatoid arthritis in tertiary care center**
Harmanjeet Singh Dhillon
- P.402** **Understanding care experiences in systemic sclerosis: Physician and patient perspectives stratified by clinical clusters**
Francesco Del Galdo, Mario Ehlers, Lizette Moros, Arpit Misra, Hyemin Song, Isabel Truman, Liane Gillespie-Akar, Dinesh Khanna
- P.403** **Systemic Sclerosis and Quality of Life: Innovative Therapeutic Approaches Through Animal-Assisted Interventions (AAI) – the Experience of Scleroderma Unit of Modena**
Amelia Spinella, Marco de Pinto, Nicola Anatra, Margherita Carretti, Luca Parenti, Daniele Tagliafico, Gabriele Amati, Martina Orlandi, Gilda Sandri, Dilia Giuglioli
- P.404** **The hidden impact of Systemic Sclerosis In Oral Health: Evidence from a Portuguese Population**
Ana Da Rocha Sá, Carlos Marques Gomes, Mariana Diz Lopes, Bárbara Esteves, Marina Oliveira, Miguel Natal, Sara Helena Amaro Lopes, Salomé Garcia, Georgina Terroso, Lúcia Costa, Raquel Miriam Ferreira
- P.405** **Clinical Characteristics and Ethnic Differences in Anti-Fibrillarlin Positive Systemic Sclerosis patients: An International Multicenter Cohort Study**
Roberto D'Alessandro, Stefano Rodolfi, Ami Shah, Laura Hummers, Adrienne Woods, Pietro Rubortone, Marie Elise Truchetet, Alix Calot, Corrado Campochiario, Veronica Codullo, Francesco Del Galdo, Ivan Castellvi Barranco, Elisabetta Zanatta, Silvia Bellando Randone, Gonzalo Boleto, Loic Raffray, Emmanuel Chatelus, Patrice Cacoub, Alexandre Le Joncour, Paolo Airò, Cristiana Sieiro Santos, Alain Lescoat, Aurore Collet, David Launay, Jerome Avouac, Christopher Denton, Yannick Allanore
- P.406** **Investigating the interplay between pulmonary functionality and advanced microangiopathy in very early diagnosis of systemic sclerosis (VEDOSS)**
Eugenio Capparelli, Eleonora Zaccara, Greta Pellegrino, Elisabetta Ricchieti, Giorgio Bonardi, Daniela Bompane, Laura Castelnovo, Antonio Tamburello, Maria Sole Chimenti, Antonino Mazzone, Paola Faggioli
- P.407** **Metabolic and clinical correlates of insulin resistance in systemic sclerosis: a cross-sectional monocentric study**
Eugenio Capparelli, Paola Faggioli, Eleonora Zaccara, Francesco Lapia, Francesca Capelli, Laura Castelnovo, Daniela Bompane, Antonio Tamburello, Sergio Finazzi, Maria Sole Chimenti, Antonino Mazzone
- P.408** **Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment**
Blaz Burja, Paco Welsing Welsing, Alain Lescoat, Andreas Eisenring, Anna-Maria Hofmann-Vold, Claire Leroy David, Dinesh Khanna, Francesco Del Galdo, Iudici Michele, Janet Pope, Julia Spierings, Madelon Vonk, Marie-Elise Trucetet, Martine Clergeau, Michael Hughes, Susan Murphy, Tracy Frech, Oliver Distler, Muriel Elhai
- P.409** **Phenotypic Variations and Clinical Pathways in Scleroderma Renal Crisis**
Katya Dolnikov, Kochava Toledano, Marius Braun, Sami Giryes, Yonit Tavor, Alexandra Balbir-Gurman, Yolanda Braun-Moscovici

- P.410** **Threefold Impact of a Scleroderma-focused Interprofessional Education Event**
Hannah Bowen, Amy Gietzen, Lee Shapiro, Steve Rosenblum
- P.411** **Phenotypic impact of diabetes mellitus on the course of systemic sclerosis: Insights from an international multicenter study**
Goncalo Boleto, Corrado Campochiario, Paolo Airò, Maria-Grazia Lazzaroni, Liala Moschetti, Elisabetta Zanatta, Andrea Benini, Gianluca Moroncini, Devis Benfaremo, Marie-Èlise Truchetet, Louis Bèbèar, Silvia Bellando Randone, Serena Guiducci, Alain Lescoat, Fabio Cacciapaglia, Nicoletta Del Papa, Marco Matucci-Cerinic, Yannick Allanore
- P.412** **Longitudinal Characterization of PreSSc/VEDOSS Patients Identifies Anti-Sci70 Antibodies as the Main Predictor of Disease Progression**
Chiara Bellocchi, Martina Iacubino, Marta Mozzo, Maurizio Lorini, Vincenzo Carbonelli, Lorenzo Beretta
- P.413** **Impact of Pharmacological Maintenance Treatment on Healthcare Costs in Hispanic Outpatients with Systemic Sclerosis**
Narda Alejandra Nieto Guerrero, Juan Pablo Gonzalez Morales, Mayra Fernanda Moguel Ehuan, Carlos Jose Montero Chavez, Valeria Cantu Martinez, Ana Cecilia Bardan Inchaustegui, Gisela Garcia Arellano, Alejandra Perez Gomez, Miguel Angel Villarreal Alarcon, Jesus Alberto Cardenas de la Garza, Dionicio Angel Galarza Delgado
- P.414** **Colombian Consortium for the Development of Research on Systemic Sclerosis (CCONDORSS) Institutional Registry: Presentation of the registry and first preliminary report**
Julian Barahona-Correa, Yulieth Garcia-Pardo, Karen Gualdrón-Chaparro, Stella Baracaldo, Oscar Gil, Anais Gallart, Ángela Ardila, Maria-Claudia Diaz, Daniel G. Fernández-Avila, Santiago Bernal-Macias
- P.415** **Clinical Characteristics and Treatment of Patients with Systemic Sclerosis Associated digital ulcers and PAH**
The Nwe Aung, Rosi Thomson, Smita Bhat
- P.416** **Lung cancer in Systemic sclerosis, a single center patients' cohort characteristic**
Balbir-Gurman Alexandra, Giryes Sami, Dolnikov Katya, Guralnik Luda, Dotan Yaniv, Tavor Yonit Araf Aiman Toledano Kohava, Braun-Moscovici Yolanda

05. INTERSTITIAL LUNG DISEASE

- P.417** **Assessing Respiratory Muscle Strength and Aerobic Capacity in Systemic Sclerosis: Insights into Pulmonary and Functional Health**
Gülsah Yamançan, Jehat Kılıç
- P.418** **Forced Vital Capacity Trajectories in Treatment-Naïve Systemic Sclerosis: A 10-Year Prospective Cohort Study**
Hee Won Cho, Eun Bong Lee, Jun Won Park, Jin Kyun Park, Yunhee Choi
- P.419** **SYSTEMIC SCLEROSIS -POLYMYOSITIS OVERLAP SYNDROM ON RITUXIMAB THERAPY DURING LONG-TERM FOLLOW-UP**
Oxana Desinova, Mayya Starovoytova, Lidiya Ananieva, Olga Koneva
- P.420** **VISCERAL INVOLVEMENT IN VERY EARLY SYSTEMIC SCLEROSIS**
Oxana Desinova, Mayya Starovoytova, Olga Koneva, Rushana Shayakhmetova, Liudmila Garzanova, Olga Ovsyannikova, Lidia Ananyeva



Every breakthrough starts with a challenge.

Like athletes, researchers train, persevere and push beyond their limits to move science forward.

Today, we celebrate the true athletes of science.

Join the Contest

- Explore the posters in the Poster Area (Level 0 and level 1, balcony)
- Scan the QR code on the branded totem
- Vote for your favourite research

The most voted projects will be awarded the title Champion of Progress, selected through both public voting and evaluation by a scientific jury.

Your vote matters: support innovation, celebrate discovery, be part of progress.

Join us. Vote. Inspire change.

GENERAL INFORMATION

Congress venue

MEGARON INTERNATIONAL CONFERENCE CENTRE

Leoforos Vasilissis Sofias and Kokkali 1
11521 Athens, Greece

How to get to Megaron

There is a metro station next to the Megaron (called Megaro Moussikis) leading you right into the city centre in one direction (6 minutes) and to the El. Venizelos International Airport in the other direction (35 minutes).

Maps, timetables, fares and route planning are available in English on the Athens Public Transport website: <https://www.athenstransport.com/english/>

Next to Megaron there is a big car park available and many taxis, trams and buses just outside the centre.

Organizing Secretariat

AIM Group International - Florence Office

Via Giovanni del Pian dei Carpi 19/21 - 50127 Florence, Italy
Tel. +39 02 566011

ssc2026@aimgroup.eu

Bar

A bar is available at the entrance of the congress center.

Cloakroom

A cloakroom is available on following days:

Thursday, March 5	from 08:00 to 21:30
Friday, March 6	from 07:30 to 19:30
Saturday, March 7	from 07:30 to 18:00

Registration desk

Onsite the registration desk will be open for participants at the following times:

Thursday, March 5	from 08:00 to 19:30
Friday, March 6	from 07:30 to 19:30
Saturday, March 7	from 07:30 to 17:30

REGISTRATION FEES

(VAT 24% included)

Late fee and onsite

Physicians	€ 1.050,00
Young Investigators/ Fellows *	€ 520,00
Phd Basic Scientists**	€ 520,00
HP (Nurses and Physiotherapists)	€ 470,00
Medical Students***	€ 320,00
Patients	€ 49,60

* For young doctors under 35 years of age. Copy of the ID or passport is requested.

** For other scientists who are not Physicians and/or MD

*** These individuals must include a letter from their program director, chief of service or faculty advisor to be eligible for reduced fees

Registration fees include:

- Congress kit,
- access to the scientific sessions,
- admission to the exhibition and poster area,
- certificate of attendance,
- coffee breaks and working lunch as indicated in the programme,
- book of abstracts.

Registration fee for patients includes:

Congress kit, access to the Opening Ceremony of the medical congress, scientific sessions of the patient congress only, coffee breaks and working lunch as indicated in the patient programme.

Patient registrations are not entitled to attend the medical congress.

Congress badges

Each participant may collect the badge at the registration desk. Participants are kindly requested to wear their badge during all congress activities and social events.

No colour: Participants

Red colour: Invited Speakers and Chairpersons

Green colour: Exhibitors

Blue colour: Patients

Internet connection

Free wi-fi connection is available as follows:

Medical congress - level 0 and level -1

Wifi: SSWC2026

Password: SSWC2026!!

Patient congress - level -2

Wifi: PATIENT2026

Password: PATIENT2026!!

Language

The official language is English.

Catering

Coffee breaks

Coffee breaks will be organized in the exhibition area, during the following times:

Friday, March 6 from 10:00 to 10:30 and from 16:30 to 17:00,

Saturday, March 7 from 10:30 to 11:00.

Lunches

A standing buffet lunch will be offered to all registered participants on *Friday, March 6* from 13:20 to 14:25 and on *Saturday, March 7* from 12:35 to 13:50 in the exhibition area.

Patient Congress

Coffee breaks and lunches will be organized at level -2.

Certificate of Attendance

Certificates of attendance will be sent by email.

Exhibition

An exhibition will be open in the following days at Level 0:

Thursday, March 5 from 13:30 to 19:00,

Friday, March 6 from 08:00 to 19:00,

Saturday, March 7 from 08:30 to 16:00.

Social Programme

Welcome Reception

Thursday, March 5 from 19:10 to 21:30

A light cocktail will be held after the Opening Lectures at level 0 for all registered participants and patients.

Congress Dinner - Friday, March 6 at 20:45

The Congress Dinner will be held at

DIONYSOS ZONAR'S

Rovertou Galli 43, - Athina 117 42, Greece

Transfer by bus will be provided upon reservation, from Hotel Crown Plaza (50, Michalakopoulou Ave) at 20:15.

Possible remaining places can be booked at the "Onsite registration" desk by Friday, March 6 at 10:00.

SCIENTIFIC INFORMATION

Oral communications

Selected papers will be orally presented by the Authors. Authors have the time indicated in the programme including the discussion.

Poster tour

See information at page 16

Poster session

See information at page 28

Meet the Expert sessions

Meet the Expert sessions will be organized on Friday, March 6 and Saturday, March 7 from 07:30 to 08:30 for young practicing physicians only, for a maximum of 40 participants each, on first come, first served basis. Possible remaining places can be booked at the "Onsite registration" desk.

Speaker Preview Room

Speaker Preview Room is available at level 0.

Speakers are kindly requested to upload their slides at least 1,5 hours before their presentation or, if their session is scheduled in the early morning, on the previous day. The opening hours of the Speaker Preview Room are:

Thursday, March 5 from 08:00 to 18:00

Friday, March 6 from 07:30 to 18:30

Saturday, March 7, from 07:30 to 17:00.

The following facilities will be provided in the Speaker Preview Room:

- computers (operating system Windows) to review, alter and upload the presentations to the server
- support by technical staff is available

The technicians will transfer the presentation to the corresponding Session Room. All speakers will easily find their presentations directly in the meeting room.

Abstract book

The digital version of the abstracts book of the oral presentations and posters is available online:

<https://web.aimgroupinternational.com/2026/scleroticcongress/abstract-book/>

You can scan the QR code here below to open it.




Important!

The abstract book as supplement of Journal of Scleroderma Foundation will be ready some months after the congress. The participants will be notified by email as soon as it is available.



CONGRESS FLOORPLANS

LEVEL 0




LEVEL 0 • EXHIBITION AREA




Booth no.	Company
1	Abbvie
2	Bristol-Myers Squibb
3	MSD
4	Boehringer Ingelheim
5	World Scleroderma Foundation
6	Argenx
7	Parmosa Biopharm
8	Glaxo Smithkline
9	Novartis
10	Cabaletta Bio
11	AstraZeneca
13	Horus - Adamo S.r.l.
14	Cesas
15	Inspectis



POSTER AREA 1, LEVEL 0 • from P.001 to P.125




POSTER AREA 2, BALCONY • from P.126 to P.418




LEVEL -1 • MC ROOMS

Pre-congress
workshops/courses
and Meet the Expert sessions






MARCH 5-7, 2026 ATHENS, GREECE



LEVEL -2 • PATIENT CONGRESS



ACKNOWLEDGEMENTS

The Congress Organisers gratefully acknowledge support received from all exhibitors and the following sponsors:

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSOR



EXHIBITORS





VISIT THE CONGRESS WEBSITE



Organizing Secretariat

AIM Group International

Florence Office

Via Giovanni del Pian dei Carpini, 19/21

50127 Firenze

Tel. +39 02 566011

ssc2026@aimgroup.eu

<https://worldsclerofound.org/ssc-world-congress/>